

Manipal Health Enterprises Private Limited  
Consolidated Balance Sheet as at


		(₹ in crore)	
	Note	March 31, 2025	March 31, 2024*
<b>ASSETS</b>			
<b>Non-current assets</b>			
Property, plant and equipment	3.1	4,224.71	3,750.23
Capital work in progress	3.2	614.03	41.59
Right-of-use assets	4	1,699.76	1,224.18
Goodwill	4	3,399.01	2,759.53
Other intangible assets	4	502.67	424.48
Investment in equity accounted investees	5	-	-
<b>Financial assets</b>			
Investments	6.1	144.92	116.17
Loans	6.2	-	0.05
Other financial assets	6.3	133.75	87.44
Deferred tax assets (net)	16	181.61	61.35
Income tax assets (net)	7	256.18	255.79
Other non-current assets	8	60.79	40.07
		<b>11,217.43</b>	<b>8,760.88</b>
<b>Current assets</b>			
Inventories	9	131.93	103.19
<b>Financial assets</b>			
Investments	10.1	1,630.76	1,004.92
Trade receivables	10.2	637.30	458.88
Cash and cash equivalents	10.3	291.28	360.88
Bank balances other than cash and cash equivalents	10.4	39.01	18.91
Loans	10.5	3.38	1.95
Other financial assets	10.6	58.79	29.29
Other current assets	11	55.66	73.44
		<b>2,848.11</b>	<b>2,051.46</b>
Assets held-for-sale	3.3	6.50	6.50
<b>Total assets</b>		<b>14,072.04</b>	<b>10,818.84</b>
<b>EQUITY AND LIABILITIES</b>			
<b>Equity</b>			
Equity share capital	12	77.06	75.63
Other equity	13	5,770.25	3,939.88
<b>Equity attributable to owners of the Company</b>		<b>5,847.31</b>	<b>4,015.51</b>
Non-controlling interest	13.8	152.84	71.99
<b>Total equity</b>		<b>6,000.15</b>	<b>4,087.50</b>
<b>Liabilities</b>			
<b>Non-current liabilities</b>			
<b>Financial liabilities</b>			
Borrowings	14.1	4,469.97	3,700.14
Lease liabilities	14.2	1,548.87	1,133.67
Other financial liabilities	14.3	34.96	-
Provisions	15	39.55	29.83
Deferred tax liabilities (net)	16	183.74	210.94
		<b>6,277.09</b>	<b>5,074.58</b>
<b>Current liabilities</b>			
<b>Financial liabilities</b>			
Borrowings	17.1	296.84	243.85
Lease liabilities	14.2	69.47	52.59
Trade payables	17.2	-	-
- total outstanding dues of micro enterprises and small enterprises		36.14	29.88
- total outstanding dues of creditors other than micro enterprises and small enterprises		1,090.45	1,100.65
Other financial liabilities	17.3	117.74	62.76
Other current liabilities	20	112.01	91.13
Provisions	18	68.71	50.69
Current tax liabilities (net)	19	3.44	25.21
		<b>1,794.80</b>	<b>1,656.76</b>
<b>Total equity and liabilities</b>		<b>14,072.04</b>	<b>10,818.84</b>
<b>Material accounting policies</b>	2.3		

\* Refer note 32 b.

The accompanying notes are an integral part of these Consolidated Financial Statements

As per our report of even date attached

For B S R & Co. LLP  
Chartered Accountants  
Firm Registration number : 101248W/W - 100022



Siddhartha Sharma  
Partner  
Membership number: 118756


Date : May 30, 2025  
Place : Bengaluru


For and on behalf of the Board of Directors of  
Manipal Health Enterprises Private Limited

Dilip Jose  
Managing Director & CEO  
DIN: 03591692  
Date : May 30, 2025

Dr. H. Sudarshan Ballal  
Chairman & Director  
DIN: 01195055  
Date : May 28, 2025

  
Sameer Agarwal  
Chief Financial Officer

  
Sathish Kolar Ramamoorthy  
Company Secretary  
Membership number: A15203  
Date : May 28, 2025

Date : May 28, 2025  
Place : Bengaluru

Manipal Health Enterprises Private Limited  
Consolidated Statement of Profit and Loss for the year ended

		(₹ in crore)	
	Note	March 31, 2025	March 31, 2024*
<b>Income</b>			
Revenue from operations	21	8,242.26	6,171.63
Other income	22	106.55	86.68
Finance income	23	14.00	6.85
<b>Total income</b>		<b>8,362.81</b>	<b>6,265.16</b>
<b>Expenses</b>			
Purchase of medical consumables and pharmacy items		1,687.74	1,274.30
Changes in inventories of medical consumables and pharmacy items	24	(7.70)	(23.10)
Employee benefits expense	25	1,219.41	857.04
Finance costs	26	511.87	454.91
Depreciation and amortisation expense	27	506.84	397.01
Other expenses	28	3,216.29	2,380.37
<b>Total expenses</b>		<b>7,134.45</b>	<b>5,340.53</b>
<b>Profit before share of loss of equity accounted investee, exceptional items and tax</b>		<b>1,228.36</b>	<b>924.63</b>
Share of loss of equity accounted investee	36, 37	-	-
<b>Profit before exceptional items and tax</b>		<b>1,228.36</b>	<b>924.63</b>
<b>Exceptional items</b>	29	13.95	(179.63)
<b>Profit before tax</b>		<b>1,242.31</b>	<b>745.00</b>
<b>Tax expense</b>			
Current tax	16	290.71	233.94
Deferred tax	16	(130.07)	(22.10)
<b>Total tax expense</b>		<b>160.64</b>	<b>211.84</b>
<b>Profit for the year</b>		<b>1,081.67</b>	<b>533.16</b>
<b>Other comprehensive loss (OCI)</b>			
Items that will not be reclassified to profit or loss:			
Re-measurement loss of defined benefit plans		(6.61)	(3.90)
Income tax effect on above		1.45	0.49
		<b>(5.16)</b>	<b>(3.41)</b>
Items that will be reclassified to profit and loss:			
Exchange differences on translation of foreign operations		0.09	0.03
		<b>0.09</b>	<b>0.03</b>
<b>OCI for the year (net of tax)</b>		<b>(5.07)</b>	<b>(3.38)</b>
<b>Total comprehensive income for the year</b>		<b>1,076.60</b>	<b>529.78</b>
<b>Profit / (loss) for the year attributable to:</b>			
Owners of the Company		1,081.67	533.16
Non-controlling interests		1,065.35	594.26
		16.32	(61.10)
<b>Other comprehensive loss for the year attributable to:</b>			
Owners of the Company		(5.07)	(3.38)
Non-controlling interests		(4.63)	(3.00)
		(0.44)	(0.38)
<b>Total comprehensive income / (loss) for the year attributable to:</b>		<b>1,076.60</b>	<b>529.78</b>
Owners of the Company		1,060.72	591.26
Non-controlling interests		15.88	(61.48)
<b>Earnings per equity share (EPS)</b>			
<b>[nominal value of share ₹ 10 (March 31, 2024: ₹ 10)]</b>			
Basic (₹)	30	9.25	5.27
Diluted (₹)		9.25	5.25

**Material accounting policies**

\* Refer note 32 b.

The accompanying notes are an integral part of these Consolidated Financial Statements

As per our report of even date attached

For B S R & Co. LLP

Chartered Accountants

Firm Registration number : 101248W/W - 100022



Siddhartha Sharma


Partner

Membership number: 118756

Date : May 30, 2025

Place : Bengaluru

For and on behalf of the Board of Directors of  
Manipal Health Enterprises Private Limited



Dilip Jose

Managing Director & CEO

DIN: 03591692


Date : May 30, 2025

Dr. H. Sudarshan Ballal

Chairman & Director

DIN: 01195055

Date : May 28, 2025




Sameer Agarwal

Chief Financial Officer

Date : May 28, 2025

Place : Bengaluru



Sathish Kolar Ramamoorthy

Company Secretary

Membership number: A15203

Date : May 28, 2025

## (a) Equity share capital #

Equity shares of ₹ 10/- each issued, subscribed and fully paid-up

Balance as at April 01, 2023

Change in equity share capital during the year

Balance as at March 31, 2024

Change in equity share capital during the year (refer note 52)

Balance as at March 31, 2025

# Also, refer note 12

## (b) Other equity \*\*

(₹ in crore)

Nos.	₹ in crore
7,56,30,045	75.63
7,56,30,045	75.63
14,32,389	1.43
7,70,62,434	77.06

	Attributable to the Owners of the Company							Total	Non-controlling Interest	Total other equity
	Reserves and Surplus									
	Securities premium	Treasury Shares ***	Employee stock options outstanding	General reserve	Retained earnings (loss) / gain of defined benefit plans	Re-measurement (loss) / gain of defined benefit plans	Other comprehensive income			
Balance as at April 01, 2023*	2,569.55	(34.36)	22.56	2.80	654.76	4.84	(15.51)	233.59	3,438.23	
Profit for the year*	-	-	-	-	594.26	-	-	(61.10)	533.16	
OCI for the year (net of tax)	-	-	-	-	(3.03)	-	-	(3.03)	(3.41)	
<b>Total comprehensive income</b>	<b>2,569.55</b>	<b>(34.36)</b>	<b>22.56</b>	<b>2.80</b>	<b>1,249.02</b>	<b>1.81</b>	<b>(15.51)</b>	<b>172.11</b>	<b>3,967.98</b>	
On account of acquisition of subsidiary (refer note 32 c)	-	-	-	-	-	-	-	(100.12)	(100.12)	
Exchange difference on translation of foreign operations	-	-	-	-	-	-	0.03	-	0.03	
Share based payments	-	-	13.53	-	-	-	-	-	13.53	
On cancellation of ESOP, options and transfer of treasury shares (refer note 42.1 and 42.2)	96.09	-	-	-	-	-	-	-	96.09	
Sale of treasury shares by MHEWT (refer note 42.1 and 42.2)	-	34.36	-	-	-	-	-	-	34.36	
Transferred on account of cancellation of ESOP options (refer note 42.1 and 42.2)	-	-	(34.16)	-	34.16	-	-	-	-	
<b>Balance as at March 31, 2024*</b>	<b>2,665.64</b>	<b>-</b>	<b>1.93</b>	<b>2.80</b>	<b>1,283.18</b>	<b>1.81</b>	<b>(15.48)</b>	<b>71.99</b>	<b>4,011.87</b>	
Profit for the year	-	-	-	-	1,065.35	-	-	16.32	1,081.67	
OCI for the year (net of tax)	-	-	-	-	(4.72)	-	-	(0.44)	(5.16)	
<b>Total comprehensive income</b>	<b>2,665.64</b>	<b>-</b>	<b>1.93</b>	<b>2.80</b>	<b>2,348.53</b>	<b>(2.91)</b>	<b>(15.48)</b>	<b>87.87</b>	<b>5,088.38</b>	
On account of acquisition of subsidiary (refer note 32 a)	-	-	-	-	-	-	-	74.70	74.70	
Acquisition of further interest in subsidiary (refer note 32 a)	-	-	-	-	(17.75)	-	-	(9.58)	(27.33)	
On account of liquidation of step-down subsidiary	-	-	-	-	-	-	-	(0.15)	(0.15)	
Exchange difference on translation of foreign operations	-	-	-	-	-	-	0.09	-	0.09	
Proceeds from right issue (refer note 52)	748.57	-	-	-	-	-	-	-	748.57	
Share based payments	-	-	38.83	-	-	-	-	-	38.83	
<b>Balance as at March 31, 2025</b>	<b>3,414.21</b>	<b>-</b>	<b>40.76</b>	<b>2.80</b>	<b>2,330.78</b>	<b>(2.91)</b>	<b>(15.39)</b>	<b>152.84</b>	<b>5,923.09</b>	

\* Refer note 32 b.

\*\* Refer note 13

\*\*\* Refer note 12.2.7



**Manipal Health Enterprises Private Limited**  
**Consolidated Statement of changes in equity for the year ended March 31, 2025**

Below is the nature and purpose of each reserve:

1. **Securities premium** - Securities premium is used to record the premium received on issue of shares. Also, includes surplus received on sale of treasury shares. However, out of this ₹ 96.09 crores is not free for distribution as it can only be used in accordance with the trust deed's terms and conditions. (refer note 42.1 and 42.2)
2. **Treasury shares** - Represents equity shares of the Company held by the controlled trusts. These are recorded at acquisition cost. As and when treasury shares are transferred to employees on exercise after satisfaction of the vesting condition the balance lying in treasury share reserve is transferred to retained earnings. (refer note 42.1 and 42.2)
3. **Employee stock option outstanding** - Employee stock option outstanding reserve is used to record the fair value of equity-settled share based payment transactions with employees.
4. **General reserve** - General reserve represents appropriation of profits.
5. **Retained earnings** - Retained earnings comprises of prior year and current year's undistributed earnings after tax.
6. **Re-measurement (loss) / gain of defined benefit plans** - Represents re-measurement gains / (losses) on defined benefit plans (net of tax).
7. **Foreign currency translation reserve** - Exchange difference relating to the translation of the results and net assets of the Company's foreign operations from their respective functional currencies to the Company's functional and presentation currency are recognized directly in other comprehensive income and accumulated in the foreign currency translation reserve.

**Material accounting policies (refer note 2.3)**

**The accompanying notes are an integral part of these Consolidated Financial Statements**

As per our report of even date attached

**For BSR & Co. LLP**  
Chartered Accountants

Firm Registration number : 101248W/W - 100022

  
Siddhartha Sharma  
Partner


Membership number: 118756

**For and on behalf of the Board of Directors of  
Manipal Health Enterprises Private Limited**




Dr. H. Sudarshan Ballal  
Chairman & Director  
DIN: 01195055  
Date : May 28, 2025

Dr. H. Sudarshan Ballal  
Chairman & Director  
DIN: 01195055  
Date : May 28, 2025

  
Dilip Jose  
Managing Director & CEO  
DIN: 03591692  
Date : May 30, 2025

Dr. H. Sudarshan Ballal  
Chairman & Director  
DIN: 01195055  
Date : May 28, 2025

  
Sathish Kolar Ramamoorthy  
Company Secretary  
Membership number: A15203  
Date : May 28, 2025

Date : May 30, 2025  
Place : Bengaluru

Date : May 28, 2025  
Place : Bengaluru

**Manipal Health Enterprises Private Limited**  
**Consolidated Statement of Cash Flow for the year ended**

(₹ in crore)

	March 31, 2025	March 31, 2024*
<b>A. Cash flow from operating activities</b>		
<b>Profit before tax</b>	<b>1,242.31</b>	<b>745.00</b>
<b>Adjustments:</b>		
Depreciation and amortisation expense	506.84	397.01
Share based payments	38.83	13.53
Loss on sale of investment in equity instruments	0.39	-
Bad debts written off	118.89	37.58
(Reversal) / Impairment on loan to others	(5.26)	0.30
Loss (reversals) on trade receivables (net)	(31.06)	(3.68)
Loss (reversals) /allowance on other receivables (net)	(0.53)	0.46
Profit on sale of investments in mutual funds (net)	(34.23)	(26.09)
Fair value gain on financial instruments at fair value through profit and loss	(67.25)	(54.07)
Liabilities/ provisions no longer required written back	-	(0.14)
Loss/ (profit) on sale of property, plant and equipment (net)	0.42	(2.37)
Finance income	(14.00)	(6.85)
Impairment of investment	-	114.07
Finance costs	479.99	430.19
(Gain) on lease liability reversal	(1.03)	(1.77)
Unrealised foreign exchange loss	0.98	0.48
<b>Operating profits before working capital changes</b>	<b>2,235.29</b>	<b>1,643.65</b>
<b>Movements in working capital :</b>		
Change in trade receivables	(190.33)	(49.69)
Change in loans	4.33	0.54
Change in other assets	15.19	(6.58)
Change in inventories	(7.70)	(23.09)
Change in other financial assets	(40.41)	(14.63)
Change in trade payables	(163.14)	116.31
Change in provisions	(5.07)	2.49
Change in other liabilities	9.45	10.45
Change in other financial liabilities	2.06	0.50
<b>Cash generated from operations</b>	<b>1,859.67</b>	<b>1,679.95</b>
Income tax paid (net)	(289.85)	(291.35)
<b>Net cash generated from operating activities (A)</b>	<b>1,569.82</b>	<b>1,388.60</b>
<b>B. Cash flow from investing activities</b>		
Acquisition of property, plant and equipment, intangible assets and right-of-use asset	(1,054.28)	(331.91)
Proceeds from sale of property, plant and equipment	4.82	4.96
Investment made in bank deposits (having original maturity of more than three months)	(242.82)	(93.18)
Maturity of bank deposits (having original maturity of more than three months)	189.41	175.59
Investment in equity instruments of a subsidiary (refer note 32 a)	(1,012.86)	-
Investment in equity instruments of other companies	(0.05)	(1.15)
Sale of investments in equity instruments	(0.14)	-
Payment of deferred consideration	-	(5.95)
Acquisition of step-down subsidiary (refer note 32 c)	-	(624.59)
Proceeds from sale of investments in mutual funds and others	4,133.98	3,148.52
Purchase of investments in mutual funds and others	(4,687.04)	(3,150.53)
Interest received	10.65	7.79
<b>Net cash flows used in investing activities (B)</b>	<b>(2,658.33)</b>	<b>(870.45)</b>
<b>C. Cash flow from financing activities</b>		
Proceeds from long-term borrowings	904.78	294.27
Repayment of long-term borrowings	(247.68)	(258.83)
Interest and processing charges paid	(337.17)	(266.32)
Interest paid on loan for purchase of capital asset	(1.31)	(0.96)
Payment of lease liability	(50.21)	(37.84)
Interest on lease liability	(114.33)	(110.85)
Sale of treasury shares by MHEWT net of tax (refer note 42.1 and 42.2)	-	408.36
Payment related to cancellation of ESOP options including tax deducted at source (refer note 42.1 and 42.2)	-	(278.04)
Proceeds from issue of equity shares (refer note 12 and 13)	750.00	-
<b>Net cash flows generated from / (used in) financing activities (C)</b>	<b>904.08</b>	<b>(250.21)</b>



**Manipal Health Enterprises Private Limited**  
**Consolidated Statement of Cash Flow for the year ended**

	(₹ in crore)	
	March 31, 2025	March 31, 2024*
<b>Net (decrease) / increase in cash and cash equivalents (A+B+C)</b>	<b>(184.43)</b>	<b>267.94</b>
Cash and cash equivalents at the beginning of the year	360.88	68.20
Cash and cash equivalents of acquired entities during the year	114.83	24.74
<b>Cash and cash equivalents at the end of the year</b>	<b>291.28</b>	<b>360.88</b>
<b>Components of cash and cash equivalents for the purpose of statement of cash flow</b>		
Cash on hand	4.96	2.98
With banks - on Current accounts	197.57	319.60
- on Deposit accounts	88.75	38.30
<b>Total cash and cash equivalents (refer note 10.3)</b>	<b>291.28</b>	<b>360.88</b>

Refer note 48 for reconciliation of movements of liabilities to cash flows arising from financing activities.

**Material accounting policies (refer note 2.3)**


The above Consolidated Statement of Cash Flow has been prepared under the "Indirect Method" as set out in Indian Accounting Standard-7, "Statement of Cash Flows".

\* Refer note 32 b.

**The accompanying notes are an integral part of these Consolidated Financial Statements**

As per our report of even date attached



**For B S R & Co. LLP**  
Chartered Accountants  
Firm Registration number : 101248W/W - 100022



Siddhartha Sharma  
Partner  
Membership number: 118756


Date : May 30, 2025  
Place : Bengaluru

**For and on behalf of the Board of Directors of**  
**Manipal Health Enterprises Private Limited**



Dilip Jose  
Managing Director & CEO  
DIN: 03591692  
Date : May 30, 2025

Dr. H. Sudarshan Ballal  
Chairman & Director  
DIN: 01195055  
Date : May 28, 2025



Saheer Agarwal  
Chief Financial Officer

Date : May 28, 2025  
Place : Bengaluru



Sathish Kolar Ramanoorthy  
Company Secretary  
Membership number: A15203  
Date : May 28, 2025

1 Corporate information

(a) The Consolidated Financial Statements comprise financial statements of Manipal Health Enterprises Private Limited (the Company or Parent or 'MHE' or 'MHEPL') its subsidiaries, step-down subsidiaries (collectively, the Group) and its Joint Venture and Associate for the year ended March 31, 2025. The Company is a private limited company domiciled in India and incorporated on February 15, 2010 under the provisions of the Companies Act, 1956 applicable in India. The registered office of the Company is located at The Annexe, #98/2, Rustam Bagh Road, HAL Airport Road, Bengaluru, 560017. The Group is engaged in the business of running/managing hospitals, and providing healthcare services. The Group operates through various Hospitals/clinics providing Healthcare services and diagnostic centres, primarily in India.

(b) Investment in subsidiaries:

The entities considered in the Consolidated Financial Statements are listed below:

Name of the Company	Country of Incorporation	Percentage of ownership interest held (directly and indirectly) and voting rights held as at	
		March 31, 2025	March 31, 2024*
Manipal Health Enterprises International Pte. Ltd. ("MHEIPL Singapore") - Subsidiary	Singapore	100.00%	100.00%
Manipal Hospitals (Dwarka) Private Limited ("MHDPL") - Subsidiary (refer point (i) and (ii))	India	100.00%	100.00%
Healthmap Diagnostics Private Limited ("Healthmap") - Subsidiary	India	50.08%	50.08%
Manipal Hospitals Private Limited ("MHPL") - Subsidiary	India	100.00%	100.00%
Manipal Hospitals (Bengaluru) Private Limited ("MHBPL") - Subsidiary	India	100.00%	100.00%
Medcis Pathlabs India Private Limited- Subsidiary of Healthmap **	India	-	50.08%
Manipal Hospitals (East) India Private Limited ("MHEIPL") (formerly known as AMRI Hospitals Private Limited and AMRI Hospitals Limited) - Subsidiary of MHPL (refer point (iii))	India	84.07%	84.07%
Manipal Hospitals Synergie Private Limited ("MHSPL") (formerly known as Medica Synergie Private Limited - Subsidiary (refer point (iv))#	India	84.94%	-
Manipal Hospitals Eastern India Private Limited ("MH Eastern") (formerly known as Medica Hospitals Private Limited - Subsidiary of MHSPL (refer point (v))#	India	84.94%	-
Manipal Hospitals Bengal Private Limited ("MH Bengal") (formerly known North Bengal Clinic Private Limited ('NBCPL') - Subsidiary of MHSPL (refer point (vi))#	India	82.24%	-
North Bengal Oncology Centre Private Limited ('NBOCPL') - Subsidiary of MH Bengal #^	India	-	-

\* Refer note 32 b.

\*\* Medcis Pathlabs India Private Limited was merged with Healthmap. Also, refer note 53

# Refer note 32 a.

^ On March 07, 2025, NBOCPL was voluntarily liquidated and the surplus has been distributed to the contributors/ stakeholders.

Joint venture in which the Company is a joint venture partner

Name of the Company	Country of Incorporation	Percentage of ownership interest held (directly and indirectly) and voting rights held as at	
		March 31, 2025	March 31, 2024
Terrals Technologies Private Limited ('Phable') - Joint Venture	India	20.59%	20.59%

Associate

Name of the Company	Country of Incorporation	Percentage of ownership interest held (directly and indirectly) and voting rights held as at	
		March 31, 2025	March 31, 2024
I-Genetics Diagnostics Private Limited	India	42.17%	42.17%
Medica TS Hospital Private Limited ('Medica TS')#	India	41.62%	-

# Refer note 32 a.

(i) Subsidiaries include a Silo - MHDPL has entered into an arrangement in India which qualifies as a "Silo" i.e. a ring fenced group of assets and liabilities within an entity and accordingly the "Silo" has been considered in the Consolidated Financial Statements.

(ii) The Company had entered into a Joint Management and Collaboration Agreement ("Collaboration Agreement") with Human Care Medical Charitable Trust ("HCMCT") to collaborate for operating and managing multi super specialty hospital being constructed on the HCMCT land in Dwarka, New Delhi.

(iii) Effective May 28, 2024, the name of the company has been changed from AMRI Hospitals Private Limited to Manipal Hospitals (East) India Private Limited.

(iv) Effective November 26, 2024, the name of the company has been changed from Medica Synergie Private Limited to Manipal Hospitals Synergie Private Limited.

(v) Effective November 26, 2024, the name of the company has been changed from Medica Hospitals Private Limited to Manipal Hospitals Eastern India Private Limited.

(vi) Effective November 26, 2024, the name of the company has been changed from North Bengal Clinic Private Limited to Manipal Hospitals Bengal Private Limited.

2.1 Basis of preparation of the Consolidated Financial Statements

(a) Statement of compliance

The Consolidated Financial Statements of the Group have been prepared in accordance with the Indian Accounting Standards ('Ind AS') as per the Companies (Indian Accounting Standards) Rules, 2015, as amended from time to time, notified under section 133 of the Companies Act, 2013 ('Act') and other relevant provisions of the Act.

The Consolidated Financial Statements are presented in Indian Rupees (₹) and all values are rounded to the nearest crores and decimals thereof, except when otherwise indicated.

The Consolidated Financial Statements were approved for issue by the Company's Board of Directors on May 28, 2025.

Details of the material accounting policies are included in Note 2.3.



(b) **Functional and presentation currency**

These Consolidated Financial Statements are presented in Indian Rupees (INR), which is also the Company's functional currency. All amounts are in Indian Rupees crores except share data and per share data, unless otherwise stated.

(c) **Basis of measurement**

The Consolidated Financial Statements have been prepared on the historical cost basis except for the following items:

Items	Measurement
Certain financial assets and liabilities (refer note 33)	Fair value
Net defined asset / liability	Fair value of plan assets less present value of defined benefit obligation

(d) **Use of estimates and judgments**

In preparing these Consolidated Financial Statements, management has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised prospectively.

**Judgements, assumptions and estimation uncertainties**

Information about judgments made in applying accounting policies that have the most significant effects on the amounts recognised in the financial statements is included in the following notes:

**Judgements:**

Note 14.2 - Leases and lease classification

Note 16 - Income taxes including deferred tax

Note 19 and 38 - Provision for Income tax and other contingencies

Note 38 - recognition and measurement of provisions and contingencies; key assumptions about the likelihood and magnitude of an outflow of resources.

**Estimates:**

Note 2.3 (d), (e) and (i) - useful life of property, plant and equipment, intangible assets and right of use assets

Note 6.1, 10.2, 10.5, 10.6 - Impairment of financial assets

Note 15 and 18 - Provisions

Note 25, 31 - Employee benefits expense, wages and bonus; key actuarial assumptions

Note 33 - Financial instruments

Note 42 - Employee Stock option plans

Note 32 - Business combination

Note 4a - Impairment assessment of goodwill

(e) **Measurement of fair values**

The Group's accounting policies and disclosures require the measurement of fair values, for both financial and non-financial assets and liabilities. Fair values are categorised into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows:

- Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level 2: inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).
- Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).

When measuring the fair value of an asset or a liability, the group uses observable market data as far as possible. If the inputs used to measure the fair value of an asset or a liability fall into different levels of the fair value hierarchy, then the fair value measurement is categorised in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire measurement. The group recognises transfers between levels of the fair value hierarchy at the end of the reporting year during which the change has occurred. Further information about the assumptions made in measuring fair values is included in the note 33 and 34 - financial instruments.

**2.2 Basis of consolidation**

The Consolidated Financial Statements comprise the financial statements of the Group as at March 31, 2025. Control is achieved when the Company is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee. Specifically, the Company controls an investee if and only if the Company has:

- (i) Power over the investee (i.e. existing rights that give it the current ability to direct the relevant activities of the investee),
- (ii) Exposure, or rights, to variable returns from its involvement with the investee, and
- (iii) The ability to use its power over the investee to affect its returns.

Generally, there is a presumption that a majority of voting rights result in control. To support this presumption and when the Company has less than a majority of the voting or similar rights of an investee, the Company considers all relevant facts and circumstances in assessing whether it has power over an investee, including:

- (i) The contractual arrangement with the other vote holders of the investee
- (ii) Rights arising from other contractual arrangements
- (iii) The Company's voting rights and potential voting rights
- (iv) The size of the company's holding of voting rights relative to the size and dispersion of the holdings of the other voting rights holders.

The Company re-assesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control. Consolidation of a subsidiary begins when the Company obtains control over the subsidiary and ceases when the Company loses control of the subsidiary. Assets, liabilities, income and expenses of a subsidiary acquired or disposed off during the year are included in the Consolidated Financial Statements from the date the Company gains control until the date the Company ceases to control the subsidiary.

Consolidated Financial Statements are prepared using uniform accounting policies for like transactions and other events in similar circumstances. If a member of the group uses accounting policies other than those adopted in the Consolidated Financial Statements for like transactions and events in similar circumstances, appropriate adjustments are made to that group member's financial statements in preparing the Consolidated Financial Statements to ensure conformity with the group's accounting policies.

The financial statements of all entities used for the purpose of consolidation are drawn up to same reporting date as that of the parent Company, i.e., year ended on 31 March. When the end of the reporting year of the parent is different from that of a subsidiary, the subsidiary prepares, for consolidation purposes, additional financial information as of the same date as the financial statements of the parent to enable the parent to consolidate the financial information of the subsidiary, unless it is impracticable to do so.



#### Consolidation Procedure

- a) Combine like items of assets, liabilities, equity, income, expenses and cash flows of the parent with those of its subsidiaries. For this purpose, income and expenses of the subsidiary are based on the amounts of the assets and liabilities recognised in the Consolidated Financial Statements at the acquisition date.
- b) Offset (eliminate) the carrying amount of the parent's investment in each subsidiary and the parent's portion of equity of each subsidiary. Business combinations policy explains how to account for any related goodwill.
- c) Eliminate in full intragroup assets and liabilities, equity, income, expenses and cash flows relating to transactions between entities of the group (profits or losses resulting from intragroup transactions that are recognised in assets, such as inventory and fixed assets, are eliminated in full). Intragroup losses may indicate an impairment that requires recognition in the Consolidated Financial Statements. Ind AS-12 "Income Taxes" applies to temporary differences that arise from the elimination of profits and losses resulting from intragroup transactions.
- d) Non-controlling interest represents that part of the total comprehensive income and net assets of subsidiaries attributable to interests which are not owned, directly or indirectly, by the parent Group. NCI are measured initially at their proportionate share of the acquiree's identifiable net assets at the date of acquisition.
- (e) The Group's interests in equity-accounted investees comprise interests in associates and a joint venture.

Associates are those entities in which the Group has significant influence, but not control or joint control, over the financial and operating policies. A joint venture is an arrangement in which the Group has joint control, whereby the Group has rights to the net assets of the arrangement, rather than rights to its assets and obligations for its liabilities.

Interests in associates and the joint venture are accounted for using the equity method. They are initially recognised at cost, which includes transaction costs. Subsequent to initial recognition, the Consolidated Financial Statements include the Group's share of the profit or loss and OCI of equity accounted investees, until the date on which significant influence or joint control ceases.

Profit or loss and each component of other comprehensive income (OCI) are attributed to the equity holders of the parent of the Group and to the non-controlling interests, even if this results in the non-controlling interest having a deficit balance. When necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies in line with the Group's accounting policies. All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full on consolidation.

A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as an equity transaction. If the Company loses control over a subsidiary, it:

- (i) Derecognises the assets (including goodwill) and liabilities of the subsidiary
- (ii) Derecognises the carrying amount of any non-controlling interests
- (iii) Derecognises the cumulative translation differences recorded in equity
- (iv) Recognises the fair value of the consideration received
- (v) Recognises the fair value of any investment retained
- (vi) Recognises any surplus or deficit in profit or loss
- (vii) Reclassifies the parent's share of components previously recognised in OCI to profit or loss or retained earnings, as appropriate, as would be required if the Group had directly disposed of the related assets or liabilities.

#### 2.3 Summary of material accounting policies

##### (a) Business combinations and goodwill

Business combinations are accounted for using the acquisition method. The cost of an acquisition is measured as the aggregate of the consideration transferred measured at acquisition date fair value and the amount of any non-controlling interests in the acquiree. For each business combination, the Group elects whether to measure the non-controlling interests in the acquiree at fair value or at the proportionate share of the acquiree's identifiable net assets. Acquisition-related costs are expensed as incurred.

At the acquisition date, the identifiable assets acquired and the liabilities assumed are recognised at their acquisition date fair values. For this purpose, the liabilities assumed include contingent liabilities representing present obligation and they are measured at their acquisition fair values irrespective of the fact that outflow of resources embodying economic benefits is not probable. However, the following assets and liabilities acquired in a business combination are measured at the basis indicated below:

Deferred tax assets or liabilities, and the assets or liabilities related to employee benefit arrangements are recognised and measured in accordance with Ind AS 12 Income Tax and Ind AS 19 Employee Benefits respectively.

When the Group acquires a business, it assesses the financial assets and liabilities assumed for appropriate classification and designation in accordance with the contractual terms, economic circumstances and pertinent conditions as at the acquisition date.

Goodwill on consolidation as on the date of transition represents the excess of cost of acquisition at each point of time of making the investment in the subsidiary over the Group's share in the net worth of a subsidiary. For this purpose, the Group's share of net worth is determined on the basis of the latest financial statements, prior to the acquisition, after making necessary adjustments for material events between the date of such financial statements and the date of respective acquisition. Capital reserve on consolidation represents excess of the Group's share in the net worth of a subsidiary over the cost of acquisition at each point of time of making the investment in the subsidiary. Goodwill arising on consolidation is not amortised, however, it is tested for impairment annually. In the event of cessation of operations of a subsidiary, the unimpaired goodwill is written off fully.

##### Common control transactions

Common control business combinations include transactions, such as transfer of subsidiaries or business, between entities within a group. Business combinations involving entities or business under common control are accounted for using the pooling of interests method. Under pooling of interest method, the assets and liabilities of the combining entities are reflected at their carrying amounts, the only adjustments that are made are to harmonise accounting policies.

Financial information in the Consolidated Financial Statements in respect of prior years are restated as if the business combination had occurred from the beginning of the preceding year in the financial statements, irrespective of the actual date of the combination. However, if business combination had occurred after that date, the prior year information is restated only from that date.

The difference, if any, between the amount recorded as share capital issued plus any additional consideration in the form of cash or other assets and the amount of share capital of the transferor is transferred to reserves and presented separately from other reserves with disclosure of its nature and purpose in the notes.

Assets (or disposal groups) that are classified as held for sale in accordance with Ind AS 105 Non-current Assets Held for Sale and Discontinued Operations are measured in accordance with that Standard.

##### (b) Investment in joint venture/ associate

A joint venture is a type of joint arrangement whereby the parties that have joint control of the arrangement/entity have rights to the net assets of the joint venture. Joint control is the contractually agreed sharing of control of an arrangement, which exists only when decisions about the relevant activities require unanimous consent of the parties sharing control.



The investments in subsidiaries, associates and Joint ventures are carried at cost as per Ind AS 27 (Separate financial statements). Investment accounted for at cost is accounted for in accordance with Ind AS 105 (Non-current assets held for sale and discontinued operations) when they are classified as held for sale and Investment carried at cost is tested for impairment as per Ind AS 36 (Impairment of assets). On disposal of investment, the difference between its carrying amount and net disposal proceeds is charged or credited to the statement of profit and loss.

The Group's investment in its joint venture/ associate is accounted for using the equity method. Under the equity method, the investment in a joint venture/ associate is initially recognised at cost. The carrying amount of the investment is adjusted to recognise changes in the Group's share of net assets of the joint venture/ associate since the acquisition date.

The statement of profit and loss reflects the Group's share of the results of operations of the joint venture/ associate. Any change in OCI of this investee is presented as part of the Group's OCI. In addition, when there has been a change recognised directly in the equity of the joint venture/ associate, the Group recognises its share of any changes, when applicable, in the statement of changes in equity. Unrealised gains and losses resulting from transactions between the Group and the joint venture/ associate are eliminated to the extent of the interest in the joint venture/ associate.

If an entity's share of losses of a joint venture/ associate equals or exceeds its interest in the joint venture (which includes any long term interest that, in substance, forms part of the Group's net investment in the joint venture/ associate), the entity discontinues recognising its share of further losses. Additional losses are recognised only to the extent that the Group has incurred legal or constructive obligations or made payments on behalf of the joint venture/ associate. If the joint venture/ associate subsequently reports profits, the entity resumes recognising its share of those profits only after its share of the profits equals the share of losses not recognised.

The aggregate of the Group's share of profit or loss of a joint venture/ associate is shown on the face of the statement of profit and loss.

The financial statements of the joint venture/ associate are prepared for the same reporting year as the Group. When necessary, adjustments are made to bring the accounting policies in line with those of the Group.

After application of the equity method, the Group determines whether it is necessary to recognise an impairment loss on its investment in its joint venture/ associate. At each reporting date, the Group determines whether there is objective evidence that the investment in the joint venture/ associate is impaired. If there is such evidence, the Group calculates the amount of impairment as the difference between the recoverable amount of the joint venture/ associate and its carrying value, and then recognises the loss as 'Share of profit of a joint venture/ associate' in the statement of profit or loss.

Upon loss of control over the joint venture/ associate, the Group measures and recognises any retained investment at its fair value. Any difference between the carrying amount of the joint venture/ associate upon loss of control and the fair value of the retained investment and proceeds from disposal is recognised in profit or loss.

**(c) Current versus non-current classification**

The Group presents assets and liabilities in the balance sheet based on current/non-current classification. An asset is treated as current when it is:

- Expected to be realised or intended to be sold or consumed in the normal operating cycle.
- Held primarily for the purpose of trading
- Expected to be realised within twelve months after the reporting year, or
- Cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting year

All other assets are classified as non-current.

A liability is treated as current when :

- It is expected to be settled in the normal operating cycle
- It is held primarily for the purpose of trading
- It is due to be settled within twelve months after the reporting year, or
- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting year.

The Group classifies all other liabilities as non-current.

Deferred tax assets and liabilities are classified as non-current assets and liabilities.

The operating cycle is the time between the acquisition of assets for processing and their realisation in cash and cash equivalents. The Group has identified twelve months as its operating cycle.

**(d) Property plant and equipment**

Property, plant and equipment is stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. The cost comprises purchase price, cost of replacing part of the plant and equipment, borrowing costs if the recognition criteria are met and directly attributable cost of bringing the asset to its location and condition necessary for the intended use. Any trade discounts and rebates are deducted in arriving at the purchase price. When significant parts of plant and equipment are required to be replaced at intervals, the Group depreciates them separately based on their specific useful lives. Likewise, when a major inspection is performed, its cost is recognised in the carrying amount of the plant and equipment as a replacement if the recognition criteria are satisfied. All other repair and maintenance costs are recognised in statement of profit and loss as incurred. The present value of the expected cost for the decommissioning of an asset after its use is included in the cost of the respective asset if the recognition criteria for a provision are met.

An item of property, plant and equipment and any significant part initially recognised is derecognised upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the statement of profit and loss when the asset is derecognised.

Subsequent expenditure is capitalised only if it is probable that the future economic benefits associated with the expenditure will flow to the Group and the cost of the item can be measured reliably.

Property, plant and equipment under installation or construction as at the balance sheet date are shown as capital work-in-progress and the related advances are shown as under Non current assets.

On transition to Ind AS (i.e. April 01, 2015), the Company has elected to continue with the carrying value of all Property, plant and equipment measured as per the previous GAAP and use that carrying value as the deemed cost of Property, plant and equipment.

Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets as follows:

<u>Category of assets</u>	<u>Useful life estimated by management</u>	<u>Useful life as per Schedule II</u>
Building	18-60 years	30 years
Equipments	13 years	10 - 15 years
Electrical installations	7 years	10 years
Furniture and fixtures	7 years	10 years
Other fixtures (included in Building)	2 years	10 years
Computers	3 years	3 - 6 years
Vehicles	3-7 years	6 - 10 years

Leasehold land is amortised over the remaining lease year (refer note 3.1)

Depreciation on additions (disposals) is provided on a pro-rata basis i.e. from (upto) the date on which asset is ready for use (disposed of).

Second hand assets are depreciated over the estimated useful life as per technical estimates.



Leasehold land/Leasehold improvements/Leasehold Building are depreciated over the primary lease period or useful life, whichever is shorter, on a straight-line basis.

The residual values, useful lives and methods of depreciation of property, plant and equipment are reviewed at each financial year end and adjusted prospectively, if appropriate.

Assets having the value upto ₹10,000 is fully depreciated in the year in which it is depreciated.

The management had estimated, supported by technical advice, the useful life of the category of assets, which are lower than those indicated in Schedule II to the Companies Act, 2013. The management believes that these estimated useful lives are realistic and reflect fair approximation of the year over which the assets are likely to be used.

**(e) Intangible assets**

Intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is their fair value at the date of acquisition. Following initial recognition, intangible assets are carried at cost less accumulated amortization and accumulated impairment losses, if any.

The useful lives of intangible assets are assessed as either finite or indefinite.

Intangible assets with finite lives are amortised over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortisation year and the amortisation method for an intangible asset with a finite useful life are reviewed at least at the end of each reporting year. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are considered to modify the amortisation year or method, as appropriate, and are treated as changes in accounting estimates. The amortisation expense on intangible assets with finite lives is recognised in the statement of profit and loss unless such expenditure forms part of carrying value of another asset.

Intangible assets with indefinite useful lives are not amortised, but are tested for impairment annually, either individually or at the cash-generating unit level. The assessment of indefinite life is reviewed annually to determine whether the indefinite life continues to be supportable. If not, the change in useful life from indefinite to finite is made on a prospective basis.

Gains or losses arising from derecognition of an intangible asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognised in the statement of profit or loss when the asset is derecognised.

Subsequent expenditure is capitalised only when it increases the future economic benefits embodied in the specific asset to which it relates. All other expenditure, including expenditure on internally generated goodwill and brands, is recognised in profit or loss as incurred.

A summary of amortization policies applied to the Group's intangible assets is as below:

<u>Category of assets</u>	<u>Useful life estimated by management</u>
Computer software - application	3-5 years
Computer software - generic	1 year
Customer contract	10-12 years
Non-compete fees	2-5 years

**(f) Impairment of non-financial assets**

Except for deferred tax assets and inventory, the Group assesses, at each reporting date, whether there is an indication that an asset may be impaired. If any indication exists, or when annual impairment testing for an asset is required, the Group estimates the asset's recoverable amount. An asset's recoverable amount is the higher of an asset's or cash-generating unit's (CGU) fair value less costs of disposal and its value in use. The recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets. Where the carrying amount of an asset or CGU exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount.

In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. In determining fair value less costs of disposal, recent market transactions are taken into account. If no such transactions can be identified, an appropriate valuation model is used.

The Group bases its impairment calculation on detailed budgets and forecast calculations, which are prepared separately for each of the Group's CGUs to which the individual assets are allocated. These budgets and forecast calculations generally cover a period of ten years. For longer years, a long term growth rate is calculated and applied to project future cash flows till perpetuity.

For impairment testing, assets are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or CGUs. Goodwill arising from a business combination is allocated to CGUs or groups of CGUs that are expected to benefit from the synergies of the combination.

Impairment losses of continuing operations, including impairment of inventories, are recognised in the statement of profit and loss.

For assets excluding goodwill, an assessment is made at each reporting date to determine whether there is an indication that previously recognised impairment losses no longer exist or have decreased. If such indication exists, the Group estimates the asset's or CGU's recoverable amount. A previously recognised impairment loss is reversed only if there has been a change in the assumptions used to determine the asset's recoverable amount since the last impairment loss was recognised. The reversal is limited so that the carrying amount of the asset does not exceed its recoverable amount, nor exceed the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognised for the asset in prior years. Such reversal is recognised in the statement of profit and loss.

Goodwill is tested for impairment annually and when circumstances indicate that the carrying value may be impaired. Impairment is determined for goodwill by assessing the recoverable amount of each CGU (or group of CGUs) to which the goodwill relates. When the recoverable amount of the CGU is less than its carrying amount, an impairment loss is recognised. They are allocated first to reduce the carrying amount of any goodwill allocated to the CGU, and then to reduce the carrying amounts of the assets in the CGU on a pro rata basis. Impairment losses relating to goodwill cannot be reversed in future years.

Intangible assets with indefinite useful lives are tested for impairment annually as at 31 March at the CGU level, as appropriate, and when circumstances indicate that the carrying value may be impaired.

**(g) Non-current assets or disposal group held for sale**

Non-current assets, or disposal groups comprising assets and liabilities, are classified as held for sale if it is highly probable that they will be recovered primarily through sale rather than through continuing use.

Such assets, or disposal groups, are generally measured at the lower of their carrying amount and fair value less costs to sell.

Any impairment loss on a disposal group is allocated first to goodwill, and then to the remaining assets and liabilities on a pro rata basis, except that no loss is allocated to inventories, financial assets, deferred tax assets, employee benefit assets, investment property or biological assets, which continue to be measured in accordance with the Group's other accounting policies.

Impairment losses on initial classification as held for sale or held for distribution and subsequent gains and losses on remeasurement are recognised in profit or loss.

Once classified as held for sale, intangible assets, property, plant and equipment and investment properties are no longer amortised or depreciated, and equity-accounted investee is no longer equity accounted.

Non-current assets classified as held-for-sale and the assets of a disposal group classified as held for sale are presented separately from the other assets in the balance sheet. The liabilities of a disposal group classified as held for sale are presented separately from other liabilities in the balance sheet.



(h) **Borrowing Cost**

Borrowing costs directly attributable to the acquisition, construction or production of an asset that necessarily takes a substantial year of time to get ready for its intended use or sale are capitalised as part of the cost of the asset. All other borrowing costs are expensed in the year in which they occur. Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds. Borrowing cost also includes exchange differences to the extent regarded as an adjustment to the borrowing costs.

(i) **Leases**

A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a year of time in exchange for consideration.

**Company as a lessee**

The Company accounts for each lease component within the contract as a lease separately from non-lease components of the contract and allocates the consideration in the contract to each lease component on the basis of the relative stand-alone price of the lease component and the aggregate stand-alone price of the non-lease components.

The Company recognises right-of-use asset representing its right to use the underlying asset for the lease term at the lease commencement date. The cost of the right-of-use asset measured at inception shall comprise of the amount of the initial measurement of the lease liability adjusted for any lease payments made at or before the commencement date less any lease incentives received, plus any initial direct costs incurred and an estimate of costs to be incurred by the lessee in dismantling and removing the underlying asset or restoring the underlying asset or site on which it is located. The right-of-use assets is subsequently measured at cost less any accumulated depreciation, accumulated impairment losses, if any and adjusted for any re-measurement of the lease liability. The right-of-use assets is depreciated using the straight-line method from the commencement date over the shorter of lease term or useful life of right-of-use asset. If ownership of the leased asset transfers to the Company at the end of the lease term or the cost reflects the exercise of a purchase option, depreciation is calculated using the estimated useful life of the asset. Right-of-use assets are tested for impairment whenever there is any indication that their carrying amounts may not be recoverable. Impairment loss, if any, is recognised in the statement of profit and loss.

At the commencement date of the lease, the Company recognises lease liabilities measured at the present value of lease payments to be made over the lease term. The lease payments are discounted using the interest rate implicit in the lease, if that rate can be readily determined. If that rate cannot be readily determined, the Company uses incremental borrowing rate. The lease payments shall include fixed payments, variable lease payments, residual value guarantees, exercise price of a purchase option where the Company is reasonably certain to exercise that option and payments of penalties for terminating the lease, if the lease term reflects the lessee exercising an option to terminate the lease. The lease liability is subsequently re-measured by increasing the carrying amount to reflect interest on the lease liability, reducing the carrying amount to reflect the lease payments made and re-measuring the carrying amount to reflect any reassessment or lease modifications or to reflect revised in-substance fixed lease payments. The Company recognises the amount of the re-measurement of lease liability due to modification as an adjustment to the right-of-use asset and statement of profit and loss depending upon the nature of modification. Where the carrying amount of the right-of-use asset is reduced to zero and there is a further reduction in the measurement of the lease liability, the Company recognises any remaining amount of the re-measurement in statement of profit and loss.

The Company had elected not to apply the requirements of Ind AS 116 Leases to short term leases of all assets that have a lease term of 12 months or less, except where it anticipates renewals and leases for which the underlying asset is of low value. The lease payments associated with these leases are recognised as an expense on a straight-line basis over the lease term.

**Company as a lessor**

At the inception of the lease the Company classifies each of its leases as either an operating lease or a finance lease. The Company recognises lease payments received under operating leases as income on a straight-line basis over the lease term. In case of a finance lease, finance income is recognised over the lease term based on a pattern reflecting a constant yearly rate of return on the lessor's net investment in the lease.

If an arrangement contains lease and non-lease components, the Company applies Ind AS 115 Revenue from contracts with customers to allocate the consideration in the contract.

(i) **Financial Instruments**

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

**Financial assets**

**Initial recognition and measurement**

Financial assets are classified, at initial recognition, as subsequently measured at amortised cost, fair value through other comprehensive income (OCI), and fair value through profit or loss.

The classification of financial assets at initial recognition depends on the financial asset's contractual cash flow characteristics and the Company's business model for managing them. With the exception of trade receivables that do not contain a significant financing component or for which the Company has applied the practical expedient, the Company initially measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss, transaction costs. Trade receivables that do not contain a significant financing component or for which the Company has applied the practical expedient are measured at the transaction price determined under Ind AS 115. Refer to the accounting policies in section (I) Revenue from contracts with customers.

In order for a financial asset to be classified and measured at amortised cost or fair value through OCI, it needs to give rise to cash flows that are 'solely payments of principal and interest (SPPI)' on the principal amount outstanding. This assessment is referred to as the SPPI test and is performed at an instrument level. Financial assets with cash flows that are not SPPI are classified and measured at fair value through profit or loss, irrespective of the business model.

The Company's business model for managing financial assets refers to how it manages its financial assets in order to generate cash flows. The business model determines whether cash flows will result from collecting contractual cash flows, selling the financial assets, or both. Financial assets classified and measured at amortised cost are held within a business model with the objective to hold financial assets in order to collect contractual cash flows while financial assets classified and measured at fair value through OCI are held within a business model with the objective of both holding to collect contractual cash flows and selling.

Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the marketplace (regular way trades) are recognised on the trade date, i.e., the date that the Company commits to purchase or sell the asset.

**Subsequent measurement**

For purposes of subsequent measurement, financial assets are classified in four categories:

- i) Financial assets at amortised cost (debt instruments)
- ii) Financial assets at fair value through other comprehensive income (FVTOCI) with recycling of cumulative gains and losses (debt instruments)
- iii) Financial assets designated at fair value through OCI with no recycling of cumulative gains and losses upon derecognition (equity instruments)
- iv) Financial assets at fair value through profit or loss

**Financial assets at amortised cost (debt instruments)**

A 'financial asset' is measured at the amortised cost if both the following conditions are met:

- a) The asset is held within a business model whose objective is to hold assets for collecting contractual cash flows, and
- b) Contractual terms of the asset give rise to cash flows that are solely payments of principal and interest (SPPI) on the principal amount outstanding.

This category is the most relevant to the Company. After initial measurement, such financial assets are subsequently measured at amortised cost using the effective interest rate (EIR) method. Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included in finance income in the profit or loss. The losses arising from impairment are recognised in the profit or loss. The Company's financial assets at amortised cost includes trade receivables, and loan to an associate and loan to a director included under other non-current financial assets. For more information on receivables, refer to Note 10.2.



#### Financial assets at fair value through profit or loss

Financial assets at fair value through profit or loss are carried in the balance sheet at fair value with net changes in fair value recognised in the statement of profit and loss.

This category includes derivative instruments and listed equity investments which the Company had not irrevocably elected to classify at fair value through OCI. Dividends on listed equity investments are recognised in the statement of profit and loss when the right of payment has been established.

#### Derecognition

A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognised (i.e. removed from the Company's consolidated balance sheet) when:

- i) The rights to receive cash flows from the asset have expired, or
- ii) The Company has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a 'pass-through' arrangement; and either (a) the Company has transferred substantially all the risks and rewards of the asset, or (b) the Company has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

When the Company has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates if and to what extent it has retained the risks and rewards of ownership. When it has neither transferred nor retained substantially all of the risks and rewards of the asset, nor transferred control of the asset, the Company continues to recognise the transferred asset to the extent of the Company's continuing involvement. In that case, the Company also recognises an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Company has retained.

Continuing involvement that takes the form of a guarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the maximum amount of consideration that the Company could be required to repay.

#### Impairment of financial assets

The Company recognises an allowance for expected credit losses (ECLs) for all debt instruments not held at fair value through profit or loss. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive, discounted at an approximation of the original effective interest rate. The expected cash flows will include cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.

ECLs are recognised in two stages. For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided for credit losses that result from default events that are possible within the next 12-months (a 12-month ECL). For those credit exposures for which there has been a significant increase in credit risk since initial recognition, a loss allowance is required for credit losses expected over the remaining life of the exposure, irrespective of the timing of the default (a lifetime ECL).

For trade receivables and other financial assets, the Company applies a simplified approach in calculating ECLs. Therefore, the Company does not track changes in credit risk, but instead recognises a loss allowance based on lifetime ECLs at each reporting date. The Company has established a provision matrix that is based on its historical credit loss experience, adjusted for forward-looking factors specific to the debtors and the economic environment.

The Company considers a financial asset in default when contractual payments are 90 days past due. However, in certain cases, the Company may also consider a financial asset to be in default when internal or external information indicates that the Company is unlikely to receive the outstanding contractual amounts in full before taking into account any credit enhancements held by the Company. A financial asset is written off when there is no reasonable expectation of recovering the contractual cash flows.

#### Financial liabilities

##### Initial recognition and measurement

Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss, loans and borrowings, payables, or as derivatives designated as hedging instruments in an effective hedge, as appropriate.

All financial liabilities are recognised initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.

The Company's financial liabilities include trade and other payables, loans and borrowings including bank overdrafts, financial guarantee contracts and derivative financial instruments.

##### Subsequent measurement

For purposes of subsequent measurement, financial liabilities are classified in two categories:

- Financial liabilities at fair value through profit or loss
- Financial liabilities at amortised cost (loans and borrowings)

##### Financial liabilities at fair value through profit or loss

Financial liabilities at fair value through profit or loss include financial liabilities held for trading and financial liabilities designated upon initial recognition as at fair value through profit or loss.

Financial liabilities are classified as held for trading if they are incurred for the purpose of repurchasing in the near term. This category also includes derivative financial instruments entered into by the Company that are not designated as hedging instruments in hedge relationships as defined by Ind AS 109. Separated embedded derivatives are also classified as held for trading unless they are designated as effective hedging instruments.

Gains or losses on liabilities held for trading are recognised in the profit or loss.

Financial liabilities designated upon initial recognition at fair value through profit or loss are designated as such at the initial date of recognition, and only if the criteria in Ind AS 109 are satisfied. For liabilities designated as FVTPL, fair value gains/ losses attributable to changes in own credit risk are recognized in OCI. These gains/ losses are not subsequently transferred to P&L. However, the Company may transfer the cumulative gain or loss within equity. All other changes in fair value of such liability are recognised in the statement of profit and loss. The Company has not designated any financial liability as at fair value through profit or loss.

##### Financial liabilities at amortised cost (Loans and borrowings)

This is the category most relevant to the Company. After initial recognition, interest-bearing loans and borrowings are subsequently measured at amortised cost using the EIR method. Gains and losses are recognised in profit or loss when the liabilities are derecognised as well as through the EIR amortisation process.

Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included as finance costs in the statement of profit and loss.

This category generally applies to borrowings.



#### Financial guarantee contracts

Financial guarantee contracts issued by the Company are those contracts that require a payment to be made to reimburse the holder for a loss it incurs because the specified debtor fails to make a payment when due in accordance with the terms of a debt instrument. Financial guarantee contracts are recognised initially as a liability at fair value, adjusted for transaction costs that are directly attributable to the issuance of the guarantee. Subsequently, the liability is measured at the higher of the amount of loss allowance determined as per impairment requirements of Ind AS 109 and the amount recognised less, when appropriate, the cumulative amount of income recognised in accordance with the principles of Ind AS 115.

#### Derecognition

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognised in the statement of profit and loss.

#### Offsetting of financial instruments

Financial assets and financial liabilities are offset and the net amount is reported in the consolidated balance sheet if there is a currently enforceable legal right to offset the recognised amounts and there is an intention to settle on a net basis, to realise the assets and settle the liabilities simultaneously.

#### (k) Inventories

Inventories of pharmacy items and medical consumables are valued at lower of cost or net realizable value. The comparison of cost and net realisable value is made on an item-by-item basis. Cost of these inventories comprises of all costs of purchase and other costs incurred in bringing the inventories to their present location after adjusting for Goods and Service Tax wherever applicable, applying the first in first out basis.

Net realisable value is the estimated selling price in the ordinary course of business, less estimated costs to be incurred to make the sale. Adequate provision is made for slow moving, non-moving and expired inventory, as determined necessary.

#### (l) Total Income

##### (i) Revenue recognition

Revenue from contracts with customers is recognised as per Ind AS 115, "Revenue from contract with customers", when control of the goods or services are transferred to the customer at an amount that reflects the consideration to which the Group expects to be entitled in exchange for those goods or services, taking into consideration defined terms of payment and excluding taxes or duties collected on behalf of the government.

##### Disaggregation of revenue

The Group disaggregates revenue into revenue from rendering hospital services, pharmacy sales and other operating income. The Group believes that this disaggregation best depicts how the nature, amount, timing and uncertainty of Group's revenues and cash flows are affected by industry, market and other economic factors.

##### Operating Income

Revenue from Hospital services is recognised as and when the services are performed, unless significant future uncertainties exists, while revenue from sale of pharmacy items is recognised when the control of the goods have passed to the buyer, usually on delivery of the goods. The Group assesses the distinct performance obligations in the contract and measures to at an amount that reflects the consideration it expects to receive, net of Goods and Services Tax and adjusted for discounts and concessions.

Management fee from hospital management agreement with entities is recognised as and when the services are rendered as per the terms of the agreement.

Income from occupational health centre and ambulance service are recorded as and when rendered.

##### Contract balances

##### Trade receivables

Unbilled revenue represents the Group's right to an amount of consideration that is unconditional (i.e., only the passage of time is required before payment of the consideration is due). Refer to accounting policies of financial assets in section (i) Financial instruments – initial recognition and subsequent measurement.

##### Contract liabilities

A contract liability is the obligation to transfer goods or services to a customer for which the Group has received consideration (or an amount of consideration is due) from the customer. If a customer pays consideration before the Group transfers goods or services to the customer, a contract liability is recognised when the payment is made or the payment is due (whichever is earlier). Contract liabilities are recognised as revenue when the Group performs under the contract.

##### (ii) Other income

##### Interest Income

For all debt instruments measured at amortised cost, interest income is recorded using the effective interest rate (EIR). EIR is the rate that exactly discounts the estimated future cash payments or receipts over the expected life of the financial instrument or a shorter year, where appropriate, to the gross carrying amount of the financial asset or to the amortised cost of a financial liability. When calculating the effective interest rate, the Group estimates the expected cash flows by considering all the contractual terms of the financial instrument (for example, prepayment, extension) but does not consider the expected credit losses. Interest income is included in finance income in the statement of profit and loss.

Interest income is recognized on a time proportion basis taking into account the amount outstanding and the applicable interest rate. Interest income is included under the head "finance income" in the statement of profit and loss.

##### Rental Income

Rental Income is recognised on an accrual basis and over the year of tenancy.

##### Dividend income

Dividend income is recognized when the Group's right to receive dividend is established by the reporting date.

#### (m) Foreign currencies

The Group's Consolidated Financial Statements are presented in INR, which is also the parent Company's functional currency. For each entity the Group determines the functional currency and items included in the financial statements of each entity are measured using that functional currency. The Group uses the direct method of consolidation and on disposal of a foreign operation the gain or loss that is reclassified to profit or loss reflects the amount that arises from using this method.

Items included in the Consolidated Financial Statements of the Group are measured using the currency of the primary economic environment in which the entity operates (i.e. the "functional currency"). The Group's financial statements are presented in Indian Rupee, which is also the Group's functional and presentation currency.



*Transactions and balances*

Transactions in foreign currencies are initially recorded by the Group's entities at their respective functional currency spot rates at the date the transaction first qualifies for recognition. However, for practical reasons, the group uses an average rate if the average approximates the actual rate at the date of the transaction.

Monetary assets and liabilities denominated in foreign currencies are translated at the functional currency spot rates of exchange at the reporting date.

Exchange differences arising on the settlement or translation of monetary items are recognised in the statement of profit or loss.

Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates at the dates of the initial transactions. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value is determined. The gain or loss arising on translation of non-monetary items measured at fair value is treated in line with the recognition of the gain or loss on the change in fair value of the item (i.e., translation differences on items whose fair value gain or loss is recognised in OCI or profit or loss are also recognised in OCI or profit or loss, respectively).

On consolidation, the assets and liabilities of foreign operations are translated into INR at the rate of exchange prevailing at the reporting date and their statements of profit or loss are translated at exchange rates prevailing at the dates of the transactions. For practical reasons, the group uses an average rate to translate income and expense items, if the average rate approximates the exchange rates at the dates of the transactions. The exchange differences arising on translation for consolidation are recognised in OCI. On disposal of a foreign operation, the component of OCI relating to that particular foreign operation is recognised in profit or loss.

(n) **Retirement and other employee benefits**

In respect of Companies incorporated in India

Defined contribution plan

Retirement benefit in the form of Provident Fund and Pension Fund are defined contribution schemes. The Group recognizes contribution payable to the schemes as an expense, when an employee renders the related service. The Group has no obligation, other than the contribution payable to the fund.

Defined benefit plan - gratuity

The Group operates a defined benefit plan for its employees for gratuity. The costs of providing benefits under this plan is determined on the basis of actuarial valuation at each year end using the projected unit credit method.

Remeasurements, comprising of actuarial gains and losses, excluding amounts included in interest on the defined benefit liability, are recognised immediately in the balance sheet with a corresponding debit or credit to retained earnings through OCI in the year in which they occur. Remeasurements are not reclassified to the statement of profit and loss in subsequent years.

Past service costs are recognised in the statement of profit or loss on the earlier of:

- The date of the plan amendment or curtailment, and
- The date that the Group recognises related restructuring costs

Interest is calculated by applying the discount rate to the defined benefit liability. The Group recognises the following changes in the defined benefit obligation as an expense in the statement of profit and loss:

- (i) Service costs comprising current service costs, past-service costs, gains and losses on curtailments and non-routine settlements, and
- (ii) Interest expense

Other long-term employee benefits - compensated absences

Accumulated leave, which is expected to be utilized within the next 12 months, is treated as short-term employee benefit. The Group measures the expected cost of such absences as the additional amount that it expects to pay as a result of the unused entitlement that has accumulated at the reporting date.

The Group treats accumulated leave expected to be carried forward beyond twelve months, as long-term employee benefit for measurement purposes. Such long-term compensated absences are provided for, based on the actuarial valuation using the projected unit credit method at the year-end. The Group presents the entire leave as a current liability in the balance sheet, since it does not have an unconditional right to defer its settlement beyond 12 months after the reporting date.

The Group recognizes termination benefit as a liability and an expense when the group has a present obligation as a result of past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. If the termination benefits fall due more than 12 months after the balance sheet date, they are measured at present value of future cash flows using the discount rate determined by reference to market yields at the balance sheet date on government bonds.

In respect of Companies incorporated outside India

Wages, salaries, bonuses and social security contributions are recognised as an expense in the financial year in which the associated services are rendered by employees. Short term accumulating compensated absences such as paid annual leave are recognised when services are rendered by employees that increase their entitlement to future compensated absence. Short term non-accumulating compensated absences such as sick leave are recognised when the absences occur.

(o) **Taxes**

Current income tax

Current income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities in. The tax rates and tax laws used to compute the amounts are those that are enacted or substantively enacted, at the reporting date in the countries where the Group operates and generates taxable income. Current income tax relating to items recognised outside the statement of profit and loss is recognised outside the statement of profit and loss (either in OCI or in equity). Current tax items are recognised in correlation to the underlying transaction either in OCI or directly in equity. Management yearly evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.

Deferred tax

Deferred tax is provided using the liability method on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date.

Deferred tax liabilities are recognised for all taxable temporary differences except:

- where deferred tax liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss.
- In respect of taxable temporary differences associated with investments in subsidiaries, associates and interests in joint ventures, when the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future



Deferred tax assets are recognised for all deductible temporary differences, the carry forward of unused tax credits and any unused tax losses. Deferred tax assets are recognised to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilised, except:

- When the deferred tax asset relating to the deductible temporary difference arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss
- In respect of deductible temporary differences associated with investments in subsidiaries, associates and interests in joint ventures, deferred tax assets are recognised only to the extent that it is probable that the temporary differences will reverse in the foreseeable future and taxable profit will be available against which the temporary differences can be utilised

The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilised. Unrecognised deferred tax assets are re-assessed at each reporting date and are recognised to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realised or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date.

Deferred tax relating to items recognised outside the statement of profit or loss is recognised outside the statement of profit or loss (either in OCI or in equity). Deferred tax items are recognised in correlation to the underlying transaction either in OCI or directly in equity.

Deferred tax assets and deferred tax liabilities are offset, if a legally enforceable right exists to set-off current tax assets against current tax liabilities and the deferred tax assets and deferred taxes relate to the same taxable entity and to the same taxation authority.

#### Goods and Services Tax (GST) paid on acquisition of assets or on incurring expenses

Expenses and assets are recognised net of the amount of GST paid, except:

When the tax incurred on a purchase of assets or services is not recoverable from the taxation authority, in which case, the tax paid is recognised as part of the cost of acquisition of the asset or as part of the expense item, as applicable

When receivables and payables are stated with the amount of tax included, the net amount of tax recoverable from, or payable to, the taxation authority is included as part of receivables or payables in the balance sheet.

#### (p) Share based payments ('ESOP') \*

Employees (including senior executives and directors) of the Group receive remuneration in the form of share-based payments, whereby employees render services as consideration for equity instruments (equity-settled transactions)

##### *Equity-settled transactions*

The cost of equity-settled transactions is determined by the fair value at the date when the grant is made using an appropriate valuation model. That cost is recognised, together with a corresponding increase in share option outstanding account in equity, over the year in which the performance and/or service conditions are fulfilled in employee benefits expense. The cumulative expense recognised for equity-settled transactions at each reporting date until the vesting date reflects the extent to which the vesting year has expired and the Group's best estimate of the number of equity instruments that will ultimately vest. The statement of profit and loss expense or credit for a year represents the movement in cumulative expense recognised as at the beginning and end of that year and is recognised in employee benefits expense.

Service and non-market performance conditions are not taken into account when determining the grant date fair value of awards, but the likelihood of the conditions being met is assessed as part of the Group's best estimate of the number of equity instruments that will ultimately vest. Market performance conditions are reflected within the grant date fair value. Any other conditions attached to an award, but without an associated service requirement, are considered to be non-vesting conditions. Non-vesting conditions are reflected in the fair value of an award and lead to an immediate expensing of an award unless there are also service and/or performance conditions.

The vesting needs to be done as per defined in the Grant Letter. There will be two categories of the vesting rights:

**Time options** - This will be vested on time basis subject to meeting the terms and conditions mentioned in the Employment Letter.

**Performance options** - The performance options vesting will be done on achievement of the performance figures as per the budget approved by the board of the previous year of the Company. In case, the same has not been achieved there will be no grant under this for that year. However, there will be a catch up year of one year wherein if the shortfall of the previous year is made up, then the options will be vested of the previous year.

No expense is recognised for awards that do not ultimately vest because non-market performance and/or service conditions have not been met. Where awards include a market or non-vesting condition, the transactions are treated as vested irrespective of whether the market or non-vesting condition is satisfied, provided that all other performance and/or service conditions are satisfied.

In case, the amount of the liability recognised on the date of modification is greater than the amount previously recognised as an increase in equity, the Group is following the accounting policy to recognise such excess as an expense in the statement of profit or loss at the date of modification.

The dilutive effect of outstanding options is reflected as additional share dilution in the computation of diluted earnings per share.

\*Refer note 42

#### (q) Earnings Per Share (EPS)

Basic EPS amounts are calculated by dividing the net profit/(loss) for the year attributable to equity shareholders (after deducting preference dividends and attributable taxes) by the weighted average number of equity shares outstanding during the year. The weighted average number of equity shares outstanding during the year is adjusted for events such as bonus issue, bonus element in a rights issue, share split, and reverse share split (consolidation of shares) that have changed the number of equity shares outstanding, without a corresponding change in resources.

For the purpose of calculating diluted earnings per share, the net profit/(loss) for the year attributable to equity shareholders and the weighted average number of shares outstanding during the year are adjusted for the effects of all dilutive potential equity shares.

Basic earnings per share is computed using the weighted average number of equity shares outstanding during the year adjusted for treasury shares held. Diluted earnings per share is computed using the weighted-average number of equity and dilutive equivalent shares outstanding during the year, using the treasury stock method for options and warrants, except where the results would be antidilutive.



(r) Provisions

Provision are recognized when the Group has a present obligation (legal or constructive) as a result of past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Where the Group expects some or all of a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when the reimbursement is virtually certain. The expense relating to any provision is presented in the statement of profit or loss net off any reimbursement

If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, when appropriate, the risks specific to the liability. When discounting is used, the increase in the provision due to the passage of time is recognised as a finance cost. These estimates are reviewed at each reporting date and adjusted to reflect the current best estimates.

*Decommissioning liability*

The Group records a provision for decommissioning costs to dismantle and remove the leasehold improvements from the leased premise. Decommissioning costs are provided at the present value of expected costs to settle the obligation using estimated cash flows and are recognised as part of the cost of the particular asset. The cash flows are discounted at a current pre-tax rate that reflects the risks specific to the decommissioning liability. The unwinding of the discount is expensed as incurred and recognised in the statement of profit and loss as a finance cost. The estimated future costs of decommissioning are reviewed annually and adjusted as appropriate. Changes in the estimated future costs or in the discount rate applied are added to or deducted from the cost of the asset.

*Onerous contract*

A contract is considered to be onerous when the expected economic benefits to be derived by the Group from the contract are lower than the unavoidable cost of meeting its obligations under the contract. The provision for an onerous contract is measured at the present value of the lower of the expected cost of terminating the contract and the expected net cost of continuing with the contract. Before such a provision is made, the Group recognises any impairment loss on the assets associated with that contract

(s) Contingent liabilities

A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events beyond the control of the Group or a present obligation that is not recognized because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in extremely rare cases where there is a liability that cannot be recognized because it cannot be measured reliably. The Group does not recognize a contingent liability but discloses its existence in the Consolidated Financial Statements unless the possibility of an outflow of resources embodying economic benefits is remote.

Contingent liabilities and commitments are reviewed by the management at each balance sheet date.

(t) Cash and cash equivalents

Cash and cash equivalent in the balance sheet comprise cash at banks and on hand and short-term deposits with an original maturity of three months or less, which are subject to an insignificant risk of changes in value.

For the purpose of the consolidated statement of cash flows, cash and cash equivalents consist of cash and short-term deposits, as defined above, net of outstanding bank overdrafts as they are considered an integral part of the Group's cash management.

(u) Segment accounting policies

The Group prepares its segment information based on its reporting to Chief Operating Decision Maker (refer note 40 on segment reporting).

(v) Corporate Social Responsibility (CSR) expenditure

CSR expenditure as per provisions of section 135 of Companies Act, 2013 read with The Companies (Corporate Social Responsibility Policy) Rules, 2014, is charged to the statement of profit and loss as an expense as and when incurred.

(w) Discontinued operations

A discontinued operation is a component of the Group's business, the operations and cash flows of which can be clearly distinguished from those of the rest of the Group and which represents a separate major line of business or geographical area of operations and

- is part of a single co-ordinated plan to dispose of a separate major line of business or geographic area of operations; or
- is a subsidiary acquired exclusively with a view to re-sale.

(x) Share Capital

*i. Equity shares*

Incremental costs directly attributable to the issue of equity shares are recognised as a deduction from equity. Income tax relating to transaction costs of an equity transaction is accounted for in accordance with Ind AS 12.

*ii. Treasury shares*

The Company has created Manipal Health Employee Welfare Trust (MHEWT) for providing share-based payment to its employees. The Company uses MHEWT as a vehicle for distributing shares to employees under the employee stock option schemes. The Company treats MHEWT as its extension and shares held by MHEWT are treated as treasury shares.

Own equity instruments that are reacquired (treasury shares) are recognised at cost and deducted from equity. No gain or loss is recognised in profit or loss on the purchase, sale, issue or cancellation of the Company's own equity instruments. Any difference between the carrying amount and the consideration, if reissued, is recognised in Securities premium. Share options exercised during the reporting period are satisfied with treasury shares.

As and when treasury shares are transferred to employees on exercise after satisfaction of the vesting condition the balance lying in treasury share reserve is transferred to retained earnings

(y) Cash flow statement

Cash flows are reported using the indirect method, whereby net profit/(loss) before tax is adjusted for the effects of transactions of a non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financing activities of the Group are segregated. Bank overdrafts are classified as part of cash and cash equivalent, as they form an integral part of an entity's cash management.



(z) Service concession agreements

HealthMap has entered into Concessionaire Agreements with select government medical colleges and district hospitals of Haryana, Odisha and Jharkhand for development, operation and maintenance of imaging diagnostic centres on PPP basis. The Group has conducted detailed analysis of the terms of the aforementioned agreements to determine the applicability of accounting under Service Concession Agreement (SCA) as per Appendix C of Ind AS 115 "Revenue from Contracts with Customers" and noted the following:

i) The concessionaire agreements do not provide any residual interest in the equipments installed by the HealthMap to the government medical colleges and district hospitals at the expiry of the term of concessionaire agreements and that the residual interest in the equipments is expected to be significant as the HealthMap is required to upgrade the equipments installed with the latest technology.

ii) The price charged for diagnostic services is regulated by the concessionaire agreements only for government patients. HealthMap is free to fix rates for private patients (only Haryana and Jharkhand) and such business constitutes a substantial portion of the total revenue and apparently is not ancillary to the government patient business.

In view of the above reasons mentioned, the management of the HealthMap is of the view that SCA does not apply in its entirety to the HealthMap.

2.4 New and amended standards

(i) Ind AS 117 Insurance Contracts

The Ministry of corporate Affairs (MCA) notified the Ind AS 117, Insurance Contracts, vide notification dated August 12, 2024, under the Companies (Indian Accounting Standards) Amendment Rules, 2024, which is effective from annual reporting periods beginning on or after April 01, 2024.

Ind AS 117 Insurance Contracts is a comprehensive new accounting standard for insurance contracts covering recognition and measurement, presentation and disclosure. Ind AS 117 replaces Ind AS 104 Insurance Contracts. Ind AS 117 applies to all types of insurance contracts, regardless of the type of entities that issue them as well as to certain guarantees and financial instruments with discretionary participation features; a few scope exceptions will apply. Ind AS 117 is based on a general model, supplemented by:

- A specific adaptation for contracts with direct participation features (the variable fee approach)
- A simplified approach (the premium allocation approach) mainly for short-duration contracts

The application of Ind AS 117 had no impact on the Consolidated Financial Statements as the Group has not entered any contracts in the nature of insurance contracts covered under Ind AS 117.

(ii) Amendment to Ind AS 116 Leases – Lease Liability in a Sale and Leaseback

The MCA notified the Companies (Indian Accounting Standards) Second Amendment Rules, 2024, which amend Ind AS 116, Leases, with respect to Lease Liability in a Sale and Leaseback.

The amendment specifies the requirements that a seller-lessee uses in measuring the lease liability arising in a sale and leaseback transaction, to ensure the seller-lessee does not recognise any amount of the gain or loss that relates to the right of use it retains.

The amendment is effective for annual reporting periods beginning on or after April 01, 2024 and must be applied retrospectively to sale and leaseback transactions entered into after the date of initial application of Ind AS 116.

The amendment does not have a material impact on the Consolidated Financial Statements.

2.5 Standards issued but not effective

(i) Amendment to Ind AS 21 The Effects of Changes in Foreign Exchange Rates

On May 07, 2025, The Ministry of Corporate Affairs notified the Companies (Indian Accounting Standards) Amendment Rules, 2025, which amend Ind AS 21 The Effects of Changes in Foreign Exchange Rates, to specify how an entity should assess whether a currency is exchangeable and how it should determine a spot exchange rate when exchangeability is lacking. The amendments also require disclosure of information that enables users of its financial statements to understand how the currency not being exchangeable into the other currency affects, or is expected to affect, the entity's financial performance, financial position and cash flows.

The amendments are effective for annual reporting periods beginning on or after 1 April 2025. When applying the amendments, an entity cannot restate comparative information.

The amendments are not expected to have a material impact on the Consolidated Financial Statements.

*(This space has been intentionally left blank)*



**Manipal Health Enterprises Private Limited**  
Notes to the Consolidated Financial Statements for the year ended March 31, 2025

**3.1 Property, plant and equipment**

	Land	Buildings	Leasehold Land	Leasehold improvements	Electrical installations	Equipments	Facility and office equipment	Furniture and fixtures	Computers	Vehicles	Total
	3.1 (a)	3.1 (b)	3.1 (c)								(₹ in crore)
<b>Cost</b>											
At April 1, 2023*	581.00	1,231.09	280.98	473.32	254.18	1,621.50	121.98	123.23	161.93	23.60	4,872.81
Additions on account of acquisition of subsidiaries (refer note 32 c)	129.61	548.30	56.81	-	179.13	283.47	-	36.36	18.81	0.63	1,253.12
Additions	-	34.14	-	17.66	36.94	140.17	0.18	10.18	29.43	14.19	282.89
Adjustments	2.13	13.10	-	(16.53)	(1.16)	(1.34)	-	4.45	1.45	-	2.10
Disposals	-	(0.01)	-	(0.23)	(1.00)	(15.24)	(2.03)	(1.88)	(1.72)	(2.37)	(24.48)
At March 31, 2024*	712.74	1,826.62	337.79	474.22	468.09	2,028.56	120.13	172.34	209.90	36.05	6,386.44
Additions on account of acquisition of subsidiaries (refer note 32 a)	49.95	218.61	-	-	3.80	209.76	-	23.55	7.89	1.99	515.55
Additions	19.00	30.07	-	29.43	39.76	193.83	-	28.71	87.67	11.40	439.87
Disposals / adjustments	(42.34)	(2.40)	-	(3.26)	(17.53)	(31.92)	(7.67)	8.08	(7.09)	(2.90)	(107.03)
At March 31, 2025	739.35	2,072.90	337.79	500.39	494.12	2,400.23	112.46	232.68	298.37	46.54	7,234.83
<b>Depreciation</b>											
At April 1, 2023*	26.98	335.38	-	236.23	146.44	866.21	109.53	97.88	123.06	14.85	1,956.56
Additions on account of acquisition of subsidiaries (refer note 32 c)	-	79.83	27.55	-	94.88	180.03	-	26.61	16.03	0.55	425.48
Charge for the year	-	41.31	0.02	33.94	49.98	105.03	4.66	14.14	23.21	3.76	276.05
Disposals	-	(0.01)	-	(0.08)	(0.50)	(14.28)	(2.01)	(1.84)	(1.71)	(1.45)	(21.88)
At March 31, 2024*	26.98	456.51	27.57	270.09	290.80	1,136.99	112.18	136.79	160.59	17.71	2,636.21
Additions on account of acquisition of subsidiaries (refer note 32 a)	-	9.78	-	-	1.35	56.49	0.01	12.35	5.02	0.85	85.85
Charge for the year	-	53.09	0.03	20.71	43.64	155.02	4.40	20.91	43.83	6.03	347.66
Disposals / adjustments	-	(2.23)	-	(1.64)	(7.43)	(29.72)	(7.66)	1.09	(10.35)	(1.66)	(59.60)
At March 31, 2025	26.98	517.15	27.60	289.16	328.36	1,318.78	108.93	171.14	199.09	22.93	3,010.12
<b>Net book value</b>											
At March 31, 2024*	685.76	1,370.11	310.22	204.13	177.29	891.57	7.95	35.55	49.31	18.34	3,750.23
At March 31, 2025	712.37	1,555.75	310.19	211.23	165.76	1,081.45	3.53	61.54	99.28	23.61	4,224.71

\* Refer note 32 b.

**Notes:**

(a) MHEIPL signed a Deed of Transfer/Exchange with the West Bengal Housing Infrastructure Development Corporation Limited, a Government of West Bengal Company wherein a parcel of freehold land was exchanged for a leasehold land and the impact of the same has been considered in the Financial Statements.

(b) Building includes those constructed on leasehold land

Gross Block: ₹ 166.94 crore (March 31, 2024: ₹ 164.52 crore)

Depreciation charge for the year: ₹ 8.34 crore (March 31, 2024: ₹ 7.82 crore)

Accumulated depreciation: ₹ 62.37 crore (March 31, 2024: ₹ 54.55 crore)

Net book value: ₹ 96.23 crore (March 31, 2024: ₹ 102.16 crore)

(c) This represents lease term of 999 years and perpetuity.

Refer note 14.1 for details of property, plant and equipment provided as security for borrowings.



Manipal Health Enterprises Private Limited  
Notes to the Consolidated Financial Statements for the year ended March 31, 2025

3.2 Capital work in progress

Particulars	March 31, 2025	March 31, 2024
Opening	41.59	39.75
Additions	1,012.31	284.73
Less: Transferred to Property, plant and equipment	(439.87)	(282.89)
Closing	614.03	41.59

(a) During the year, Group has capitalised an aggregate borrowing cost of ₹ 4.54 crore (March 31, 2024: ₹ Nil), on assets lying in capital work in progress

Capital work in progress ageing schedule

Particulars	Amount in CWIP for a year of			Total
	Less than 1 year	1-2 years	2-3 years	
Projects in progress	606.35	5.88	1.80	614.03
Projects temporarily suspended	-	-	-	-
Total	606.35	5.88	1.80	614.03

Particulars	Amount in CWIP for a year of			Total
	Less than 1 year	1-2 years	2-3 years	
Projects in progress	35.63	5.66	0.30	41.59
Projects temporarily suspended	-	-	-	-
Total	35.63	5.66	0.30	41.59

There are no capital work-in-progress for which the completion is overdue or has exceeded its cost compared to its original budget.

Refer note 14.1 for details of Capital work in progress provided as security for borrowings.

3.3 Assets held for sale

Particulars	March 31, 2025	March 31, 2024
Land	6.50	6.50
	6.50	6.50

(3.3.1) Land held for sale pertains to land situated at Meerut ₹ 6.50 crore (March 31, 2024: ₹ 6.50 crores)

(3.3.2) As of March 31, 2025, MHPL is actively responding to evolving market conditions and ongoing infrastructure developments in and around Meerut. Efforts to market the land are ongoing, with the aim of achieving optimal realisation through a potential sale.



Manipal Health Enterprises Private Limited  
Notes to the Consolidated Financial Statements for the year ended March 31, 2025

4 Goodwill, Other intangible assets and Right-of-use asset

	Goodwill 4 (a)	Intangible Assets				Right-of-use asset [refer note 2.3(f)]						Total		
		Customer contracts	Brand	Computer software	Non-compete fee	Total	Leasehold land (refer note 3.1.a)	Buildings	Equipments	Computer	Computer software		Vehicle installations	Electrical installations
<b>Cost</b>														
At April 1, 2023*	1,663.94	338.83	42.60	120.55	6.41	508.39	565.85	579.65	94.44	18.58	24.33	0.68	-	1,283.53
Additions on account of acquisition of subsidiaries (refer note 32 c)	1,223.45	57.40	-	13.11	-	70.51	187.80	14.84	0.87	-	-	-	-	203.51
Additions	-	-	-	43.50	-	43.50	(0.10)	55.21	52.31	9.93	-	-	-	117.45
Adjustments	-	-	-	(0.02)	-	(0.02)	-	(10.19)	(4.14)	-	-	-	-	(0.10)
Disposal	-	-	-	-	-	-	-	-	-	-	-	-	-	(14.33)
At March 31, 2024*	2,887.39	396.23	42.60	177.14	6.41	622.38	753.55	639.51	143.48	28.51	24.33	0.68	-	1,590.06
Additions on account of acquisition of subsidiary (refer note 32 a)	639.92	29.40	-	5.61	52.50	87.51	4.75	38.31	0.26	-	-	-	-	43.32
Additions	-	-	-	79.22	-	79.22	2.22	394.65	42.92	3.45	-	-	50.10	493.34
Disposals / adjustments	-	-	-	(0.47)	-	(0.47)	42.34	(15.90)	-	-	-	-	-	26.44
At March 31, 2025	3,527.31	425.63	42.60	261.50	58.91	788.64	802.86	1,056.57	186.66	31.96	24.33	0.68	50.10	2,153.16
<b>Amortisation / depreciation</b>														
At April 1, 2023*	13.79	34.82	5.33	95.78	3.38	139.31	39.49	163.07	56.60	8.27	18.51	0.68	-	286.62
Additions on account of acquisition of subsidiaries (refer note 32 c)	-	-	-	9.67	-	9.67	1.23	9.51	0.59	-	-	-	-	11.33
Charge for the year	-	22.28	5.33	18.29	3.03	48.93	2.71	51.75	10.10	5.30	2.17	-	-	72.03
Disposals / adjustments	-	-	-	(0.01)	-	(0.01)	-	(4.10)	-	-	-	-	-	(4.10)
Impairment	114.07	-	-	-	-	-	-	-	-	-	-	-	-	-
At March 31, 2024*	127.86	57.10	10.66	123.73	6.41	197.90	43.43	220.23	67.29	13.57	20.68	0.68	-	365.88
Additions on account of acquisition of subsidiary (refer note 32 a)	-	-	-	4.75	13.12	17.87	0.04	5.67	0.22	-	-	-	-	5.93
Charge for the year	-	24.89	5.33	32.43	7.88	70.53	4.61	58.82	10.10	10.02	1.58	-	3.52	88.65
Disposals / adjustments	0.44	-	-	(0.33)	-	(0.33)	-	(10.20)	-	-	-	-	-	(10.20)
Charge for the year transferred to CWIP	-	-	-	-	-	-	-	3.14	-	-	-	-	-	3.14
At March 31, 2025	128.30	81.99	15.99	160.58	27.41	285.97	48.08	277.66	77.61	23.59	22.26	0.68	3.52	453.40
<b>Net book value</b>														
At March 31, 2024*	2,759.53	339.13	31.94	53.41	-	424.48	710.12	419.28	76.19	14.94	3.65	-	-	1,224.18
At March 31, 2025	3,399.01	343.64	26.61	100.92	31.50	502.67	754.78	778.91	109.05	8.37	2.07	-	46.58	1,699.76

\* Refer note 32 b.

Refer note 14.1 for details of immovable assets provided as security for borrowings.



Manipal Health Enterprises Private Limited  
Notes to the Consolidated Financial Statements for the year ended March 31, 2025

4 (a) Impairment testing of goodwill with indefinite lives

For impairment testing, goodwill acquired through business combinations with indefinite lives has been allocated to the below mentioned CGUs  
Carrying amount of goodwill allocated to each of the CGUs:

	South cluster	North cluster	East cluster	West cluster	HealthMap Radiology	HealthMap Pathology	Total
At April 01, 2023*	952.93	248.21	72.33	72.00	104.56	200.12	1,650.15
Additions on account of acquisition of subsidiary (refer note 32 c)	-	-	1,223.45	-	-	-	1,223.45
Impairment	-	-	-	-	-	(114.07)	(114.07)
At March 31, 2024*	952.93	248.21	1,295.78	72.00	104.56	86.05	2,759.53
Additions on account of acquisition of subsidiary (refer note 32 a)	-	-	639.92	-	-	-	639.92
Liquidation of step-down subsidiary	-	-	(0.44)	-	-	-	(0.44)
At March 31, 2025	952.93	248.21	1,935.26	72.00	104.56	86.05	3,399.01

\* Refer note 32 b.

The Group performed its annual impairment test for years ended March 31, 2025 and March 31, 2024. The estimated value-in-use of this CGU is based on the future cash flows using a 5.00% (March 31, 2024: 5.00%) annual growth rate for periods subsequent to the forecast period of 5 years and pre-tax discount rate of 11.00% (March 31, 2024: 11.00%). An analysis of the sensitivity of the computation to a change in key parameters (operating margin, discount rates and long term average growth rate), based on reasonable assumptions, did not identify any probable scenario in which the recoverable amount of the CGU would decrease below its carrying amount. Key assumptions upon which the Company has based its determinations of value-in-use include :

- Estimated cash flows based on internal budgets and industry outlook for a period of five years and a terminal growth rate thereafter
  - The estimated value-in-use of this investment is based on the future cash flows using a 5.00% (March 31, 2024: 5.00%) annual growth rate for periods subsequent to the forecast period of 5 years (March 31, 2024: 5 years). This long term growth rate takes into consideration external macroeconomic sources of data. Such long-term growth rate considered does not exceed that of the relevant business and industry sector
  - Pre-tax Discount rate of 11.00% (March 31, 2024: 11.00%), which reflect current market assessment of the risks.
- The Group believes that any reasonably possible change in the key assumptions on which a recoverable amount is based would not cause the aggregate carrying amount to exceed the aggregate recoverable amount



5 Investments accounted for using the equity method

	(₹ in crore)			
	No of Shares		Amounts	
	March 31, 2025	March 31, 2024	March 31, 2025	March 31, 2024 <sup>a</sup>
<b>5.1 Investment in equity instruments of a Joint Venture and Associate Company</b>				
Terrals Technologies Private Limited [net of impairment (Refer note 5.1.1)]- Joint Venture	100	100	-	-
Igenetic Diagnostics Private Limited [net of impairment (Refer note 5.1.2)]- Associate #	73,496	73,496	-	-
Medica TS Hospital Private Limited [net of impairment (Refer note 37 b)] - Associate	7,40,000	-	-	-
<b>Investment in preference shares of a Joint Venture and Associate Company</b>				
Terrals Technologies Private Limited [net of impairment (Refer note 5.1.1)]- Joint Venture				
[0.01% Series A Compulsorily Convertible Preference shares ('Series A CCPS') of ₹ 100 each fully paid-up in refer note (5.1.1) below]	7,845	7,845	-	-
[0.01% Series B Compulsorily Convertible Preference shares ('Series B CCPS') of ₹ 100 each fully paid-up in refer note (5.1.1) below]	2,197	2,197	-	-
Medica TS Hospital Private Limited [net of impairment] (Refer note 37 b)- Associate	2,30,05,182	-	-	-
[0.01% Optionally Convertible Redeemable Preference shares of ₹ 10 each, fully paid up refer note 37 b]				
<b>Aggregate value of investments</b>			-	-
<b>Aggregate value of provision for impairment</b>			63.82	41.59

\* Refer note 32 b.

5.1.1 The Company has signed a Share Subscription Agreement on December 22, 2020 to invest an amount of upto ₹ 80.00 crore in Terrals Technologies Private Limited (Phable) in upto three tranches. The first tranche of ₹ 40.00 Crores was invested on February 26, 2021 by subscribing to 100 equity shares of ₹ 10 each and 7,845 compulsorily convertibles preference shares of ₹ 100 each. In the year ended March 31, 2022 a further ₹ 29.99 crore was invested for 2,197 compulsorily convertibles preference shares of ₹ 100 each.

During the year ended March 31, 2023, the Company has made provision for impairment of its investment in Terrals Technologies Private Limited (Phable) of ₹ 41.59 crores, as it does not expect any recoverable amount (net) from its investment.

5.1.2 During the year ended March 31, 2022, the Company acquired 73,496 shares of Igenetic Diagnostics Private Limited for a total consideration of ₹ 47.8 crore. During the year ended March 31, 2023, Igenetic has filed an application with NCLT to demerge the business of conducting routine and specialized pathological tests, varied diagnostic tests, and operations and management of diagnostic centres into Healthmap Diagnostics Private Limited. The Company will continue to have a controlling stake in Healthmap Diagnostics Private Limited post this acquisition.

During the year ended March 31, 2025, NCLT approval was received, and the effect of the scheme was reflected in the Consolidated Financial Statements. Also, refer note 32(b)

# Investments are tested for impairment annually and when circumstances indicate that the carrying value may be impaired. Impairment is determined by assessing the recoverable amount of each investment. When the recoverable amount of the investment is less than its carrying amount, an impairment loss is recognized. The recoverable amounts of the above investments have been assessed using a value-in-use model. Key assumptions upon which the Group has based its determinations of value-in-use include:

- Estimated cash flows based on internal budgets and industry outlook for a period of five years and a terminal growth rate thereafter.
- The estimated value-in-use of this investment is based on the future cash flows using a 5.00% (March 31, 2024: 5.00%) annual growth rate for periods subsequent to the forecast period of 5 years (March 31, 2024: 5 years). This long term growth rate takes into consideration external macroeconomic sources of data. Such long-term growth rate considered does not exceed that of the relevant business and industry sector
- Pre-tax discount rate of 11.00% (March 31, 2024: 11.00%), which reflect current market assessment of the risks specific to the investment. The Group believes that any reasonably possible change in the key assumptions on which a recoverable amount is based would not cause the aggregate carrying amount to exceed the aggregate recoverable amount of the investment

6 Non-current financial assets

6.1 Investments

	(₹ in crore)			
	No of Shares		Amounts	
	March 31, 2025	March 31, 2024	March 31, 2025	March 31, 2024
<b>Investments at fair value through profit and loss</b>				
<b>1) Investments in other Companies/Trust</b>				
Renew Wind Energy (Karnataka) Private Limited	18,600	18,600	0.57	0.57
[Equity shares of ₹ 100 each fully paid-up]				
Swasth Digital Health Foundation	5,000	5,000	0.05	0.05
[Equity shares of ₹ 100 each fully paid-up]				
Investment in O2 Renewable Energy				
[Equity shares of ₹ 10 each fully paid-up] (refer note 6.1.1)	1,15,900	1,15,900	0.12	0.12
[Compulsory Convertible Debentures of ₹ 1,000 each fully paid-up]	10,424	10,424	1.04	1.04
Arctem Healthcare Private Limited (net of impairment charge amounting to ₹ 5.00 crore (March 31, 2024: ₹ 5.00 crore))	4,968	4,968	-	-
[Equity shares of ₹ 10 each fully paid-up] (refer note 6.1.2)				
Atria Wind Power (Basavana Bagewadi) Private Limited ('Atria')	2,500	-	0.05	-
[Equity shares of Rs. 100 each fully paid-up] (refer note 6.1.3)				
<b>Aggregate value of unquoted investments</b>	(A)		1.83	1.78
Investments in mutual funds (quoted) ^			143.09	114.39
<b>Aggregate book value/ market value of quoted investments</b>	(B)		143.09	114.39
<b>Aggregate value of investments (A+B)</b>			144.92	116.17
<b>Aggregate value of provision for impairment</b>			5.00	5.00

6.1.1 On October 23, 2023, MHPL acquired 1,15,900 equity shares and 10,424 Series B compulsory convertible debentures of O2 Renewable Energy X Private Limited constituting to 32.54% shareholding of O2 Renewable Energy X Private Limited on a fully diluted basis.

6.1.2 During the year ended March 31, 2024, loan given to Arctem has been converted into equity shares for a consideration of ₹ 5.00 crores and made provision for impairment of its investment amounting to ₹ 5.00 crores.

6.1.3 MHEPL, MHPL and MHBPL on January 16, 2025 has invested an amount of ₹ 0.05 crore in Atria by subscribing to 2,500 equity shares as a captive power consumer.

6.1.4 Information about the Group's exposure to fair value measurement and credit and market risks is included in Note 33 & 34

^ Refer note 14.1 for details of Investments provided as security for borrowings.

6.2 Loans (Unsecured considered good unless otherwise stated)

	(₹ in crore)	
	March 31, 2025	March 31, 2024 <sup>a</sup>
<b>Loan to others</b>		
Considered good	-	0.05
Considered doubtful	-	-
Less: Allowance for doubtful loans	-	-
	-	0.05

\* Refer note 32 b.



6.3 Other financial assets (Unsecured considered good unless otherwise stated)

Margin money deposit with banks and financial institutions (refer note 6.3.1)  
Deposits with banks due to mature after twelve months from the reporting date (refer note 6.3.2)  
Interest accrued but not due on fixed deposits  
Security deposits (refer note 43)

(₹ in crore)	
March 31, 2025	March 31, 2024*
18.20	6.03
53.26	25.34
-	0.09
62.29	55.98
<b>133.75</b>	<b>87.44</b>

\* Refer note 32 b.

6.3.1 Margin money deposits with a carrying amount of ₹ 18.20 crore (March 31, 2024: ₹ 6.03 crore) are subject to charge to secure the Group's letter of credit facility for capital purchases and margins against performance guarantees.

6.3.2 It pertains to Debt Service Reserve Account (DSRA) maintained by the Group with Banks amounting to ₹ 31.24 crore (March 31, 2024: ₹ 25.02 crore)

7 Income tax assets (net)

Income tax assets (net of provision for income tax)

(₹ in crore)	
March 31, 2025	March 31, 2024*
256.18	255.79
<b>256.18</b>	<b>255.79</b>

\* Refer note 32 b.

8 Other non-current assets (Unsecured considered good unless otherwise stated)

Capital advances  
Less: Provision against capital advances  
Prepaid expenses  
Balances with government authorities

(₹ in crore)	
March 31, 2025	March 31, 2024
26.11	25.70
(17.88)	(17.88)
21.59	26.88
30.97	5.37
<b>60.79</b>	<b>40.07</b>

9 Inventories (valued at lower of cost and net realizable value)

Pharmacy items  
Medical consumables

(₹ in crore)	
March 31, 2025	March 31, 2024*
54.87	58.28
77.06	44.91
<b>131.93</b>	<b>103.19</b>

\* Refer note 32 b.

Refer note 14.1 for details of inventories provided as security for borrowings.

10 Current financial assets

10.1 Investments

Investments at fair value through profit and loss  
Investments in mutual funds (quoted)

(₹ in crore)	
March 31, 2025	March 31, 2024
1,337.93	1,004.92

Investments at amortised cost (unquoted)  
Other investments

292.83	-
--------	---

Aggregate book value/ market value of quoted and unquoted investments  
Refer note 14.1 for details of Investments provided as security for borrowings

<b>1,630.76</b>	<b>1,004.92</b>
-----------------	-----------------

10.2 Trade receivables

(Unsecured considered good unless otherwise stated)

Considered good  
Credit impaired

(₹ in crore)	
March 31, 2025	March 31, 2024*
637.30	458.88
121.22	79.77
758.52	538.65
(121.22)	(79.77)
<b>637.30</b>	<b>458.88</b>

Less: loss allowance on trade receivables

(10.2.1) There are no trade receivables which have significant increase in credit risk.

(10.2.2) Refer note 14.1 for details of trade receivables provided as security for borrowings.

(10.2.3) Ageing for trade receivables from the due date of payment for each of the category is as follows:

As at March 31, 2025

Particulars	Outstanding for following years from due date of payment						Total
	Not due #	Less than 6 Months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	
Undisputed Trade Receivables - considered good	348.68	267.45	18.48	2.69	-	-	637.30
Undisputed Trade Receivables - which have significant increase in credit risk	-	-	-	-	-	-	-
Undisputed Trade receivable - credit impaired	0.14	34.58	53.59	12.89	3.69	16.33	121.22
Disputed Trade receivables - considered good	-	-	-	-	-	-	-
Disputed Trade receivables - which have significant increase in credit risk	-	-	-	-	-	-	-
Disputed Trade receivables - credit impaired	-	-	-	-	-	-	-
<b>Total</b>	<b>348.82</b>	<b>302.03</b>	<b>72.07</b>	<b>15.58</b>	<b>3.69</b>	<b>16.33</b>	<b>758.52</b>



As at March 31, 2024\*

Particulars	Outstanding for following years from due date of payment						Total
	Not due #	Less than 6 Months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	
Undisputed Trade Receivables - considered good	266.70	159.61	19.89	7.70	3.52	1.46	458.88
Undisputed Trade Receivables - which have significant increase in credit risk	-	-	-	-	-	-	-
Undisputed Trade receivable - credit impaired	2.09	28.45	30.93	12.02	5.18	1.10	79.77
Disputed Trade receivables - considered good	-	-	-	-	-	-	-
Disputed Trade receivables - which have significant increase in credit risk	-	-	-	-	-	-	-
Disputed Trade receivables - credit impaired	-	-	-	-	-	-	-
<b>Total</b>	<b>268.79</b>	<b>188.06</b>	<b>50.82</b>	<b>19.72</b>	<b>8.70</b>	<b>2.56</b>	<b>538.65</b>

\* Refer note 32 b.

# includes unbilled revenue of ₹ 61.42 crore (March 31, 2024: 42.54 crores).

10.3 Cash and cash equivalents

	₹ in crore)	
	March 31, 2025	March 31, 2024
Balances with banks:		
· On current accounts	197.57	319.60
· Deposits with original maturity of less than three months	88.75	38.30
Cash on hand	4.96	2.98
	<b>291.28</b>	<b>360.88</b>

Refer note 14.1 for details of Cash and cash equivalents provided as security for borrowings

10.4 Bank balances other than cash and cash equivalents

	₹ in crore)	
	March 31, 2025	March 31, 2024
Deposits with banks original maturity with more than three months but less than twelve months	39.01	18.91
	<b>39.01</b>	<b>18.91</b>

Refer note 14.1 for details of Bank balances other than cash and cash equivalents provided as security for borrowings.

10.5 Loans (Unsecured considered good unless otherwise stated)

	₹ in crore)	
	March 31, 2025	March 31, 2024*
Loans to employees	3.38	1.95
Loans to related parties (refer note 43)	-	3.60
Less: Allowance for loans to related parties	-	(3.60)
	<b>3.38</b>	<b>1.95</b>

\* Refer note 32 b.

Refer note 14.1 for details of Loans provided as security for borrowings

10.6 Other financial assets (Unsecured considered good unless otherwise stated)

	₹ in crore)	
	March 31, 2025	March 31, 2024*
Security deposits	0.64	0.66
Interest accrued on fixed deposits	3.63	1.73
Deposits with banks original maturity with more than twelve months	1.00	-
Interest accrued on other investments	2.32	-
Margin money deposit with banks and financial institutions	24.91	6.79
Interest accrued on inter corporate deposits to related parties (refer note 10.6.1)		
Considered good	-	-
Considered doubtful	-	1.58
Less: Provision against Interest accrued on inter corporate deposits to related parties	-	(1.58)
	-	-
Earnest money deposit	0.23	0.23
Other receivables (refer note 10.6.1)		
Considered good	26.06	19.88
Considered doubtful	0.76	1.29
Less: loss allowance on other receivables	(0.76)	(1.29)
Net other receivables	<b>26.06</b>	<b>19.88</b>
	<b>58.79</b>	<b>29.29</b>

\* Refer note 32 b.

(10.6.1) includes receivables from related parties (refer note 43)

Refer note 14.1 for details of Other financial assets provided as security for borrowings

11 Other current assets (Unsecured considered good unless otherwise stated)

	₹ in crore)	
	March 31, 2025	March 31, 2024*
Prepaid expenses	31.86	28.67
Advances to suppliers		
Considered good	16.13	22.00
Considered doubtful	2.76	-
Less: Provision against advances to suppliers	(2.76)	-
Net advances to suppliers	<b>16.13</b>	<b>22.00</b>
Balance with government authorities	7.67	22.77
	<b>55.66</b>	<b>73.44</b>

\* Refer note 32 b.

Refer note 14.1 for details of Other assets provided as security for borrowings.



12. Equity Share capital	(₹ in crore)	
	March 31, 2025	March 31, 2024
<b>12.1 Authorised shares (Nos.)</b> 135,000,000 Equity Shares of ₹ 10/- each (March 31, 2024: 135,000,000 Equity Shares of ₹ 10/- each)	135.00	135.00
<b>12.2 Issued, subscribed and fully paid-up shares (Nos.)</b> 77,062,434 Equity Shares of ₹ 10/- each (March 31, 2024: 75,630,045 Equity Shares of ₹ 10/- each)	77.06	75.63
<b>Total issued, subscribed and fully paid-up share capital</b>	<b>77.06</b>	<b>75.63</b>

**Notes:**

(12.2.1) During the year ended March 31, 2025, the Company offered 14,32,389 equity shares on rights basis to its existing shareholders for raising upto ₹ 750 crore. The rights issue was fully subscribed and allotment concluded on June 20, 2024.

(12.2.2) On July 13, 2023, Kabru Investments Pte Ltd (Kabru) acquired 2,535,477 equity shares (3.35%) and 7,940,048 equity shares (10.50%) from Cypress Holdings and Manipal Global Health Services (MGHS) respectively. On January 10, 2024, Phoenix Hear Investments LLC acquired 787,278 equity shares (1.04%) and Novo Holdings Invest Asia A/S acquired 944,734 equity shares (1.25%) from Kabru. On January 31, 2024, Seventy Second Investment Company LLC acquired 2,830,015 equity shares (3.74%) from Kabru. On August 20, 2024 Ammar Sdn Bhd acquired 1,476,535 equity shares (1.92%) from Kabru. Therefore, as of March 31, 2025 Kabru holds 5.90% (March 31, 2024: 7.82%) in the Company.

(12.2.3) On July 13, 2023, Kangto Investments Pte Ltd (Kangto) acquired 2,04,20,112 equity shares (27.00%) of the Company from MGHS.

(12.2.4) Kabru, Kangto and Imperius Healthcare Investments Pte Ltd (collectively referred to be as Temasek Group) collectively holds 51.03% shareholding of the Company as of March 31, 2025 (March 31, 2024: 52.95%).

(12.2.5) On July 14, 2023 TPG Asia VI SF Pte Ltd (TPG) transferred 7,952,578 equity shares of the Company to MGHS. Further, on July 19, 2023 TPG transferred 8,319,305 equity shares of the Company to Manipal Research and Management Services International (MRMSI). On July 19, 2023 MRMSI transferred 8,319,305 equity shares amounting to 11% shareholding of the Company to TPG SG Magazine Pte Ltd.

(12.2.6) On July 14, 2023 National Investment Infrastructure Fund - II transferred its entire shareholding of 6,390,739 equity shares to MGHS.

(12.2.7) Manipal Hospitals Employee Welfare Trust (MHEWT) was holding 1,133,200 equity shares of the Company which it transferred to MGHS on August 23, 2023. The proceeds of the sale of shares were utilized to liquidate the outstanding employee stock options.

(12.2.8) Pursuant to the share transfers between MGHS and Kabru, Kangto, TPG, NIIIF and MHEWT, the shareholding of MGHS stood at 20.46% as of March 31, 2024. Cypress Holdings held 3.87% as of March 31, 2024. As MGHS did not participate in the rights issue and renounced its rights in favour of Cypress Holdings, MGHS holds 20.08% as of March 31, 2025 and Cypress Holdings hold 4.25% as of March 31, 2025.

**12.3 Reconciliation of the number of equity shares outstanding at the beginning and at the end of the reporting year:**

Equity Shares	March 31, 2025		March 31, 2024	
	Nos.	(₹ in crore)	Nos.	(₹ in crore)
At the beginning of the year	7,56,30,045	75.63	7,56,30,045	75.63
Add: Issued during the year	14,32,389	1.43	-	-
<b>At the end of the year</b>	<b>7,70,62,434</b>	<b>77.06</b>	<b>7,56,30,045</b>	<b>75.63</b>

**12.4 Terms/rights attached to equity shares**

The Company has only one class of equity shares having par value of ₹10 per share. Each holder of equity shares is entitled to one vote per share. The Company declares and pays dividends in Indian rupees. The final dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting. During the year, the Company has not declared any dividend.

In the event of liquidation of the Company, the holders of equity shares would be entitled to receive remaining assets of the Company after distribution of all preferential amounts. The distribution will be in proportion to number of equity shares held by shareholders.

**12.5 Shares held by holding / ultimate holding company and / or their subsidiaries / associates**

As of March 31, 2025 and March 31, 2024 there is no holding / ultimate holding company and / or their subsidiaries / associates for the Company.

**12.6 Details of shareholders holding more than 5% shares in the company**

	March 31, 2025		March 31, 2024	
	Nos.	% holding in the class	Nos.	% holding in the class
<b>Equity shares of ₹ 10 each (March 31, 2024: ₹ 10 each) fully paid</b>				
Kabru Investments Pte. Ltd.	45,48,961	5.90%	59,13,498	7.82%
Kangto Investments Pte. Ltd.	2,08,06,857	27.00%	2,04,20,112	27.00%
TPG SG Magazine Pte. Ltd.	84,76,868	11.00%	83,19,305	11.00%
Manipal Global Health Services, Mauritius	1,54,76,517	20.08%	1,54,76,517	20.46%
Imperius Healthcare Investments Pte Ltd.	1,39,73,956	18.13%	1,37,14,217	18.13%
Manipal Education and Medical Group India Private Limited	42,25,661	5.48%	41,47,117	5.48%

As per the records of the Company, including its register of shareholders/ members and other declaration received from shareholders regarding beneficial interest, the above shareholding represent both legal and beneficial ownership of shares.

**12.7 Shares allotted for consideration other than cash**

(a) There have been no issue of bonus shares, buy back of shares, issue of shares for consideration other than cash for the period of five years immediately preceding the balance sheet date.

**12.8 As at March 31, 2025 and March 31, 2024, the Group does not have any shares reserved for issue under options and contracts or commitments for the sale of shares except Employee Stock Option Plans (refer note 42).**

**13 Other equity**

	(₹ in crore)	
	March 31, 2025	March 31, 2024*
<b>13.1 Securities premium</b>		
Balance at the beginning of the year	2,665.64	2,569.55
Add: Addition during the year (refer note 52, 42.1 and 42.2)	748.57	96.09
<b>Balance at the end of the year</b>	<b>3,414.21</b>	<b>2,665.64</b>
<b>13.2 Treasury Shares</b>		
Balance at the beginning of the year	-	(34.36)
Add: sale of shares by MHEWT (refer note 42.1 and 42.2)	-	34.36
<b>Balance at the end of the year</b>	<b>-</b>	<b>-</b>
<b>13.3 Employee stock options outstanding account</b>		
Balance at the beginning of the year	1.93	22.56
Add: Share based expense for the year	38.83	13.53
Less: Transferred to retained earnings on cancellation of ESOP options (refer note 42.1 and 42.2)	-	(34.16)
<b>Balance at the end of the year</b>	<b>40.76</b>	<b>1.93</b>
<b>13.4 General reserve</b>		
Balance at the beginning of the year	2.80	2.80
Add: Addition during the year	-	-
<b>Balance at the end of the year</b>	<b>2.80</b>	<b>2.80</b>



	₹ in crore)	
	March 31, 2025	March 31, 2024 <sup>a</sup>
<b>13.5 Retained earnings</b>		
Balance at the beginning of the year	1,283.18	654.76
Add: Profit for the year	1,065.35	594.26
Less: Acquisition of further interest in subsidiary	(17.75)	-
Add: Transfer from Share options outstanding account (refer note 42.1 and 42.2)	-	34.16
<b>Balance at the end of the year</b>	<b>2,330.78</b>	<b>1,283.18</b>
<b>13.6 Re-measurement (loss) / gain of defined benefit plans</b>		
Balance at the beginning of the year	1.81	4.84
Less: Other comprehensive loss for the year (net of tax)	(4.72)	(3.03)
<b>Balance at the end of the year</b>	<b>(2.91)</b>	<b>1.81</b>
<b>13.7 Foreign currency translation reserve (item of OCI)</b>		
Balance at the beginning of the year	(15.48)	(15.51)
Add: Additions during the year	0.09	0.03
<b>Balance at the end of the year</b>	<b>(15.39)</b>	<b>(15.48)</b>
<b>Total of other equity</b>	<b>5,770.25</b>	<b>3,939.88</b>
<b>13.8 Non-controlling interest</b>		
Balance at the beginning of the year	71.99	233.59
Add / (less): Share of profit / (loss) and other comprehensive loss for the year	15.88	(61.48)
Add / (less): On account of acquisition of subsidiary (refer note 32.a and c)	74.70	(100.12)
Less: Acquisition of further interest in subsidiary	(9.58)	-
Less: On account of liquidation of step-down subsidiary	(0.15)	-
<b>Balance at the end of the year</b>	<b>152.84</b>	<b>71.99</b>

\* Refer note 32 b.

**14 Non-current financial liabilities**

**14.1 Borrowings (secured unless other-wise stated)**

	₹ in crore)	
	March 31, 2025	March 31, 2024
<b>Non-current Borrowings</b>		
Term loan from banks (refer note 14.1.1 to 14.1.2)	3,703.68	3,499.10
Term loan from financial institutions (refer note 14.1.1 to 14.1.2)	1,047.59	430.25
Term loan from others (unsecured) (refer note 14.1.5)	0.03	-
Loan for purchase of capital asset (refer note 14.1.3 and 14.1.4)	15.51	14.64
<b>(A) Less: Current maturities - disclosed under the head Short term Borrowings</b>	<b>4,766.81</b>	<b>3,943.99</b>
Term loan from banks	250.12	219.03
Term loan from financial institutions	42.12	21.00
Term loan from others	0.03	-
Loan for purchase of capital asset	4.57	3.82
<b>(B)</b>	<b>296.84</b>	<b>243.85</b>
<b>(A-B)</b>	<b>4,469.97</b>	<b>3,700.14</b>

**As at March 31, 2025**

Particulars	Interest Rate as on March 31, 2025	Frequency	Number of structured installments	Year of Maturity	Principal Outstanding (net of transaction cost)
Secured Term loan (Bank 1)	7.94% - 8.19%	Quarterly	Upto 52 Installments	March 31, 2040	1,017.44
Secured Term loan (Bank 2)	8.15%	Quarterly	Upto 40 Installments	August 31, 2038	801.93
Secured Term loan (Bank 3)	7.84% - 8.22%	Quarterly	Upto 41 Installments	March 31, 2040	740.61
Secured Term loan (Bank 4)	9.10% - 9.15%	Quarterly	Upto 36 Installments	April 30, 2032	73.39
Secured Term loan (Bank 5)	7.94% - 8.25%	Quarterly	Upto 40 Installments	September 30, 2035	529.06
Secured Term loan (Bank 6)	8.00% - 8.25%	Quarterly	Upto 40 Installments	March 31, 2036	517.48
Secured Term loan (Bank 7)	9.10% - 9.25%	Monthly	Upto 60 Installments	December 07, 2027	0.63
Secured Term loan (Bank 8)	9.36% - 9.86%	Monthly	Upto 131 Installments	July 05, 2029	4.44
Secured Term loan (Bank 9)	8.44% - 9.86%	Monthly	Upto 72 Installments	February 01, 2029	8.35
Secured Term loan (Bank 10)	8.31% - 8.79%	Monthly	Upto 77 Installments	August 20, 2030	9.58
Secured Term loan (Bank 11)	9.75%	Monthly	Upto 13 Installments	September 02, 2025	0.77
Secured Term loan (Financial institution 1)	8.75% - 9.25%	Quarterly	Upto 57 Installments	March 31, 2039	454.27
Secured Term loan (Financial institution 2)	8.25%	Quarterly	Upto 100 Installments	December 31, 2049	593.32
<b>Total</b>					<b>4,751.27</b>

**As at March 31, 2024**

Particulars	Interest Rate as on March 31, 2024	Frequency	Number of structured installments	Year of Maturity	Principal Outstanding (net of transaction cost)
Secured Term loan (Bank 1)	8.35% - 8.65%	Quarterly	Upto 52 Instalments	March 31, 2040	943.55
Secured Term loan (Bank 2)	8.40%	Quarterly	Upto 40 Instalments	August 31, 2038	836.04
Secured Term loan (Bank 3)	8.22% - 8.49%	Quarterly	Upto 41 Instalments	March 31, 2040	612.14
Secured Term loan (Bank 4)	9.15%	Quarterly	Upto 36 Instalments	April 30, 2032	75.77
Secured Term loan (Bank 5)	8.32% - 8.72%	Quarterly	Upto 40 Instalments	September 30, 2035	561.04
Secured Term loan (Bank 6)	8.25% - 8.5%	Quarterly	Upto 40 Instalments	March 31, 2036	469.76
Secured Term loan (Bank 7)	9.25%	Monthly	Upto 60 Instalments	December 07, 2027	0.80
Secured Term loan (Financial institution 1)	8.75%	Quarterly	Upto 57 Instalments	March 31, 2039	430.25
<b>Total</b>					<b>3,929.35</b>

**14.1.2 The terms and conditions of all the term loans from banks and financial institutions are similar and are as follows:**

During the year ended March 31, 2025, the Company entered into facility agreement with its lenders and offered consolidated security as below:-

a) First ranking pari passu Security Interest over all movable fixed assets and current assets of the Company along with MHEIPL, MHDPL, MHBPL & MHPL including but not limited to movable plant and machinery, machinery spares, tools and accessories, furniture, fixtures, intangible assets (including goodwill, trademarks and patents) and all other movable properties of whatsoever nature (both present and future) (other than any debt service reserve amounts (including in the form of fixed deposits or lien marked mutual funds) or debt service reserve accounts required to be maintained or maintained with respect to the Facilities) as per the facility agreement.

b) First ranking pari passu Security Interest over specific Immovable Properties of the Company, MHEIPL, MHDPL, & MHPL.

c) First ranking pari passu Security Interest, by way of hypothecation, over all leasehold improvements of all Immovable Properties and Excluded Properties.



d) exclusive Security Interest over the debt service reserve amounts (including in the form of fixed deposits or lien marked mutual funds) or debt service reserve accounts required to be maintained or maintained with respect to such Facility)

e) Term loan taken by Healthmap secured by:-

- (i) a first and exclusive charge over all present and future movable property plant and equipment and current assets pertaining to other than Jharkhand project of Healthmap and project funded by other lenders  
(ii) a first and exclusive charge over all and current assets pertaining to other than Jharkhand project of Healthmap and project funded by other lenders.

f) Equipment loan taken by MH Eastern secured by:-

- (i) First and Exclusive Hypothecation on Financed Equipment

g) The terms and conditions of term loans from banks taken by MH Bengal as at March 31, 2025 are as follows:-

i) Term loan of ₹ 0.88 crore is secured by:

- a) Primary Security - Extension of mortgage on Medica Cancer Hospital at Rangapani, District Darjeeling and Medica North Bengal Clinic Hospital at Meghnad Saha Sarani, District Darjeeling  
b) Collateral Security-First Charge by way of hypothecation on entire movable fixed assets and current assets of the company both present and future.

ii) Term loan of ₹ 3.57 crore is secured by:

- a) Equitable Mortgage on land and building Medica Cancer Hospital at Rangapani, District Darjeeling and Medica North Bengal Clinic Hospital at Meghnad Saha Sarani, District Darjeeling  
b) Exclusive Hypothecation of Stock and Book-debits.

Both the term loan are secured by:

- a) Corporate guarantee of Manipal Hospitals Synergie Private Limited , Holding Company (Formerly known as Medica Synergie Private Limited)  
b) Personal guarantee of Mr. Rana Udayan Lahiry (upto July 01, 2024) and Mr. Sudhanshu Roy (upto November 11, 2024)

h) The terms and conditions of equipment loans from banks taken by MH Bengal as at March 31, 2025 are as follows:-

- a) Primary Security -Exclusive charge by way of Hypothecation of Medical Equipments funded out of Term Loan  
b) Collateral Security-First Charge by way of hypothecation of Medica Cancer Hospital at Rangapani, District Darjeeling and Medica North Bengal Clinic Hospital at Meghnad Sarani, Pradhan Nagar, Siliguri, District Darjeeling.  
c) First Charge by way of hypothecation on entire movable fixed assets and current assets of the company both present and future.  
d) Corporate guarantee of Manipal Hospitals Synergie Private Limited , Holding Company (Formerly known as Medica Synergie Private Limited)  
e) Personal guarantee of Mr. Rana Udayan Lahiry (upto July 01, 2024) and Mr. Sudhanshu Roy (upto November 11, 2024)

i) The terms and conditions of Working Capital Term Loan from HDFC Bank taken by MH Bengal with outstanding of ₹ Nil are as follows:-

- a) Extension of second ranking charge over existing primary and collateral securities including mortgages created in favour of the Bank.  
b) Corporate guarantee of Manipal Hospitals Synergie Private Limited , Holding Company (Formerly known as Medica Synergie Private Limited)  
c) Personal guarantee of Mr. Rana Udayan Lahiry (upto July 01, 2024) and Mr. Sudhanshu Roy (upto November 11, 2024)

During the year ended March 31, 2024, the Company entered into facility agreement with its lenders and offered consolidated security as below:-

- a) A first pari-passu charge over all movable, immovable fixed assets and current assets of the Company along with MHDPL, MHPL, MHBPL & MHEIPL other than fixed Deposits and mutual funds kept as DSRA & immovable properties mentioned as excluded properties in facility agreements.  
b) Exclusive security interest over the amount in the Debt Service Reserve Accounts required to be maintained by MHEPL  
c) Irrevocable and unconditional corporate guarantee by MIIBPL, MHDPL and MHPL. MHEIPL assets also offered to lenders as security subsequent to acquisition of MHEIPL. Also refer note 38 (D)

d) Term loan taken by Healthmap secured by:-

- (i) a first and exclusive charge over all present and future movable property plant and equipment and current assets pertaining to other than Jharkhand project of Healthmap and project funded by other lenders  
(ii) a first and exclusive charge over all and current assets pertaining to other than Jharkhand project of Healthmap and project funded by other lenders

14.1.3 Details of principal outstanding, effective interest rate and repayment terms for loan for purchase of capital asset:-

	March 31, 2025	March 31, 2024
Principal outstanding (₹ in crore)	15.51	14.64
Effective Interest Rate	(7.35% to 10.00%)	(7.35% to 10.00%)
Repayment Terms	2025 to 2033	2025 to 2032

14.1.4 The Group obtained vehicle under financing arrangements from Bank and secured against such vehicle.

14.1.5 The Group has obtained loan from others having principal outstanding of ₹ 0.03 crore (March 31, 2024 ₹ Nil ) which is repayable on demand

14.2 Lease liabilities

	(₹ in crore)	
	March 31, 2025	March 31, 2024*
Opening balance	1,186.26	1,099.61
Additions on account of acquisition of subsidiary (refer note 32 a and c)		6.04
Add: New leases during the year	20.23	
Add: Interest accrued	440.00	113.67
Add: Interest capitalised	136.04	125.51
Less: Lease paid	7.08	-
Less: Interest paid	(50.21)	(37.84)
Less: Lease liability reversed	(114.33)	(110.85)
	(6.73)	(9.88)
	<b>1,618.34</b>	<b>1,186.26</b>
Non-current	1,548.87	1,133.67
Current	69.47	52.59

\* Refer note 32 b.

14.2.1 Notes

Refer notes 2.3(i) in relation to accounting policy for leases.

Refer note 4 for depreciation charge for right-of-use assets by class of underlying asset and additions to right-of-use assets and the carrying amount of right-of-use assets at the end of the reporting year by class of underlying asset.

Refer note 28.1 in relation to short term leases and leases of low-value assets accounted for applying paragraph 6 of Ind AS 116.

The Company has taken on lease certain building for hospital operations, diagnostic centres hostels for staff, equipments and office spaces and certain software for use in the course of its business.

Refer note 34 (c) disclosure on maturity analysis of lease payments

Refer note 48 disclosure on cash outflows for lease liabilities

14.3 Other financial liabilities

	(₹ in crore)	
	March 31, 2025	March 31, 2024
Other payable	34.96	-
	<b>34.96</b>	<b>-</b>

15 Provisions

	(₹ in crore)	
	March 31, 2025	March 31, 2024*
Non-current		
Provision for gratuity (refer note 31)	39.55	29.83
	<b>39.55</b>	<b>29.83</b>

\* Refer note 32 b



16

**Income tax**

The major components of income tax expense for the years ended March 31, 2025 and March 31, 2024 are:

**Statement of Profit and loss:**

		(₹ in crore)	
		March 31, 2025	March 31, 2024
<b>Current income tax:</b>			
	Current income tax charge	300.18	248.59
	Adjustment of tax relating to earlier years	(9.47)	(14.65)
	(A)	290.71	233.94
<b>Deferred tax:</b>			
	Origination and reversal of temporary differences (refer note 16.1.1)	(130.07)	(22.10)
	(B)	(130.07)	(22.10)
	<b>Income tax expense reported in the statement of profit and loss</b>	<b>160.64</b>	<b>211.84</b>
	(A+B)		

**OCI section**

		(₹ in crore)	
		March 31, 2025	March 31, 2024
Deferred tax related to items recognised in other comprehensive income during the year			
	Net loss on remeasurement of defined benefit plan	(1.45)	(0.49)
	<b>Income tax expense reported in other comprehensive income</b>	<b>(1.45)</b>	<b>(0.49)</b>

16.1.1 During the year ended March 31, 2025, MHEIPL recognised Deferred Tax Assets (Net) of ₹ 95.79 crores on unabsorbed depreciation of earlier years given it is probable that taxable profit will be available.

**Reconciliation of tax expense and the accounting profit multiplied by India's domestic tax rate for the year ended March 31, 2025 and March 31, 2024:**

		(₹ in crore)	
		March 31, 2025	March 31, 2024*
	Profit before tax	1,242.31	745.00
	Income tax at applicable statutory tax rate	312.69	187.52
	Tax adjustment pertaining to earlier years	(10.05)	(14.51)
	Impact of statutory tax rate changes on capital gains	(37.82)	-
	Deferred tax recognised basis reasonable certainty	(106.42)	(47.47)
	Tax effect of non-deductible expenses	1.34	34.73
	Losses for which no deferred tax asset is recognised	3.26	39.42
	Others	(2.36)	12.15
	<b>Tax expense as reported</b>	<b>160.64</b>	<b>211.84</b>

Certain entities of the Group have incurred losses during the relevant year, which has resulted in reduction of profit / increase of losses in the Consolidated Financial Statements. However, the tax liability has been discharged by the respective entities on a standalone basis. Further, in view of absence of reasonable certainty, the Group has not recognised deferred tax asset in certain companies.

\* Refer note 32 b.

**Deferred tax**

		(₹ in crore)			
		Recognised in balance sheet		Recognised in profit and loss and OCI	
		March 31, 2025	March 31, 2024*	March 31, 2025	March 31, 2024*
Property plant equipment	Impact of difference between tax depreciation as per Income Tax Act, 1961 over depreciation/ amortization as per Companies Act, 2013.	(601.50)	(555.87)	68.16	(31.55)
	Impact of expenditure charged to the statement of profit and loss in the current year but allowed for tax purposes on payment basis ^#	476.93	337.36	(140.34)	(12.64)
	Provision for doubtful debts and advances	38.24	16.34	(19.74)	5.82
	Fair valuation of investments in mutual fund	(21.36)	(14.30)	7.07	9.72
	Deferred tax on short term capital loss	(0.13)	6.43	6.56	3.32
	Deferred tax on long term capital loss	5.38	5.62	0.25	0.04
	Deferred tax assets not recognised on account of no reasonable certainty of sufficient profits	(35.90)	(91.16)	(46.11)	(109.76)
	Deferred tax assets recognised on unabsorbed depreciation and tax losses	208.98	170.18	1.31	78.46
	Recognised on acquisition	(94.95)	(79.81)	(6.46)	(4.70)
	Provision for impairment of investment	0.73	1.14	0.42	0.12
	Deferred tax on fair valuation of preference shares	(0.17)	(0.40)	(0.23)	(0.22)
	MAT credit entitlement	0.95	-	-	-
	Others	20.67	54.88	(2.41)	38.80
	<b>Deferred tax charge</b>			<b>(131.52)</b>	<b>(22.59)</b>
	<b>Net deferred tax liabilities</b>	<b>(2.13)</b>	<b>(149.59)</b>		

^ Includes items under 43B such as Leave encashment, gratuity and bonus.

# Gratuity amount routed through Other Comprehensive Income pertaining to remeasurement of defined benefit plan

\* Refer note 32 b.

**Deferred tax balances:**

		(₹ in crore)	
		March 31, 2025	March 31, 2024
	Deferred tax assets	181.61	61.35
	Deferred tax liabilities	(183.74)	(210.94)
	<b>Deferred tax liabilities (net)</b>	<b>(2.13)</b>	<b>(149.59)</b>

Note: Deferred tax assets/(liabilities) has been disclosed basis entity wise net deferred tax assets/(liabilities) as at year-end.

**Reconciliation of deferred tax liability**

		(₹ in crore)	
		March 31, 2025	March 31, 2024
	<b>Opening balance</b>		
	Recognised on acquisition of subsidiary (refer note 32)	(149.59)	(157.73)
	Tax charge during the year recognised in profit or loss	15.93	(14.45)
	<b>Subtotal</b>	<b>130.07</b>	<b>22.10</b>
	Tax charge during the year recognised in OCI	(3.59)	(150.08)
	<b>Closing balance</b>	<b>1.45</b>	<b>0.49</b>
		<b>(2.13)</b>	<b>(149.59)</b>



**Unrecognised deferred tax asset:**

Deferred tax assets have not been recognised in respect of the following items, because it is not probable that future taxable profit will be available against which the Group can use the benefits therefrom.

(₹ in crore)

	March 31, 2025		March 31, 2024	
	Gross Amount	Unrecognised tax effect	Gross Amount	Unrecognised tax effect
Carried forward business losses	54.54	13.73	8.32	2.09
Carried forward unabsorbed depreciation	84.56	21.28	603.75	151.95
Carried forward short / long term capital losses	11.97	3.01	21.85	5.00
	<b>151.07</b>	<b>38.02</b>	<b>633.92</b>	<b>159.04</b>

**Tax losses carried forward:**

Tax losses for which no deferred tax asset was recognised expire as follows:

	March 31, 2025		March 31, 2024	
	Amount (₹ in cr)	Expiry date	Amount (₹ in cr)	Expiry date
Carried forward business losses		FY 2024-25 to FY 2032-33		FY 2023-24 to FY 2026-27
Carried forward unabsorbed depreciation	84.56	Not Applicable	603.75	Not Applicable
Carried forward long term capital losses	11.97	FY 2031-32	21.85	FY 2029-30

**17 Current financial liabilities**

**17.1 Borrowings**

(₹ in crore)

Current maturities of long-term borrowings (refer note 14.1)

March 31, 2025	March 31, 2024
296.84	243.85
<b>296.84</b>	<b>243.85</b>

**17.2 Trade payables**

Trade payables

- total outstanding dues of micro enterprises and small enterprises
- total outstanding dues of creditors other than micro enterprises and small enterprises

(₹ in crore)

March 31, 2025	March 31, 2024*
36.14	29.88
1,090.45	1,100.65
<b>1,126.59</b>	<b>1,130.53</b>

For details relating to payable to related parties refer note 43.

**As at March 31, 2025**

Particulars	Outstanding for following years from due date of payment					
	Not due (Including provision for expense)	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
Outstanding dues of micro enterprises and small enterprises	26.56	9.35	0.06	0.01	0.16	36.14
Outstanding dues of creditors other than micro enterprises and small enterprises	874.62	177.45	10.49	11.11	16.78	1,090.45
Disputed dues of micro enterprises and small enterprises	-	-	-	-	-	-
Disputed dues of creditors other than micro enterprises and small enterprises	-	-	-	-	-	-
<b>Total</b>	<b>901.18</b>	<b>186.80</b>	<b>10.55</b>	<b>11.12</b>	<b>16.94</b>	<b>1,126.59</b>

**As at March 31, 2024\***

Particulars	Outstanding for following years from due date of payment					
	Not due (Including provision for expense)	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
Outstanding dues of micro enterprises and small enterprises	20.38	9.18	0.31	0.01	-	29.88
Outstanding dues of creditors other than micro enterprises and small enterprises	917.07	121.72	34.64	15.14	12.08	1,100.65
Disputed dues of micro enterprises and small enterprises	-	-	-	-	-	-
Disputed dues of creditors other than micro enterprises and small enterprises	-	-	-	-	-	-
<b>Total</b>	<b>937.45</b>	<b>130.90</b>	<b>34.95</b>	<b>15.15</b>	<b>12.08</b>	<b>1,130.53</b>

There were no disputed dues from Micro enterprises and small enterprises and creditors other than micro enterprises and small enterprises.

\* Refer note 32 b.

**17.3 Other financial liabilities**

(₹ in crore)

- Interest accrued but not due on borrowings (refer note 17.3.1)
- Capital creditors (refer note 17.3.2)
- Sundry deposits
- Retention money
- Other payables

March 31, 2025	March 31, 2024*
2.09	0.96
84.44	53.07
2.28	1.65
13.42	6.71
15.51	0.37
<b>117.74</b>	<b>62.76</b>

17.3.1 The details of interest rates, repayment and other terms are disclosed under note 14.1

17.3.2 As at March 31, 2025, outstanding amount of ₹ 5.05 crore (March 31, 2024: ₹ 2.72 crore) is due to micro and small enterprises. There are no interest due or outstanding on the same. There were no amounts paid to micro and small enterprises beyond the appointed date during the current and the previous years.

\* Refer note 32 b.



18	Provisions	(₹ in crore)	
		March 31, 2025	March 31, 2024*
	<b>Current</b>		
	Provision for gratuity (refer note 31)	2.26	0.88
	Provision for compensated absences	66.45	49.81
		<b>68.71</b>	<b>50.69</b>
	* Refer note 32 b.		
19	Current tax liabilities (net)	(₹ in crore)	
		March 31, 2025	March 31, 2024
	Current tax liabilities (net)	3.44	25.21
		<b>3.44</b>	<b>25.21</b>
20	Other current liabilities	(₹ in crore)	
		March 31, 2025	March 31, 2024*
	Unearned revenue	0.05	-
	Statutory dues	47.90	37.75
	Advance received from customer (refer note 21 b)	33.41	22.26
	Stamp duty payable	15.22	15.22
	Donations and other funds	15.38	15.82
	Liability towards free services	0.05	0.08
		<b>112.01</b>	<b>91.13</b>
	* Refer note 32 b.		

(This space has been intentionally left blank)



	(₹ in crore)	
	March 31, 2025	March 31, 2024*
<b>21 Revenue from operations</b>		
Hospital services **	7,814.45	5,913.74
Diagnostic services **	219.07	190.38
Pharmacy sales	312.60	222.96
Less: Discounts	(212.41)	(247.69)
<b>Total (a)</b>	<b>8,133.71</b>	<b>6,079.39</b>
<b>Other operating income</b>		
Management fees from hospitals **	42.58	34.72
Occupational health centre and ambulance service	32.62	24.38
Rental income **	8.26	6.34
Others	25.09	26.80
<b>Total (b)</b>	<b>108.55</b>	<b>92.24</b>
<b>Total (a+b)</b>	<b>8,242.26</b>	<b>6,171.63</b>

\*\* includes transactions with related parties (refer note 43)

a) The revenue from contracts with customer at disaggregation is provided above.

b) Changes in contract liabilities- Advance received from customers

	(₹ in crore)	
	March 31, 2025	March 31, 2024*
<b>Balance at the beginning of the year</b>	<b>22.26</b>	<b>24.65</b>
Less: Revenue recognised that was included in the balance at the beginning of the year	(22.26)	(24.65)
Add: Increase due to advance from patients received, net of unbilled revenue (refer note 20)	33.41	22.26
<b>Balance at the end of the year</b>	<b>33.41</b>	<b>22.26</b>
<b>Expected revenue recognition from remaining performance obligations:</b>		
- Within one year	33.41	22.26

c) Contract balances

	(₹ in crore)	
	March 31, 2025	March 31, 2024*
<b>Receivables</b>		
- Trade receivables	637.30	458.88
<b>Contract liabilities</b>		
- Advance received from customer (refer note 20)	33.41	22.26

Unbilled revenue is relating to the service rendered where the invoicing is not done and Trade receivable are non-interest bearing and are generally on a terms of 30 to 120 days.

Contract liabilities relates to the advances received from the customers to deliver the hospital service. There is no significant changes in the contract liabilities during the year.

d) The Group's performance obligation is to provide the hospital service to patients, this is part of a contract that has an original expected duration of less than one year, hence the Group has taken the practical expedient related to performance obligation disclosure as provided by Ind AS 115.

\* Refer note 32 b

	(₹ in crore)	
	March 31, 2025	March 31, 2024*
<b>22 Other income</b>		
Profit on sale of investments in mutual funds (net)	34.23	26.09
Fair value gain on financial instruments at fair value through profit and loss	67.25	54.07
Profit on sale of property, plant and equipment (net)	-	2.37
Liabilities/provisions no longer required written back	-	0.14
Interest on income tax refund	5.07	3.74
Others	-	0.27
	<b>106.55</b>	<b>86.68</b>

\* Refer note 32 b.

	(₹ in crore)	
	March 31, 2025	March 31, 2024*
<b>23 Finance income</b>		
Interest income on financial assets at amortised cost	4.72	1.65
Interest income on bank deposits	8.71	5.20
Interest income - others	0.57	-
	<b>14.00</b>	<b>6.85</b>

\* Refer note 32 b.

	(₹ in crore)	
	March 31, 2025	March 31, 2024*
<b>24 Changes in inventories of medical consumables and pharmacy items</b>		
<b>Pharmacy items</b>		
Inventory at the beginning of the year	58.28	34.62
Inventory on account of acquisition of subsidiary (refer note 32 a and c)	2.90	-
Less: Inventory at the end of the year	(54.87)	(58.28)
	<b>6.31</b>	<b>(23.66)</b>
<b>Medical consumables</b>		
Inventory at the beginning of the year	44.91	30.15
Inventory on account of acquisition of subsidiary (refer note 32 a and c)	18.14	15.32
Less: Inventory at the end of the year	(77.06)	(44.91)
	<b>(14.01)</b>	<b>0.56</b>
	<b>(7.70)</b>	<b>(23.10)</b>

\* Refer note 32 b.



25 Employee benefits expense	(₹ in crore)	
	March 31, 2025	March 31, 2024*
Salaries, wages and bonus	1,052.91	740.18
Contribution to provident and other funds (refer note 31)	63.09	45.91
Gratuity expenses (refer note 31)	13.81	7.60
Share based payments (refer note 42 and 43)	38.83	13.53
Staff welfare expenses	50.77	49.82
	<b>1,219.41</b>	<b>857.04</b>

\* Refer note 32 b.

26 Finance costs	(₹ in crore)	
	March 31, 2025	March 31, 2024*
Bank charges	31.88	24.72
Interest		
- on bank and financial institution loan	331.37	264.38
- on leases (refer note 14.2)	136.04	125.51
- on vehicle loan	1.31	0.96
- on self-assessment tax	0.01	0.71
- on defined benefit obligation (refer note 31)	2.97	1.60
- on others	6.84	11.63
Loan processing fees		
- on financial liabilities measured at amortised cost	1.45	25.40
<b>Total interest expense</b>	<b>479.99</b>	<b>430.19</b>
	<b>511.87</b>	<b>454.91</b>

\* Refer note 32 b.

27 Depreciation and amortisation expense	(₹ in crore)	
	March 31, 2025	March 31, 2024*
Depreciation of property, plant and equipment (refer note 3.1)	347.66	276.05
Depreciation of right-of-use assets (refer note 4)	88.65	72.03
Amortisation of other intangible assets (refer note 4)	70.53	48.93
	<b>506.84</b>	<b>397.01</b>

\* Refer note 32 b.

28 Other expenses	(₹ in crore)	
	March 31, 2025	March 31, 2024*
Doctors professional fees **	1,758.43	1,324.83
House keeping, including consumables	182.73	135.23
Power, fuel and other utilities	117.82	96.50
Security charges	56.74	42.21
Rent (refer note 28.1) **	65.55	46.37
Contractual manpower	108.50	77.51
Rates and taxes	10.88	24.04
Insurance **	15.31	11.83
Repairs and maintenance		
- Buildings	7.57	7.45
- Plant and machinery	99.00	78.01
- Others	141.77	78.11
Corporate social responsibility (refer note 41) **	14.74	7.68
Advertising and sales promotion	317.60	236.06
Travelling and conveyance	35.02	28.01
Communication costs	9.91	8.01
Printing and stationery	28.84	24.10
Legal and professional fees **	116.65	78.96
Bad debts/advances written off	118.89	37.58
Loss (reversals) on trade receivables (net)	(31.06)	(3.68)
Loss (reversals) /allowance on other receivables (net)	(0.53)	0.46
(Reversal) / Impairment on loan to others	(5.26)	0.30
Foreign exchange loss (net)	0.98	0.48
Loss on sale of property, plant and equipment (net)	0.42	-
Loss on sale of investment in equity instruments	0.39	-
Miscellaneous expenses	45.40	40.32
	<b>3,216.29</b>	<b>2,380.37</b>

\* Refer note 32 b.

\*\* includes transactions with related parties (refer note 43)

28.1 Represents amounts incurred by the Company towards expenses relating to short-term leases, leases of low-value assets and ineligible GST on lease payments written off. Also, refer note 2.3 (i)

28.2 Payment to auditors #	(₹ in crore)	
	March 31, 2025	March 31, 2024
<b>As auditor:</b>		
Audit fee	4.74	3.48
Limited review	0.65	0.55
<b>In other capacity:</b>		
Other services	-	0.16
Reimbursement of expenses	0.45	0.30
	<b>5.84</b>	<b>4.49</b>

# Amount inclusive of Goods and Service Tax (GST).



**Manipal Health Enterprises Private Limited**  
**Notes to the Consolidated Financial Statements for the year ended March 31, 2025**

**29 Exceptional items**

(i) Pursuant to an enquiry conducted against Dr. Sanjeev Bagai ("Dr. Bagai"), the Company terminated his services as Whole-time Director and Vice Chairman in accordance with the provisions of Section 169 of the Companies Act, 2013. The matter was referred to arbitration and the Hon'ble Arbitrator issued an order dated June 24, 2023, awarding compensation of ₹38.73 crores. The appeal filed by MHDEL was admitted by the Hon'ble High Court of Delhi. Subsequently, the Hon'ble High Court of Delhi has partially set aside the arbitral award. Accordingly, the Company has reversed the previously recognized provision for compensation amounting to ₹ 16.35 crores in the current year.

(ii) The Group has incurred certain project fees, legal and professional fees towards its executed/ planned business expansion / tender amounting to ₹ 2.40 crore (March 31, 2024: ₹ 21.67 crore). The Group has disclosed the same as exceptional item in the Consolidated Financial Statements.

(iii) During the year ended March 31, 2024, the Group has impaired goodwill arising on its investment in Healthmap Diagnostics Private Limited amounting to ₹ 114.07 crore (refer note 32 b).

(iv) During the year ended March 31, 2024, National Company Law Tribunal (NCLT), Bengaluru Bench has approved the Scheme of Amalgamation ("the Scheme") of Manipal Hospitals (Jaipur) Private Limited, ("Transferor Company") with Manipal Hospitals (Dwarka) Private Limited ("Transferee Company"). The Company has incurred expenses of ₹ Nil for the year ended March 31, 2025 (March 31, 2024: ₹ 5.16 crores) towards stamp duty in the relation to the same.

**30 Earnings per share (EPS)**

The following reflects the profit and share data used in the basic and diluted EPS computations:

	(₹ in crore)	
	March 31, 2025	March 31, 2024*
Profit attributable to the Owners of the Company for basic EPS	1,065.35	594.26
Weighted average number of equity shares for calculating basic EPS	7,68,09,566	7,51,84,196
Effect of share split (refer note 30.1.1)	38,40,47,829	37,59,20,980
Effect of bonus issue (refer note 30.1.2)	76,80,95,658	75,18,41,960
<b>Weighted average number of equity shares for calculating basic EPS considering share split and bonus issue</b>	<b>1,15,21,43,487</b>	<b>1,12,77,62,940</b>
Effect of dilution:		
Stock option granted under ESOP Schemes	-	40,19,865
<b>Weighted average number of equity shares in calculating diluted EPS</b>	<b>1,15,21,43,487</b>	<b>1,13,17,82,805</b>

Basic earnings per share (₹)  
Diluted earnings per share (₹)

9.25  
9.25

(30.1.1) Subsequent to the year ended March 31, 2025, the Company sub-divided its equity shares by reducing the nominal value of each equity share from ₹ 10 to ₹ 2. Accordingly, each equity share of ₹ 10 was sub-divided into five equity shares of ₹ 2 each. As a result, the Authorised Capital of ₹ 135,00,00,000 which was earlier divided into 13,50,00,000 equity shares of ₹ 10 each was changed to 675,00,00,000 equity shares of ₹ 2 each and the Issued and Paid up Capital of ₹ 77,06,24,340 which was earlier divided into 77,06,24,340 equity shares of ₹ 10 each was changed to 385,312,170 equity shares of ₹ 2 each.

(30.1.2) Subsequent to the year ended March 31, 2025, the Company issued 770,624,340 bonus shares in accordance with Section 63 of the Companies Act, 2013 in the ratio of 2:1 to all equity shareholders with equity shares of face value of ₹ 2 each on April 22, 2025. The weighted average number of shares for the year ended March 31, 2024 have been adjusted to reflect the impact of bonus issue as per Ind AS 33.

In compliance with IND AS - 33 Earnings Per Share, the disclosure of basic and diluted earnings per share for all years presented has been arrived at after giving effect to the above sub-division and bonus issue.

\* Refer note 32 b.



**31 Employee benefit plan**

**(i) Defined contribution plan:**

Amount recognised and included in note 25, 'Contribution to provident and other funds' in statement of profit and loss of ₹ 63.09 crores (March 31, 2024\*: ₹ 45.91 crores)

**(ii) Defined benefit plan:**

The Group has a defined benefit gratuity plan. Under this plan, every employees who are entitled as per the Gratuity Act, gets a gratuity on departure at 15 days of last drawn salary for each completed year of service. The scheme is unfunded and funded. However, the Group has created a trust on March 30, 2013.

The following tables summarize the components of net benefit expense recognized in the statement of profit and loss and amounts recognized in the balance sheet.

(₹ in crore)

**a) Statement of profit and loss and other comprehensive income**

**March 31, 2025**      **March 31, 2024\***

**i) Net employee benefit expense recognized in the statement of profit or loss**

Current service cost	13.81	6.11
Past service cost	-	1.49
Interest cost on benefit obligation	3.33	1.94
Expected return on plan assets	(0.36)	(0.34)
<b>Net benefit expense charged to statement of profit or loss</b>	<b>16.78</b>	<b>9.20</b>

**ii) Remeasurement**

Actuarial changes arising from changes in financial assumptions	3.91	2.42
Actuarial changes arising from changes in demographic assumptions	1.69	1.04
Experience adjustments	1.52	0.39
Return on plan assets excluding interest income	(0.50)	0.05
<b>Total amount recognised in other comprehensive income</b>	<b>6.62</b>	<b>3.90</b>

**b) Balance Sheet**

**Net liability arising from defined benefit obligation**

Non current	39.55	29.83
Current	2.26	0.88
<b>Plan liability</b>	<b>41.81</b>	<b>30.71</b>

**c) Change in projected benefit obligations**

Defined benefit obligation at the beginning of the year	30.70	15.79
Additions on account of acquisition of subsidiary (refer note 32)	15.18	10.31
Fair value of plan asset at the beginning of the year	51.77	44.60
Current service cost	13.82	10.56
Past service cost	-	1.49
Interest cost	6.63	4.89
Benefits paid	(9.32)	(9.02)
<b>Remeasurement of (gain)/ loss in other comprehensive income:</b>	-	-
Actuarial loss /(gain) arising from change in financial assumptions	3.91	2.42
Actuarial loss /(gain) arising from change in demographic assumptions	1.69	1.04
Actuarial loss/ (gain) on account of experience adjustments	1.52	0.39
Fair value of plan asset at the end of the year	(74.09)	(51.77)
<b>Obligations at end of the year</b>	<b>41.81</b>	<b>30.70</b>

**d) Fair value of plan assets**

Fair value of plan assets at the beginning of the year	51.77	38.07
Additions on account of acquisition of subsidiary (refer note 32)	-	6.53
Interest income	3.66	3.29
Contributions by the Employer	24.70	12.43
Benefit Paid	(6.54)	(8.43)
Return on plan assets, excluding interest income	0.50	(0.12)
<b>Fair value of plan assets at the end of the year</b>	<b>74.09</b>	<b>51.77</b>

The Group expects to pay ₹ 4.40 crore in contributions to its defined benefit plans in FY 2025-26

**e) Investment details of plan assets:**

Insurer managed funds

	<b>74.09</b>	<b>51.77</b>
--	--------------	--------------



f) The principal assumptions used in determining gratuity liability for the Group's plan are shown below:

Discount rate	6.55% to 6.75%	7.15% to 7.25%
Increase in compensation cost	5.00% to 6.00%	5.00% to 7.00%
Retirement Age	60 years	60 years

Employee turnover - for all age groups

Age (Years)		Rate (p.a.)	
March 31, 2025	March 31, 2024*	March 31, 2025	March 31, 2024*
21 - 30	21 - 30	24.63%	24.04%
31 - 34	31 - 34	10.17%	5.81%
35 - 44	35 - 44	8.34%	4.73%
45 - 50	45 - 50	2.87%	0.75%
51 - 54	51 - 54	1.63%	0.10%
55 - 59	55 - 59	3.92%	0.03%

As per Indian Assured lives Mortality (2012-014) Ult. (March 31, 2024: Indian Assured Lives Mortality (2012-014) Ult.)

The estimates of future salary increases, considered in actuarial valuation take account of inflation, seniority, promotion and other relevant factors, such as supply and demand in the employment market.

g) Maturity profile of defined benefit obligation:

	₹ in crore	
	March 31, 2025	March 31, 2024*
Within 1 year	10.90	7.27
Between 2 and 5 years	42.66	30.34
Between 6 and 10 years	40.87	30.42
Beyond 10 years	138.66	130.48

The average duration of the defined benefit plan obligation at the end of the reporting year is 7.88 years (March 31, 2024: 9.42 years)

\* Refer note 32 b.

(This space has been intentionally left blank)



32 Business combination

a. Manipal Hospitals Synergie Private Limited ("MHSP") (formerly known as Medica Synergie Private Limited)

On June 25, 2024, Company acquired 0.69% shareholding in Manipal Hospitals Synergie Private Limited ("MHSP") (formerly known as Medica Synergie Private Limited) engaged in the business of running/managing hospitals and providing healthcare services for an equity consideration of ₹ 8.17 crores. Subsequently, on July 01, 2024, the Company acquired an additional 81.96% shareholding, bringing its total stake to 82.65% for an aggregate equity value consideration of ₹ 985.53 crores.

Further, during the quarter ended September 30, 2024, the Company acquired an additional 2.29% shareholding and voting rights in MHSP for an equity consideration of ₹ 27.33 crores. The Group acquired MHSP to expand its healthcare services business.

Accordingly, effective July 01, 2024, MHSP became a subsidiary of the Company and has been included in the Consolidated Financial Statements for the year ended March 31, 2025

The purchase price has been allocated based on management's estimates and independent appraisal of fair values as at July 01, 2024.

Component		(₹ in crore)		
Consideration paid on date of acquisition along with stamp duty charges		985.53		
<b>Total purchase consideration at fair value (A)</b>		<b>985.53</b>		
Assets	Valuation methodology	Acquiree's carrying amount	Fair value adjustments	Purchase price allocated
Property, plant and equipment	Fair value	343.91	85.80	429.71
Right of use asset	Fair value	26.76	10.60	37.36
Capital work in progress	Book value *	2.25	-	2.25
Intangible asset	Fair value	40.24	29.40	69.64
Inventories	Book value *	21.04	-	21.04
Trade receivables	Book value *	75.92	-	75.92
Cash and cash equivalents	Book value *	114.83	-	114.83
Bank balances other than cash and cash equivalents	Book value *	12.70	-	12.70
Loans	Book value *	0.45	-	0.45
Other financial assets	Book value *	34.12	-	34.12
Deferred tax assets	Fair value	37.52	(21.59)	15.93
Income tax assets (net)	Book value *	23.03	-	23.03
Other assets	Book value *	21.85	-	21.85
<b>Total assets</b>	<b>(B)</b>	<b>754.62</b>	<b>104.21</b>	<b>858.83</b>
Liabilities				
Borrowings	Book value *	164.25	-	164.25
Trade payables	Book value *	159.26	-	159.26
Lease liability	Book value *	20.23	-	20.23
Other financial liabilities	Book value *	60.11	-	60.11
Provisions	Book value *	23.23	-	23.23
Other liabilities	Book value *	11.43	-	11.43
<b>Total liabilities</b>	<b>(C)</b>	<b>438.51</b>	<b>-</b>	<b>438.51</b>
<b>Net assets</b>	<b>(D)=(B)-(C)</b>	<b>316.11</b>	<b>104.21</b>	<b>420.32</b>
Non-controlling interest	Non-controlling interests measured at fair value (E)			(74.70)
<b>Goodwill #</b>	<b>Residual method (F)=(A)-(D)-(E)</b>			<b>639.92</b>

\* Book values represent fair values as the assets will be realised and the liabilities will be settled at the book value post the acquisition.

# Goodwill is attributable to the expected increase in market share and the synergies expected to be achieved from control of MHSP. Goodwill is not income tax deductible.

The Consolidated Statement of Profit and Loss for the year ended March 31, 2025 includes revenue from operations of ₹ 554.50 crore and loss after tax of ₹ 3.03 crore resulting from acquisition of MHSP. Had the business combination occurred at the beginning of the accounting year the revenue from operations would have been higher by ₹ 184.18 crore and profit after tax higher by ₹ 5.44 crore, for the year ended March 31, 2025.

b. Business combination - Igenetic Diagnostics Private Limited

On September 13, 2024, National Company Law Tribunal (NCLT) has approved the Scheme of Arrangement ("the Scheme") of Healthmap Diagnostics Private Limited ("the Transferee Company" or "Healthmap") and Igenetic Diagnostics Private Limited ("the Transferor Company" or "Igenetic"), with Healthmap with the appointed date of April 01, 2022. The merger being under acquisition method, has been accounted in accordance with Ind AS 103 Business Combinations.



The arrangement will help in leveraging the combined resources, reaping the benefits in the form of higher net worth, combined cash pool resulting in greater integration, financial strength and flexibility of the merged entity, which will help in improving the competitive position of the combined entity

The arrangement will lead to synergies of operations and will help the merged entity in reaping the economies of scale, improving organizational capability to enable the entity to compete in an increasingly competitive healthcare industry.

The arrangement has been accounted under the "acquisition method" as per Ind AS 103 "Business Combinations". Pursuant to the Scheme, the assets and liabilities of Igenetic as at April 01, 2022 have been incorporated in the financial statements of the Company at their respective book values as appearing in the financial statements of the Company. The difference between the purchase consideration and the value of net assets acquired is adjusted against "goodwill".

Component	(₹ in crore)
Issue of Equity Shares	210.00
<b>Total purchase consideration at fair value (A)</b>	<b>210.00</b>

**Details of assets acquired and liabilities recognised as at April 01, 2022**

Assets	Valuation methodology	Acquiree's carrying amount as on April 01, 2022	Fair value adjustments	Purchase price allocated
Property, plant and equipment	Fair value	4.44	1.56	6.00
Right of use asset	Book value *	5.17	-	5.17
Intangible asset	Fair value	0.03	71.30	71.33
Inventories	Book value *	1.79	-	1.79
Trade receivables	Book value *	7.80	-	7.80
Cash and cash equivalents	Book value *	0.21	-	0.21
Other financial assets	Book value *	2.85	-	2.85
Income tax assets (net)	Book value *	1.76	-	1.76
Other assets	Book value *	0.20	-	0.20
<b>Total assets</b>	<b>(B)</b>	<b>24.25</b>	<b>72.86</b>	<b>97.11</b>
<b>Liabilities</b>				
Trade payables	Book value *	5.50	-	5.50
Lease liability	Book value *	5.44	-	5.44
Other financial liabilities	Book value *	0.16	-	0.16
Provisions	Book value *	0.27	-	0.27
Current liabilities	Book value *	1.79	-	1.79
<b>Total liabilities</b>	<b>(C)</b>	<b>13.16</b>	<b>-</b>	<b>13.16</b>
<b>Net assets</b>	<b>(D)=(B)-(C)</b>	<b>11.09</b>	<b>72.86</b>	<b>83.95</b>
<b>Goodwill #</b>	<b>Residual method (F)-(A)-(D)</b>	<b>198.91</b>	<b>(72.86)</b>	<b>126.05</b>

As per the scheme of arrangement order, 25,846 Equity Share of ₹ 10 each will be issued by Healthmap to shareholder of Igenetic against 102 Equity Shares of ₹100 each.

\* Book values represent fair values as the assets will be realised and the liabilities will be settled at the book value post the acquisition.

# Goodwill is attributable to the expected increase in market share and the synergies expected to be achieved from control of Igenetic. Goodwill is not income tax deductible

**On receipt of approval from NCLT, the effect of the scheme is incorporated in the Consolidated Financial Statements for the year ended March 31, 2024 which is presented below:**

**Summary of Statement of Profit and Loss**

Particulars	(₹ in crore)		
	As per Audited Consolidated Financial Statements as at March 31, 2024	Adjustments*	As at March 31, 2024
Total income	6,238.04	27.12	6,265.16
Total expense	(5,297.58)	(42.95)	(5,340.53)
Share of loss on equity accounted investee and exceptional items	(79.66)	(99.97)	(179.63)
Tax expense	(211.84)	-	(211.84)
<b>Profit after tax</b>	<b>648.96</b>	<b>(115.80)</b>	<b>533.16</b>



Summary of Balance sheet

	(₹ in crore)		
	As per Audited Consolidated Financial Statements as at March 31, 2024	Adjustments*	As at March 31, 2024
<b>Assets:</b>			
Property, plant and equipment and other intangible assets	4,117.81	56.90	4,174.71
Goodwill	2,747.55	11.98	2,759.53
Other assets **	3,911.70	(27.10)	3,884.60
<b>Total assets</b>	<b>10,777.06</b>	<b>41.78</b>	<b>10,818.84</b>
<b>Equity and liabilities:</b>			
Equity attributable to owners of the Company	4,028.63	(13.12)	4,015.51
Non-controlling interest	26.53	45.46	71.99
Other liabilities **	6,721.90	9.44	6,731.34
<b>Total equity and liabilities</b>	<b>10,777.06</b>	<b>41.78</b>	<b>10,818.84</b>

\* Represents amount pertaining to Igenetic business extracted from audited financial statements of Igenetic for the year ended March 31, 2024 as per the NCLT order and necessary consolidation adjustments.

\*\* Includes current and non-current, financial and non-financial, assets and liabilities.

c. **Business combination - Manipal Hospitals (East) India Private Limited ("MHEIPL") (formerly known as AMRI Hospitals Private Limited and AMRI Hospitals Limited)**

On September 20, 2023, the Manipal Hospitals Private Limited, subsidiary of Manipal Health Enterprises Private Limited acquired 84.07% shareholding and voting shares of MHEIPL on a fully diluted basis. MHEIPL is engaged in the business of running/ managing hospitals, and providing healthcare services for an equity value consideration of ₹ 366.06 crores. The Company also acquired Compulsorily convertible debentures of MHEIPL for a consideration of ₹ 314.57 crores. The Group acquired MHEIPL to enlarge the business of healthcare services.

Accordingly, effective such date MHEIPL is a subsidiary of the Company having 84.07% voting interest and has been included in the Consolidated Financial Statements for the year ended March 31, 2024.

The purchase price has been allocated based on management's estimates and independent appraisal of fair values as at September 20, 2023:

		(₹ in crore)		
<b>Component</b>		<b>Purchase price</b>		
Consideration paid on date of acquisition along with stamp duty charges		680.63		
<b>Total purchase consideration at fair value (A)</b>		<b>680.63</b>		
<b>Assets</b>	<b>Valuation methodology</b>	<b>Acquiree's carrying amount</b>	<b>Fair value adjustments</b>	<b>Purchase price allocated</b>
Property, plant and equipment	Fair value	828.94	(1.30)	827.64
Right of use asset	Book value *	192.18	-	192.18
Intangible asset	Fair value	3.44	57.40	60.84
Cash and cash equivalents	Book value *	24.74	-	24.74
Current assets	Book value *	213.20	-	213.20
<b>Total assets</b>	<b>(B)</b>	<b>1,262.50</b>	<b>56.10</b>	<b>1,318.60</b>
<b>Liabilities</b>				
Borrowings	Book value *	1,735.10	-	1,735.10
Lease liability	Book value *	6.04	-	6.04
Current liabilities	Book value *	205.95	-	205.95
Deferred tax liabilities	Fair value	-	14.45	14.45
<b>Total liabilities</b>	<b>(C)</b>	<b>1,947.09</b>	<b>14.45</b>	<b>1,961.54</b>
<b>Net assets</b>	<b>(D)=(B)-(C)</b>	<b>(684.59)</b>	<b>41.65</b>	<b>(642.94)</b>
Non-controlling interest	Non-controlling interests measured at fair value (E)	-	-	100.12
<b>Goodwill #</b>	<b>Residual method (F)=(A)-(D)-(E)</b>	<b>1,365.22</b>	<b>(41.65)</b>	<b>1,223.45</b>

\* Book values represent fair values as the assets will be realised and the liabilities will be settled at the book value post the acquisition.

# Goodwill is attributable to the expected increase in market share and the synergies expected to be achieved from control of MHEIPL. Goodwill is not income tax deductible.

The Consolidated Statement of Profit and Loss for the year ended March 31, 2024 includes revenue from operations of ₹ 568.05 crore and profit after tax of ₹ 4.51 crore resulting from acquisition of MHEIPL. Had the business combination occurred at the beginning of the accounting year the revenue from operations would have been higher by ₹ 506.73 crore and loss after tax higher by ₹ 10.79 crore, for the year ended March 31, 2024.



**33 Fair value hierarchy**

The Group uses the following hierarchy for determining and disclosing the fair value of financial instruments by valuation technique:

Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities

Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).

Level 3 - Inputs for the assets or liabilities that are not based on observable market data (unobservable inputs).

The fair value of the financial assets and liabilities is included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale.

The following methods and assumptions were used to estimate the fair value:

- The fair value of the quoted mutual funds are at Level 1 of Fair value hierarchy and are measured based on Net Asset Value (NAV) in active markets at the reporting date.

- The fair value of the financial assets (other than mutual funds) and financial liabilities were based on amortised cost at the reporting date.

The following table provides the fair value measurement hierarchy of financial assets and liabilities of the Group as at March 31, 2025 and March 31, 2024.

Quantitative disclosures fair value measurement hierarchy valued as at March 31, 2025:

March 31, 2025	Note No.	Level 1	Level 2	Level 3	Total
<b>Financial assets (at FVTPL)</b>					
Investment in mutual funds (quoted) (non-current)	6.1	143.09	-	-	143.09
Investment in mutual funds (quoted) (current)	10.1	1,337.93	-	-	1,337.93
		<b>1,481.02</b>	<b>-</b>	<b>-</b>	<b>1,481.02</b>

Quantitative disclosures fair value measurement hierarchy valued as at March 31, 2024:

March 31, 2024	Note No.	Level 1	Level 2	Level 3	Total
<b>Financial assets (at FVTPL)</b>					
Investment in mutual funds (quoted) (non-current)	6.1	114.39	-	-	114.39
Investment in mutual funds (quoted) (current)	10.1	1,004.92	-	-	1,004.92
		<b>1,119.31</b>	<b>-</b>	<b>-</b>	<b>1,119.31</b>

Set out below, is a comparison by class of the carrying amounts and fair value of the Company's financial instruments.

As at March 31, 2025

	Note No.	Carrying value		
		FVTPL	Amortised Cost	Total
<b>Financial assets: #</b>				
Investment in mutual funds (quoted) (non-current)	6.1	143.09	-	143.09
Other financial assets (non-current)	6.3	-	133.75	133.75
Investment in mutual funds (quoted) (current)	10.1	1,337.93	-	1,337.93
Other investments (unquoted) (current)	10.1	-	292.83	292.83
Trade receivables	10.2	-	637.30	637.30
Cash and cash equivalents	10.3	-	291.28	291.28
Bank balances other than cash and cash equivalents	10.4	-	39.01	39.01
Loans (current)	10.5	-	3.38	3.38
Other financial assets (current)	10.6	-	58.79	58.79
		<b>1,481.02</b>	<b>1,456.34</b>	<b>2,937.36</b>
<b>Financial liabilities:</b>				
Borrowings (non-current and current)	14.1	-	4,766.81	4,766.81
Lease liabilities (non-current and current)	14.2	-	1,618.34	1,618.34
Other financial liabilities (non-current)	14.3	-	34.96	34.96
Trade payables	17.2	-	1,126.59	1,126.59
Other financial liabilities (current)	17.3	-	117.74	117.74
		<b>-</b>	<b>7,664.44</b>	<b>7,664.44</b>

As at March 31, 2024\*

	Note No.	Carrying value		
		FVTPL	Amortised Cost	Total
<b>Financial assets: #</b>				
Investment in mutual funds (quoted) (non-current)	6.1	114.39	-	114.39
Loans (non-current)	6.2	-	0.05	0.05
Other financial assets (non-current)	6.3	-	87.44	87.44
Investment in mutual funds (quoted)	10.1	1,004.92	-	1,004.92
Trade receivables	10.2	-	458.88	458.88
Cash and cash equivalents	10.3	-	360.88	360.88
Bank balances other than cash and cash equivalents	10.4	-	18.91	18.91
Loans (current)	10.5	-	1.95	1.95
Other financial assets (current)	10.6	-	29.29	29.29
		<b>1,119.31</b>	<b>957.40</b>	<b>2,076.71</b>
<b>Financial liabilities:</b>				
Borrowings (non-current and current)	14.1	-	3,943.99	3,943.99
Lease liabilities (non-current and current)	14.2	-	1,186.26	1,186.26
Trade payables	17.2	-	1,130.53	1,130.53
Other financial liabilities (current)	17.3	-	62.76	62.76
		<b>-</b>	<b>6,323.54</b>	<b>6,323.54</b>

# excludes investment in equity instruments

\* Refer note 32 b.

There have been no transfers among Level 1, Level 2 and Level 3 during the year.

The management assessed that fair value of cash and cash equivalents and bank balances other than cash and cash equivalents, trade receivables, trade payables and other financial assets and liabilities approximate their carrying amounts largely due to the short-term maturities of these instruments. Fair value of non-current financial liabilities has not been disclosed as there is no significant difference between carrying value and fair value.



34 Financial risk management

The Group's principal financial liabilities, comprise loans and borrowings, trade and other payables. The main purpose of these financial liabilities is to finance the Group's operations. The Group's principal financial assets include loans, investments, trade and other receivables, and cash and cash equivalents that derive directly from its operations.

The Group's activities expose it to market risk, credit risk and liquidity risk. The Group's management oversees the management of these risk and works towards minimizing the potential adverse effects, if any, on its financial performance.

A. Market risk

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprises interest rate risk and currency rate risk. Financial instruments affected by market risk include loans and borrowings, payables, investments and deposits. The sensitivity analyses in the following sections relate to the position as at March 31, 2025 and March 31, 2024. The sensitivity of the relevant Profit and Loss item is the effect of the assumed changes in the respective market risks. This is based on the financial assets and financial liabilities held as of March 31, 2025 and March 31, 2024.

(i) Interest rate risk

Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company's exposure to the risk of changes in market interest rates relates primarily to the Company's debt obligations with floating interest rates in form of Term loans.

Interest rate sensitivity

Fixed rate instruments	March 31, 2025	March 31, 2024
<b>Financial asset</b>		
Margin money deposit with banks and financial institutions	43.11	12.82
Deposits with banks due to mature after twelve months from the reporting date	53.26	25.34
Bank Deposits due to mature within twelve months from the reporting date	39.01	18.91
Deposits with banks original maturity with more than twelve months	1.00	-
Earnest money deposit	0.23	0.23
Deposits with original maturity of less than three months	88.75	38.30
Other investments	292.83	-
<b>Financial liability</b>		
Borrowings	404.89	430.45
<b>Variable rate instruments</b>	<b>March 31, 2025</b>	<b>March 31, 2024</b>
<b>Financial asset</b>		
Investments in mutual funds (quoted)	1,481.02	1,119.31
<b>Financial liability</b>		
Borrowings	4,361.92	3,513.54

Sensitivity analysis for fixed rate instruments

Based on the closing balance of fixed rate instruments, an increase/ decrease in interest rate by 1%, with all other variables remaining constant would result in increase/ decrease in interest cost by ₹ -1.10 crore (year ended March 31, 2024: ₹ 3.35 crore).

Sensitivity analysis for variable rate instruments

Based on the closing balance of variable rate instruments, an increase/ decrease in interest rate by 1%, with all other variables remaining constant would result in increase/ decrease in interest cost by ₹ 28.80 crore (year ended March 31, 2024: ₹ 23.94 crore).

(ii) Foreign currency risk

Foreign currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. The Group's exposure to the risk of changes in foreign exchange rates relates primarily to the Group's operating activities (when revenue or expense is denominated in a foreign currency), the Company's net investments in foreign subsidiaries and financial guarantees given to foreign subsidiaries.

Particulars of unhedged foreign currency exposure as at the reporting date:

Particulars	March 31, 2025		March 31, 2025		March 31, 2024	
	USD (million)	(₹ in crore)	EURO (million)	(₹ in crore)	USD million	(₹ in crore)
Import trade payable	0.21	1.81	-	-	0.03	0.20
Capital creditors	0.03	0.30	0.70	5.70	0.06	0.48
Trade receivables	0.01	0.11	-	-	0.02	0.16
Capital Advances	-	-	-	-	0.01	0.04

Foreign currency risk sensitivity

The sensitivity of profit or loss to changes in exchange rates arises mainly from foreign currency denominated financial instruments and the impact on equity arises from changes in foreign exchange rates relating to the Company's net investments in foreign subsidiaries which are primarily in USD. The sensitivity to a reasonably possible change in USD exchange rates, with all other variables held constant:

Depreciation of INR against USD and EURO by 1% results in decrease in profit before tax by ₹ 0.08 (March 31, 2024 by ₹ Nil) and appreciation of INR against USD and EURO by 1% results in increase by such amount.

B. Credit risk

Credit risk is the risk that the counterparty will not meet its obligation under a financial instrument or customer contract, leading to financial loss. The credit risk arises principally from its operating activities (primarily trade receivables) and from its investing activities, including deposits with banks and financial institutions and other financial instruments.

Credit risk is controlled by analysing credit limits and creditworthiness of customers on a continuous basis to whom credit has been granted after obtaining necessary approvals for credit. The collection from the trade receivables are monitored on a continuous basis by the management of the Group.



(i) Trade receivables:

The Group establishes an allowance for impairment that represents its estimate of expected losses in respect of trade receivables based on the past and the recent collection trend. The maximum exposure to credit risk as at reporting date is primarily from trade receivables amounting to ₹ 637.30 crore (March 31, 2024: ₹ 458.88 crore). The movement in allowance for impairment in respect of trade receivables during the year was as follows:

	(₹ in crore)	
	March 31, 2025	March 31, 2024*
Opening balance	79.77	80.26
Additions on account of acquisition of subsidiary (refer note 32 a and c)	72.50	4.94
Reversal of provision for unbilled revenue	-	(1.72)
Loss (reversals) on trade receivables (net)	(31.05)	(3.71)
Closing balance	<u>121.22</u>	<u>79.77</u>

There is no significant concentration of credit risk and no single customer accounted for more than 10% of the revenue as of March 31, 2025 and March 31, 2024.

\* Refer note 32 b.

(ii) Other receivables:

The Company establishes an allowance for impairment that represents its estimate of expected losses in respect of other receivables based on the past and the recent collection trend. The maximum exposure to credit risk as at reporting date is primarily from other receivables amounting to ₹ 26.06 crore (March 31, 2024: ₹ 19.88 crore). The movement in allowance for impairment in respect of trade and other receivables during the year was as follows:

	(₹ in crore)	
	March 31, 2025	March 31, 2024
Opening balance	1.29	0.62
Additions on account of acquisition of subsidiary (refer note 32 a and c)	-	0.04
Loss (reversals) /allowance on other receivables (net)	(0.53)	0.63
Closing balance	<u>0.76</u>	<u>1.29</u>

(iii) Loans to others:

The Company establishes an allowance for impairment that represents its estimate of expected losses in respect of loans to others based on the past and the recent collection trend. The maximum exposure to credit risk as at reporting date is primarily from loans to others amounting to ₹ Nil (March 31, 2024: ₹ 0.05 crore). The movement in allowance for impairment in respect of trade and other receivables during the year was as follows:

	(₹ in crore)	
	March 31, 2025	March 31, 2024
Opening balance	-	5.00
Reclassified to investment	-	(5.00)
Closing balance	<u>-</u>	<u>-</u>

(v) Financial instruments and cash deposits:

Credit risk on cash and cash equivalents and deposits is limited as the Group generally transacts with banks with high credit ratings assigned by international and domestic credit rating agencies. Investments of surplus funds, temporarily, are made only with approved counterparties, who meet the minimum threshold requirements under the counterparty risk assessment process. The Group's maximum exposure for financial guarantees is given in note 38.

C. Liquidity risk

Liquidity risk is the risk that the Group will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Group's approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when they are due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Group's reputation. Also, the Group has unutilized credit limits with banks.

The Group's corporate treasury department is responsible for liquidity, funding as well as settlement management. In addition, processes and policies related to such risks are overseen by senior management.

The table below summarises the maturity profile of the Group's financial liabilities based on contractual undiscounted payments.

	(₹ in crore)		
	As at March 31, 2025		
	Less than 1 year	More than 1 year	Total
Borrowings	678.18	6,911.40	7,589.58
Lease liabilities	193.13	5,177.02	5,370.15
Trade payables	1,126.59	-	1,126.59
Other financial liabilities	117.74	34.96	152.70
	As at March 31, 2024*		
	Less than 1 year	More than 1 year	Total
Borrowings	570.26	5,488.25	6,058.51
Lease liabilities	153.55	3,901.20	4,054.75
Trade payables	1,130.53	-	1,130.53
Other financial liabilities	62.76	-	62.76

\* Refer note 32 b.

35(A) Capital management

The primary objective of Group's capital management is to ensure that it maintains an optimum financing structure and healthy returns in order to support its business and maximize shareholder value.

The Group manages its capital structure and makes adjustments, in light of the changes in economic conditions or business requirements.

The Group monitors capital using a gearing ratio which is net debt divided by total equity plus net debt as shown below.

- Net debt includes borrowings, lease liabilities (long term and short term) less cash and cash equivalents, investment in mutual funds and other investments and
- Total equity comprises of issued share capital and all other equity components attributable to equity share holders



	(₹ in crore)	
	March 31, 2025	March 31, 2024*
Borrowings (refer note 14.1)	4,766.81	3,943.99
Lease liabilities (refer note 14.2)	1,618.34	1,186.26
Less: Cash and cash equivalents (refer note 10.3)	(291.28)	(360.88)
Less: Investments in mutual funds and other investments (refer note 6.1 & 10.1)	(1,773.85)	(1,119.31)
<b>Net debt (A)</b>	<b>4,320.02</b>	<b>3,650.06</b>
Total equity attributable to the equity share holders of the Group	5,806.55	4,013.58
<b>Total capital (B)</b>	<b>5,806.55</b>	<b>4,013.58</b>
<b>Capital and net debt (C = A+B)</b>	<b>10,126.57</b>	<b>7,663.64</b>
<b>Gearing ratio (D = A / C)</b>	<b>43%</b>	<b>48%</b>

\* Refer note 32 b.

**35 B** During the year ended March 31, 2023, the Income tax department conducted a search under section 132 of the Income tax Act, 1961 at the registered office of MHEPL and certain hospital locations. During the course of the search proceedings, certain information and documents were sought by the department. On March 29, 2024, the Group has received assessment orders for MHEPL, MHPL and MHBPL, with respect of above-mentioned matter, comprising demand u/s 156 of the Income-tax Act, 1961 for the Assessment Year (AY) 2019-20 amounting to ₹ 5.90 crore (including interest) and AY 2022-23 amounting to ₹ 7.98 crore (including interest) towards disallowance of certain expenses which are routine in nature and are in ordinary course of business. In April, 2024, the Group had filed appeals with CIT (A) against the same. On May 28, 2024, MHEPL, received rectification orders u/s 154 for AY 2019-20 and AY 2022-23 revising the demand raised earlier. Total Group's tax demand revised to Rs. 1.69 crore (including interest) and Rs. 11.85 crore (including interest) for AY 2019-20 and AY 2022-23 respectively. In the year ended March 31, 2025, the Group has received assessment orders for MHEPL, MHPL and MHBPL, with respect of above mentioned matter, comprising demand u/s 156 of the Income Tax Act, 1961 for AY 2020-21 amounting to ₹ 23.06 crore (including interest), for AY 2021-22 amounting to ₹ 7.07 crore(including interest) and for AY 2023-24 amounting to ₹ 8.97 crore (including interest) towards disallowance of certain expenses which are routine in nature and are in ordinary course of business. The Group has filed appeals with CIT (A).

The Group is confident that its position will be upheld for above income tax litigations and the likelihood of an adverse outcome is remote. Accordingly, the outcome of these litigations is not expected to have a material effect on the Consolidated Financial Statements.

(This space has been intentionally left blank)



**36 Investment in Joint Venture**

The Group has interest in Terrals Technologies Private Limited, involved in the business of providing digital healthcare technology to patients and doctors, providing a secure repository for storing medical data, designing and developing machine learning and artificial intelligence algorithms on healthcare data, aggregated reports on healthcare data and patient care services.

The Group's equity interest in Terrals Technologies Private Limited is accounted for as a Joint Venture using the equity method as per Ind AS 28 "Investments in Associates and Joint Ventures" effective from February 26th, 2021 in the consolidated financial statements. Summarised financial information of the joint venture, based on its unaudited financial statements (prepared by its management), and reconciliation with the carrying amount of the investment in consolidated financial statements are set out below:

	March 31, 2025	March 31, 2024
<b>Proportion of the Group's ownership</b>	20.59%	20.59%

<b>Carrying amount of the investment</b>	-	-
------------------------------------------	---	---

Summarised statement of profit and loss of Terrals Technologies Private Limited:

	(₹ in crore)	
	March 31, 2025	March 31, 2024
Revenue from contracts with customers	-	-
Other income	-	-
Purchase of medical consumables and pharmacy items	-	-
Employee benefits expense	-	-
Finance cost	-	-
Other expenses	-	-
<b>(Loss) before tax and exceptional item</b>	-	-
Exceptional item	-	-
<b>(Loss) before tax</b>	-	-
Total tax expense including deferred tax charge/(credit) ₹ Nil crore (March 31, 2024 : ₹ Nil crore)	-	-
<b>(Loss) for the year</b>	-	-
Other comprehensive income for the year	-	-
<b>Total comprehensive income for the year</b>	-	-
<b>Group's share of loss including other comprehensive income for the year</b>	-	-
Gain on dilution of share holding included in other income	-	-
<b>Group's share of loss for the year</b>	-	-

There is no quoted market prices available for the company. There is no unrecognised share of losses of joint venture.

In the absence of information about the Joint Venture, the Group has impaired its entire investment.

Investment in Terrals Technologies Private Limited ("Terrals") is fully impaired with no further funding obligation as on date. Financial information of Terrals is not available and this investment is not material to the Consolidated Financial Statements.

Refer note 5.1.1 for impairment.

*(This space has been intentionally left blank)*



37 Investment in Associate Company

37 a I-Genetics Diagnostics Private Limited

The Group has interest in I-Genetics Diagnostics Private Limited, involved in the business of providing affordable healthcare services including genetic diagnostics, molecular diagnostics, other diagnostics, clinical trial services, epigenomics. It will also undertake, promote, or engage in all kind of research and development work required to promote, assist or engage in setting up diagnostics setup.

The Group's equity interest in I-Genetics Diagnostics Private Limited is accounted for as a Associate using the equity method as per Ind AS 28 "Investments in Associates and Joint Ventures" effective from March 02, 2022 in the Consolidated Financial Statements.

The investment is accounted for using the equity method from the date on which it becomes an associate. On acquisition of the investment, the difference between the investment value and the entity's share of the net fair value of the investee's identifiable assets and liabilities is identified as Goodwill amounting to ₹ 39.74 crore which is included in the investment value.

Summarised financial information of the associate, based on its Financial Statements, and reconciliation with the carrying amount of the investment in Consolidated Financial Statements are set out below:

Summarised balance sheet

	(₹ in crore)	
	March 31, 2025	March 31, 2024*
Current assets	-	-
Non-current assets	0.01	0.02
Current liabilities	(1.33)	(0.80)
Non-current liabilities	(0.01)	(0.01)
<b>Equity</b>	<b>(1.33)</b>	<b>(0.79)</b>
<b>Proportion of the Group's ownership</b>	<b>42.17%</b>	<b>42.17%</b>

Carrying amount of the investment

Summarised statement of profit and loss of Igenetics:

	(₹ in crore)	
	March 31, 2025	March 31, 2024*
Revenue from operations	-	-
Other income	-	-
Finance income	-	-
<b>Total Income</b>	<b>-</b>	<b>-</b>
Purchase of medical consumables and pharmacy items	-	-
Employee benefits expense	0.53	0.38
Finance costs	-	-
Depreciation and amortization expense	0.01	0.01
Other expenses	0.01	-
<b>Total expense</b>	<b>0.55</b>	<b>0.39</b>
<b>Loss for the year</b>	<b>0.55</b>	<b>0.39</b>
Other comprehensive income for the year	-	-
<b>Total comprehensive income for the year</b>	<b>0.55</b>	<b>0.39</b>
<b>Group's share of loss including other comprehensive income for the year</b>	<b>0.23</b>	<b>0.16</b>

\* Refer note 32 b.

There is no quoted market prices available for the company. Unrecognised share of losses of associate is ₹ 0.89 crore (March 31, 2024: ₹ 0.66 crore).

37 b Medica TS Hospital Private Limited

The Group has interest in Medica TS Hospital Private Limited ('Medica TS'), involved in the business of providing healthcare services.

The Group's equity interest in Medica TS is accounted for as a Associate using the equity method as per Ind AS 28 "Investments in Associates and Joint Ventures" effective from July 01, 2024 in the Consolidated Financial Statements.

The investment is accounted for using the equity method from the date on which it becomes an associate. Medica TS was acquired as part MHSPL acquisition. MHSPL has made provision for impairment of its investment in Medica TS of ₹ 22.23 crore as it does not expect any recoverable amount from its investment.

Summarised financial information of the associate, based on its Financial Statements, and reconciliation with the carrying amount of the investment in Consolidated Financial Statements are set out below:



Manipal Health Enterprises Private Limited  
Notes to the Consolidated Financial Statements for the year ended March 31, 2025

Summarised balance sheet

	(₹ in crore)
	March 31, 2025
Current assets	15.17
Non-current assets	36.75
Current liabilities	(6.71)
Non-current liabilities	(1.53)
<b>Equity</b>	<b>43.68</b>

Proportion of the Group's ownership

41.62%

Carrying amount of the investment

-

Summarised statement of profit and loss for the period starting from July 01, 2024 till March 31, 2025:

	March 31, 2025
Revenue from operations	25.48
Other income	0.47
Finance income	-
<b>Total Income</b>	<b>25.95</b>
Purchase of medical consumables and pharmacy items	6.20
Change in inventories	0.02
Employee benefits expense	10.22
Finance costs	0.13
Depreciation and amortization expense	2.46
Other expenses	8.32
<b>Total expense</b>	<b>27.35</b>
<b>Loss for the year</b>	<b>(1.40)</b>
Other comprehensive income for the year	(0.05)
<b>Total comprehensive income for the year</b>	<b>(1.45)</b>
Group's share of loss including other comprehensive income for the year	(0.60)

(This space has been intentionally left blank)



38 Contingent liabilities

Particulars	(₹ in crore)	
	March 31, 2025	March 31, 2024*
(A) Claims against the Group not acknowledged as debts		
(a) Patient Compensation	32.47	168.31
(b) Income Tax Demand	97.82	58.85
(c) Indirect Tax Demand	88.11	31.29
(B) Guarantees		
(a) Bank guarantees	15.21	9.55
	<b>233.61</b>	<b>268.00</b>

\* Refer note 32 b.

(A) (a) Patient Compensation

There are certain claims made against the Company in respect of patient compensation. The cases are pending with various Consumer Disputes Redressal Commissions. Based, on the legal counsel's views, the management does not expect these claims to succeed. Accordingly, no provision for liability has been recognized in the Consolidated Financial Statements.

There are certain litigations for the period prior to February 18, 2014 as stated in Annexure 23 of the BTA entered by Manipal Hospitals (Jaipur) Private Limited (merged with MHDPL) with Soni Hospital Private Limited amounting to ₹ 5.03 crore in respect of patient compensation. The cases are pending with various judicial authorities. Pursuant to Section 4.13 (iii and iv) of the BTA, any claims including penalties arising on these litigations shall be borne by Soni Hospital Private Limited.

The Group is confident that its position will be upheld for above litigations and accordingly no provision has been made in the Consolidated Financial Statements.

(A) (b) Income Tax Demand

(i) MHEPL received two demand notices u/s 156 of the Income Tax Act, 1961 for AY 2014-15 relating to disallowance of back-office charges, disallowance u/s 14A and demand of Dividend Distribution tax and non consideration of self-assessment tax paid. The Company filed an appeal before CIT (Appeals) and got favorable order for back-office charges. Subsequently, the Company filed an appeal with ITAT for disallowance u/s 14A and the Assessing Officer had filed an appeal with ITAT for back-office charges. Both matters were held in favor of the Company by the ITAT. In relation to demand of Dividend Distribution tax and non consideration of self assessment tax paid, the Company had filed a rectification request to the AO and the same is still pending disposal. Total contingency of ₹ 3.30 crores (March 31, 2024: ₹ 3.48 crores)

During the year ended March 31, 2019, MHEPL had received the ITAT order dated June 27, 2018, for AY 2011-12 in which ITAT had held that Manipal Health Systems Private Limited ('MHS') and Manipal Health Enterprises Private Limited ('MHE') demerger is not a slump sale and also allowed the back-office expenses, partial depreciation and remanded back one matter to AO. Against ITAT order, the department had filed an appeal in the High Court of Karnataka. Karnataka HC held the matters in favour of the Company except one matter which is remanded back to AO for reconsideration. The matters of one consultancy fee and 14A disallowance are with AO for reconsideration having a tax impact of ₹ 1.28 crore (March 31, 2024: ₹ 1.28 crore).

During the year ended March 31, 2020, MHEPL has received the order U/s 143(3) of the Income Tax Act, 1961 for AY 2017-18 as per which AO has not allowed short term capital loss on account of relinquishment of its investment in the shares of a subsidiary and disallowed certain other expense. The aforesaid disallowances have resulted in a tax impact of ₹ 27.61 crore (March 31, 2024: ₹ 27.61 crore). The Company has filed an appeal before CIT (Appeals) and the same has been admitted.

During the year ended March 31, 2021, MHEPL has received demand notices of ₹ 21.20 crore (March 31, 2024: ₹ 21.20 crore) under section 156 of the Income-tax Act, 1961 for AY 2018-19 towards disallowance of back-office expenses, provision for doubtful debts, Ind-AS adjustment, disallowance under section 14A and set off of brought forward capital loss. The Company has filed appeal before CIT (Appeals) against the demand notices.

(ii) MHBPL has received demand notice of Rs 1.15 crore w.r.t to AY 2018-19 towards disallowance of entire depreciation on leasehold improvements, dis-allowed portion of rent and interest on security deposits. The Company has filed an appeal with CIT (Appeals). On Feb 26, 2025, CIT(Appeals) held these matters in favour of the Company and deleted the additions. Total Contingency of ₹ Nil (March 31, 2024: ₹ 1.15 crore)

(iii) MHBPL has received demand notice for penalty of Rs 0.66 crore under section 271(1)(C) of the Income-tax Act, 1961 for the Assessment Year (AY) 2012-13 in March 2022 towards disallowance of interest expenses. The Company has filed appeal before CIT (Appeals) against the above demand notice. On Feb 28, 2025, CIT (Appeals) held the matter in favour of the Company and that the penalty is liable to be deleted. Total Contingency of ₹ Nil (March 31, 2024: ₹ 0.66 crore)

(iv) During the year ended March 31, 2025, MHBPL has received the order u/s 201 of the Income Tax Act, 1961 for AY 2019-20 as per which Assessing Officer has created a demand of ₹ 0.03 crore towards short deduction of TDS. The Company has filed an appeal before CIT (Appeals) and the same has been admitted.

(v) Healthmap had disputed Income tax demand raised by Income tax authorities for the assessment years 2016-17. Healthmap had filed appeal before CIT (Appeals) and also filed rectification application against the said order. The aggregate amount of disputed tax not provided for is ₹ 3.47 crore.

(vi) During the year ended March 31, 2024, MH Eastern had received the order u/s 143(3) of the Income Tax Act, 1961 for AY 2022-23 as per which AO has made disallowances in respect of non-deduction of TDS, provision of expense, provision for doubtful debt and unexplained cash credits having a tax impact of ₹ 34.44 crore. The Company has filed an appeal before CIT (Appeals) and the same has been admitted. During the year ended March 31, 2025, the Company has paid pre-deposit of ₹ 6.89 crore towards this demand and received stay order on recovery of demand till disposal of appeal.

(vii) During the year ended March 31, 2019, MH Bengal had received the order u/s 143(3) of the Income Tax Act, 1961 for AY 2016-17 as per which AO has made disallowances in respect of business losses carried forward from the amalgamated Company NBOCPL and bad debt written off having a total tax impact of ₹ 0.42 crore. The Company has filed an appeal before CIT (Appeals) and the same has been admitted.



(viii) During the year ended March 31, 2020, MH Bengal had received the order u/s 143(3) of the Income Tax Act, 1961 for AY 2017-18 as per which AO has made disallowances in respect of business losses carried forward from the amalgamated Company NBOCPL having a tax impact of ₹ 0.42 crore. The Company has filed an appeal before CIT (Appeals) and the same has been admitted.

(ix) During the year ended March 31, 2025, MH Bengal has received the order u/s 143(3) of the Income Tax Act, 1961 for AY 2023-24 as per which Assessing Officer has made disallowances of various expenses like consumables, marketing exps. etc. creating a demand of ₹ 3.96 crore. The Company has filed an appeal before CIT (Appeals) and the same has been admitted.

(x) During the year ended March 31, 2021, MHSPL had received the order u/s 143(3) of the Income Tax Act, 1961 for AY 2018-19 as per which Assessing Officer has made disallowances in respect of variance in revenue reported in ITR vs 26AS having a tax impact of ₹ 4.45 crore. The Company has filed an appeal before CIT (Appeals) and the same has been admitted. The said assessment order was further rectified suo moto by Assessing Officer u/s 154 on May 05, 2021 giving benefit of brought forward losses and reducing the final tax impact to ₹1.69 crore.

The Group is confident that its position will be upheld for above income tax litigations and accordingly no provision has been made in the Consolidated Financial Statements.

**(A) (c) Indirect Tax Demand**

(i) MHEPL has received a show cause notice under section 124 of the Customs Act, 1962, for the financial year 2012-13, from Assistant Commissioner of Customs, as to why customs duty of ₹ 0.08 crore (March 31, 2024: ₹ 0.08 crore) with interest and penalty should not be demanded with regard to short payment of customs duty due to incorrect classification of goods.

(ii) MHEPL received a demand order from the Commercial Tax officer, wherein a Luxury Tax adjustment of ₹ 2.40 crore (March 31, 2024: ₹ 2.40 crore) has been made on claim for improper exemption for financial years 2010-11, 2011-12 and 2012-13.

(iii) During the year ended March 31, 2021, MHEPL has received two notice from the Customs Department asking to submit the Proof of Evidence fulfilling the Export Obligation mentioned in EPCG License. During the six months ended September 30, 2024, Export Obligation stipulated in the License has been met in full vide Export obligation discharge certificate issued by DGFT accordingly the contingent liability in this regard is ₹ Nil (March 31, 2024: ₹ 3.50 crore).

(iv) During the year ended March 31, 2021, MHEPL has received proposition notice for an amount of ₹ 1.09 crore (March 31, 2024: ₹ 1.09 crore) (including interest) from the Assistant Commissioner of Commercial Taxes, (Luxury Tax) asking to furnish the details of accommodation charges collected in ICU as well as in ward for FY 2012-13. The Company has replied to the department stating that the case is time barred and requested to drop the proceedings. Further there is no communication from the department. However, the same has been disclosed as contingent liability.

(v) During the year ended March 31, 2025, MHEPL has received an order issued by Joint Commissioner for the period March'21 to September'22, wherein GST demand of ₹ 5.63 crore and equal amount of ₹ 5.63 crore as penalty with interest is raised towards Non- Payment of GST on Supply of COVID-19 vaccines and its related vaccination charges. Aggrieved by the impugned order, subsequent to the year end, the Company has filed a Writ before Hon'ble High Court of Karnataka and obtained the stay.

(vi) MHPL went in for Advance Ruling seeking clarification on chargeability of GST on activities performed by its employees at the Corporate office in the course of or in relation to employment viz., accounting, other administrative and IT system maintenance for its units located in states outside of the Karnataka. The Authority for Advance Ruling passed an order calling it as supply and hence chargeable to GST. Aggrieved by the order, MHPL appealed against the said order with the Appellate Authority of Advance Ruling (AAAR) which again passed the order in favour of Revenue. Aggrieved by the order passed by AAAR, MHPL has filed a writ petition with the Hon'ble high court of Karnataka on 26th April 2019 to quash the said order. Fresh Interlocutory Applications, challenging the validity of constitution of AAR/AAAR was listed for hearing in April 2021. The matter was heard and the respondents (Union and State) were directed to file objections. Expected liability as on March 31, 2025 is ₹ 12.38 crore (As on March 31, 2024: ₹ 10.71 crore).

(vii) In MHPL, During the year 2016-17, while filing TRAN-1- Transitional ITC for CENVAT Credit and Value added Tax (VAT) credit, MHPL has inadvertently claimed SGST credit in TRANS-1 amounting to ₹ 0.47 crore while there was no VAT credit available to be transitioned to Goods and Service Tax (GST). Upon realizing its mistake, MHPL has voluntarily remitted back the same amount. Subsequently, the department issued notice for difference in credit claimed as per Tran 1 and VAT returns and has demanded interest of ₹ 0.07 crore and penalty of ₹ 0.05 crore as applicable under KGST Act. MHPL has thereafter made payment of the interest in 2021. Considering the above fact, MHPL has already remitted the impugned amount even before the authorities identified along with the interest, MHPL believes it has a good case and the penalty imposed would be set aside.

(viii) In MHPL, Commissioner, Central Tax (Audit-I, Commissionerate) has issued show cause notice no.54/2020-21 CTA-1/Commr. dtd.30.12.2020 towards non-reversal of Cenvat credit/non-payment of Service Tax payable under provisions of Rule 6 of the Cenvat Credit Rules, 2004 in respect of exempted services for the period from October 1, 2014 to June 30, 2017 for an amount of ₹ 10.10 crore including interest and penalty. MHPL has remitted the tax amount of ₹3.55 crore under protest and filed response to the notice before the Principal Commissioner/ Commissioner of Central Tax, East Commissionerate on February 26, 2021. The authorities vide OIO No. 57/2021 dt. November 30, 2021 confirmed the aforesaid demand including interest and penalty. Aggrieved by the impugned order, the Company has filed the appeal with CESTAT on April 18, 2022.

(ix) In MHPL, Deputy Commissioner, Circle IV, Central Tax (Audit-I, Commissionerate) has issued show cause notice no.47/2020-21 CTA-1/Dy Commr. dtd. December 18, 2020 towards non-payment of Service Tax under reverse charge on services received from Director of MHPL payable under Section 68(2) of the Finance Act, 1994 for an amount of ₹ 1.30 crore (March 31, 2024: ₹ 1.30 crore) including interest and penalty. MHPL has filed its response to the show cause notice before the Deputy/Assistant Commissioner of Central Tax East division -5, Bangalore East Commissionerate on January 18, 2021. The authorities vide OIO No. 199/2022 dt. March 31, 2022 confirmed the aforesaid demand including interest and penalty. Aggrieved by the impugned order, the Company filed the appeal with Commissioner of Service Tax(Appeals) on June 16, 2022 and remitted the tax amount of ₹ 0.31 crore under protest.

(x) During the year ended March 31, 2025, MHPL has received an order issued by Joint Commissioner for the period March'21 to September'22, wherein GST demand of Rs.2.38 crore and equal amount of penalty with interest is raised towards Non- Payment of GST on Supply of COVID-19 vaccines and its related vaccination charges. Aggrieved by the impugned order, subsequently the Company has filed a Writ before Hon'ble High Court of Karnataka and obtained the stay.



(xi) During the year ended March 31, 2024, due to acquisition of Manipal Hospitals (East) India Private Limited (formerly known as AMRI Hospitals Private Limited), Service tax demand of ₹1.99 crore (March 31, 2024: ₹ 1.99 crore) existed towards renting of immovable property and pending before Additional Commissioner, CGST & CX, Kolkata. The authority confirmed the aforesaid demand including interest and penalty. Aggrieved by the impugned order, the Company filed the appeal with Commissioner(Appeal-I). As per share purchase agreement entered into with the erstwhile shareholder of the company, the case is fully indemnified in the event of an unfavourable outcome.

(xii) During the year ended March 31, 2025, Manipal Hospitals (East) India Private Limited (formerly known as AMRI Hospitals Private Limited and AMRI Hospitals Limited), has received the demand order from Additional Commissioner for the period 2017-18 till 2021-22, wherein demand of ₹ 27.13 crores raised towards Non payment of GST on renting of immovable property. Aggrieved by the impugned order, the Company has filed a writ petition with the Hon'ble High Court of Kolkata. As per share purchase agreement entered into with the erstwhile shareholder of the company, the case is fully indemnified in the event of an unfavourable outcome.

(xiii) MH Eastern has received demand order from Deputy Commissioner for the FY 2018-19, wherein demand of ₹6.95 crore raised towards short payment of GST on supply of drugs and consumables to in-patients. Aggrieved by the impugned order, the Company has filed the appeal with Additional Commissioner, CGST & CX.

(ix) MH Eastern has received demand order from Deputy Commissioner for the FY 2019-20, wherein demand of ₹7.51 crore raised towards short payment of GST on supply of drugs and consumables to in-patients. Aggrieved by the impugned order, the Company has filed the appeal with Additional Commissioner, CGST & CX.

(x) MH Eastern, for the FY 2014-15, Deputy Commissioner of Commercial Taxes raised demand of ₹ 0.73 crore towards differences in purchase values identified in Annual Return vis-à-vis Trading account filed and for under reporting of sales turnover. Aggrieved by the impugned order, the Company has filed the appeal with Joint Commissioner of Commercial Tax (Appeals)

(xi) MH Eastern had received assessment order issued by Commercial tax officer for the FY 2013-14, wherein VAT demand of ₹ 0.06 crore raised towards supply of drugs and consumables to in-patients. Aggrieved by the impugned order, the Company has filed the appeal with Joint Commissioner of Commercial tax (Appeals).

(xii) MH Eastern had received assessment order issued by Commercial tax officer for the FY 2014-15, wherein VAT demand of ₹ 0.21 crore and CST demand of ₹ 0.04 crore raised towards supply of drugs and consumables to in-patients. Aggrieved by the impugned order, the Company has filed the appeal with Joint Commissioner of Commercial tax (Appeals).

Additionally, the Group is also involved in other disputes, lawsuits and claims, including commercial matters, which arise from time to time in the ordinary course of business. The Group is confident that its position will be upheld for above indirect tax litigations and will not have material effect on the Consolidated Financial Statements and accordingly no provision has been made in the Consolidated Financial Statements.

Pending resolution of the respective proceedings, it is not practicable for the Group to estimate the timings of cash outflows, if any, in respect of the above as it is determinable only on receipt of judgements/decisions pending with various forums/authorities.

**(A) (d) Others**

(i) The Company, as per the Employees' provident Fund (EPF) and Miscellaneous provisions Act, 1952 ('the Act') is required to contribute provident fund at a certain defined percentage on basic wages (including certain allowances) and along with employee's contribution it has to be deposited with the EPF authorities. On February 28, 2019, the Supreme Court of India held that allowances meeting certain conditions paid by establishments to its employees should also be considered as "basic wages" while computing provident fund amounts for employees whose basic wages is less than certain statutory thresholds. This court ruling may have an impact of increasing Company's liability towards provident fund contributions which is a defined contribution plan. However, the Company based on the legal advice in this EPF matter believes that there is a considerable uncertainty due to which provision cannot be estimated reliably of the retrospective impact on EPF contribution.

**(C) Indemnities for performance given on behalf of third parties**

During the year ended March 31, 2021, the Company has given indemnity against performance of third parties to RSDH (Malaysia) Sdn Bhd, MYR 36.96 crore (March 31, 2024: MYR 37.00 crore) equivalent to ₹ 711.20 crore (March 31, 2024: ₹ 652.50 crore) relating to the sale of Manipal Hospitals Sdn Bhd., Malaysia.

**(D)** The Company along with MHPL, MHBPL, MHDPL and MHEIPL have provided security to various lenders in the form of first ranking pari passu charge over Immovable properties including lease hold improvements, Movable Fixed Assets, Intangibles assets and Current Assets (as defined in the facility agreements) for the term loans amounting to ₹ 4,663.53 crore (March 31 2024: ₹ 3,883.13 crore) availed by the Company, MHPL, MHBPL, MHDPL, HCMCT (Silo), MHEIPL and MH Eastern.

**39 Capital and other commitments**

a. As at March 31, 2025, the Group has a commitment towards purchase of capital assets of ₹ 1175.44 crore (March 31, 2024: ₹ 483.90 crore) subject to fulfilment of certain CP conditions.

b. Healthmap has entered into Concession Agreements with select government medical colleges and district hospitals ('District Hospitals') of Haryana, Jharkhand and Orissa Government for development, operation and maintenance of imaging diagnostic centres on PPP basis. The District Hospitals have provided rent free accommodation to the Company to establish these imaging diagnostic centres. In lieu of this, the Company has committed for the following over the term of the Concession Agreement:

- for Haryana perform agreed number of scans free of charge for the patients referred by the District Hospitals.

c. As at March 31, 2024, pursuant to agreement with Jharkhand Medical and Health Infrastructure Development and Procurement Corporation, the Company is required to start and operate 1 more centre, post receipt of letter of allotment of the site for the respective centre from respective sadar hospital in Jharkhand. The Company is yet to receive the letter of allotment of the site from the Government.



**40 Segment information:**

The Board of Directors of the Group has been identified as the Chief Operating Decision Maker (CODM) as defined by Ind AS 108, Operating Segments. The CODM evaluates the Group's performance and allocates resources based on an analysis of healthcare services in India.

The Group is primarily engaged in the business of healthcare services, which in the opinion of CODM falls under a single business segment and accordingly, there are no additional disclosure to be provided in terms of Ind AS 108 on 'Operating Segments'.

**41 Corporate Social Responsibility ('CSR') expenditure**

Consequent to the requirements of Section 135 and Schedule VII of the Companies Act, 2013, the Group is required to contribute 2% of its average net profits during the immediately three preceding financial years in pursuance of its Corporate Social Responsibility Policy.

The Group has constituted a CSR committee in accordance with the provisions of the Companies Act, 2013. The focus of CSR activities of the Group comprise promotion of healthcare, education, gender equality, ensuring environment sustainability, training for rural sports and rural development objects. The amount required to be spent towards the CSR activities as per Section 135 and the CSR activities undertaken by the Group is given below:

(a) Gross amount required to be spent by the Group during the year is ₹ 14.74 crore (March 31, 2024 : ₹ 7.68 crore).

(b) Amount spent:

Promoting healthcare, education, gender equality, ensuring environment sustainability, training for rural sports and rural development objects.

	(₹ in crore)		
	In cash	Yet to be paid in cash	Total
Year ended March 31, 2025	14.74	-	14.74
Year ended March 31, 2024	7.68	-	7.68

(c) Details related to spent / unspent obligations:

	(₹ in crore)	
	March 31, 2025	March 31, 2024
(i) Contribution to Public Trust	0.25	-
(ii) Contribution to Charitable Trust (refer note 43)	13.60	7.68
(iii) Contribution to others *	0.89	-
(iv) Unspent amount in relation to:		
- Ongoing project	-	-
- Other than ongoing project	-	-
	14.74	7.68

\* Expense towards programme run by the MH Eastern for providing preventive healthcare named Kolkata Accidents Response & Medical Assistance.

Details of other than ongoing project

(₹ in crore)				
As on March 31, 2025				
Opening balance	Amount deposited in Specified Fund of Sch. vii within 6 months	Amount required to be spent during the year	Amount spent during the year	Closing balance
-	-	14.59	14.74	-

(₹ in crore)				
As on March 31, 2024				
Opening balance	Amount deposited in Specified Fund of Sch. vii within 6 months	Amount required to be spent during the year	Amount spent during the year	Closing balance
-	-	7.68	7.68	-

(This space has been intentionally left blank)



42. Employee Stock option plans

The Group provides share-based payment schemes to its employees. The relevant details of respective schemes and grants are as below:

42.1 Manipal Health Enterprises Stock Option Scheme ('old Scheme')

On March 15, 2011, the board of directors approved the Equity Settled Scheme for issue of stock options to the key employees and directors of the Company. According to the old scheme, the employee selected by the compensation committee from time to time are entitled to options, subject to satisfaction of the prescribed vesting conditions as per the old Scheme. The contractual life (comprising the vesting period and the exercise period) of options granted is 6 years from the date of grant.

The relevant terms of the grant as per old Scheme are as below:

Vesting year	6 months to 3 years
Exercise year	6 years
Expected Life	2.79 years
Exercise price	₹ 100
Market price	₹ 100

	March 31, 2025		March 31, 2024	
	No. of options	Weighted Average Exercise Price (₹)	No. of options	Weighted Average Exercise Price (₹)
Outstanding and Exercisable at the beginning of the year	-	-	1,46,600	100.15
Lapse/ forfeited during the year	-	-	-	-
Encashed/cancelled	-	-	1,46,600	-
Outstanding and Exercisable at the end of the year	-	-	-	-

42.2 Manipal Health Enterprises Stock Option Scheme - 2016 ('new Scheme')

During the year ended March 31, 2020, the board of directors approved equity settled Manipal Health Enterprises Stock Option Scheme - 2016 ('new Scheme') for issue of stock options to the key employees and directors of the Company. According to the new scheme, the employee selected by the compensation committee from time to time are entitled to options, subject to satisfaction of the prescribed vesting conditions based on performance and passage of time. The contractual life (comprising the vesting period and the exercise period) of options granted is 6 years from the date of grant.

The relevant terms of the grant as per new Scheme are as below:

Vesting year	1 to 4 years
Exercise year	6 years
Expected Life	3.5 to 5 years
Exercise price	Ranges from ₹ 610 to ₹ 979 per option.
Fair value of options as per Black Scholes model	Ranges from ₹ 113.30 to 553.94 per option.

	March 31, 2025		March 31, 2024	
	No. of options	Weighted Average Exercise Price (₹)	No. of options	Weighted Average Exercise Price (₹)
Outstanding at the beginning of the year	-	-	10,05,353	1,222
Granted during the year	-	-	-	-
Lapse/ forfeited during the year	-	-	13,000	-
Encashed/cancelled	-	-	9,92,353	-
Outstanding at the end of the year	-	-	-	-
Exercisable at the end of the year	-	-	-	-

The weighted average remaining contractual life of the stock options outstanding as at March 31, 2025 is Nil (March 31, 2024: Nil).

The expected life of the share options is based on historical data and current expectations and is not necessarily indicative of exercise patterns that may occur. The expected volatility reflects the assumption that the historical volatility over a period similar to the life of the options is indicative of future trends, which may not necessarily be the actual outcome.

On February 28, 2012, a trust called "Manipal Hospitals Employees Welfare Trust" ('MHEWT') was constituted to administer all the employee stock option schemes and other employee benefit schemes. The Company treats MHEWT as its extension and the same is consolidated in this financial statements. The shares held by MHEWT are treated as treasury shares and deducted from other equity. Refer note 12.2 for details.

During the year ended March 31, 2024, Manipal Global Health Services (MGHS), one of the shareholder, proposed to purchase the entire ESOP shares from the Manipal Hospitals Employee Welfare Trust ('MHEWT'). These shares were held by MHEWT for the sole purpose of allotment to employees under the Manipal Health Enterprises Stock Option Scheme 2011 and 2016. During the current year, the employees were given an option to surrender their eligible ESOP Options. Consequently, the Group accelerated vesting of unvested options, at an additional charge of ₹ 13.23 crores which is recognized in the statement of profit and loss. The employees exercised this option and surrendered 100% of their eligible ESOP Options. All the options under the ESOP plan is cancelled and amount is paid to the employees at the fair value on the date of cancellation for surrender of all of their Options and forego / release their right to receive shares of Company. Subsequently, MHEWT transferred 11,33,200 equity shares of the Company to MGHS. This is considered as 'equity' transaction i.e. transaction amongst shareholders under Ind AS. The net impact of sale of treasury shares amounting to ₹ 96.09 crores [i.e., sale of shares of ₹ 434.52 crores less amount paid to employee (including tax deducted at source) of ₹278.04 crores, tax on sale of shares of ₹ 26.03 crores and cost of investment of ₹ 34.36 crores] is disclosed in Securities Premium under the head Other Equity in the Consolidated Financial Statements.

42.3 Manipal Health Enterprises Employee Stock Option Plan - 2024 ('New Scheme 2024')

During the year ended March 31, 2025, the board of directors approved equity settled Manipal Health Enterprises Employee Stock Option Plan - 2024 ('New Scheme 2024') for issue of stock options to the key employees and directors of the Company. According to the New Scheme 2024, the employee selected by the compensation committee from time to time are entitled to options, subject to satisfaction of the prescribed vesting conditions based on performance and passage of time. The contractual life (comprising the vesting period and the exercise period) of options granted is 6 years from the date of grant. The stock options granted under the scheme vest in a graded manner over the vesting period.



The relevant terms of the grant as per new Scheme are as below:

Vesting period	1 to 4 years
Exercise period	6 years
Expected Life	3.5 to 4.5 years
Exercise price	₹ 5,236 per option
Fair value of options as per Black Scholes model	Ranges from ₹ 802.36 to ₹ 1023.82 per option

	March 31, 2025	
	No. of options	Weighted Average Exercise Price (₹)
Outstanding at the beginning of the year	-	-
Granted during the year	7,99,950	5,236
Lapse/ forfeited during the year	(13,600)	5,236
Outstanding at the end of the year	7,86,350	5,236
Exercisable at the end of the year	-	-

The weighted average remaining contractual life of the stock options outstanding as at March 31, 2025 is 4 years.

The following tables list the inputs to the models used for the year ended March 31, 2025 :

	March 31, 2025
Weighted average fair values at the measurement date	₹ 860.58
Expected volatility (%)	24.55%
Risk-free interest rate (%)	7.06%
Dividend yield	Nil
Expected life of share options	6 years
Weighted average share price (₹)	₹ 4,188.00
Model used	Black Scholes

The expected life of the share options is based on historical data and current expectations and is not necessarily indicative of exercise patterns that may occur. The expected volatility reflects the assumption that the historical volatility over a period similar to the life of the options is indicative of future trends, which may not necessarily be the actual outcome.

The expense recognised for employee services received during the year is given below:

	(₹ in crore)	
	March 31, 2025	March 31, 2024
Expense (net of reversals) arising from equity settled share based payment transactions	33.94	13.23

#### 42.4 Healthmap Diagnostics Private Stock Option Scheme - 2020 ('ESOP Scheme')

During the year ended March 31, 2021, the board of directors approved equity settled Stock Option Scheme - 2020 ('ESOP Scheme') for issue of stock options to the key employees and directors of the Company. According to the ESOP scheme, the employee and directors selected by the Board of Directors from time to time are entitled to options, subject to satisfaction of the prescribed vesting conditions based on performance and passage of time. The contractual life (comprising the vesting period and the exercise period) of options granted is 6 years from the date of grant.

The relevant terms of the grant as per new Scheme are as below:

Vesting period	1 to 4 years
Exercise period	6 years from the date of grant
Exercise price	Ranges from ₹ 25 to ₹45 per option
Fair value of options as per Black Scholes model	Ranges from Rs 10.69 to ₹ 32.85 per option

	March 31, 2025		March 31, 2024	
	No. of options	Weighted Average Exercise Price (₹)	No. of options	Weighted Average Exercise Price (₹)
Outstanding at the beginning of the year	16,20,000	25	16,20,000	25
Granted during the year	27,10,000	38	-	-
Outstanding at the end of the year	43,30,000	33	16,20,000	25
Exercisable at the end of the year	25,80,000	25	16,20,000	25

The weighted average remaining contractual life of the stock options outstanding as at March 31, 2025 is 3.78 years (March 31, 2024: 2.46 years).

The following tables list the inputs to the models used for the years ended March 31, 2025 and March 31, 2024, respectively:

	March 31, 2025	March 31, 2024
Weighted average fair values at the measurement date	16.66	12.00
Expected volatility (%)	28.36%	38.51%
Risk free interest rate (%)	6.84%	6.24%
Dividend yield	Nil	Nil
Expected life of the options (years)	4 years	4 years
Weighted average share price (INR)	43.26	28.11
Model used	Black Scholes	Black Scholes

The expected life of the options is based on current expectations and is not necessarily indicative of exercise patterns that may occur. The expected volatility is based on historical volatility of listed companies in similar industry, which may not necessarily be the actual outcome.

The expense recognised for employee services received during the year is given below:

	(₹ in crore)	
	March 31, 2025	March 31, 2024
Expense arising from equity settled share based payment transactions (refer note 25)	4.89	0.30



43 Related party transactions

(a) Names of related parties where control exists irrespective of whether transactions have occurred or not:

Ultimate Holding Company	- MEMG International Limited, Mauritius (upto July 13, 2023)
--------------------------	--------------------------------------------------------------

(b) Names of other related parties as per Ind AS 24 with whom transactions have taken place during the year:

Joint venture	- Terrals technologies Private Limited [also, refer note 36]
Associate	- Igenetic Diagnostics Private Limited [also, refer note 37 a] - Medica TS Hospital Private Limited [also, refer note 37 b] (from July 01, 2024)
Enterprises/Individuals having joint control over the Company	- Kabru Investments Pte. Ltd. - Kangto Investments Pte. Ltd. - Imperius Healthcare Investments Pte Ltd. - Manipal Global Health Services, Mauritius - Manipal Education and Medical Group India Private Limited - Cypress Holdings - Dr. Ranjan Pai - TPG SG Magazine Pte. Ltd.
Other related parties  (Enterprise under significant influence of ultimate holding company/holding company upto July 13, 2023)  (Enterprise over which KMP has significant influence from July 13, 2023)	- Manipal Health Systems Private Limited - MEMG International Limited, Mauritius - MEMG International India Private Limited - Akna Medical Specialities Private Limited (from July 01, 2024) - Manipal Global Education Services Private Limited - Manipal Global Health Services, Mauritius - Merittrac Services Private Limited - ManipalCigna Health Insurance Company Limited - Polaris Healthcare Investments Pte. Ltd. - Sikkim Manipal University - Stempeutics Research Private Limited - Manipal Academy of Higher Education (MAHE) - UNext Learning Private Limited - Signify Innovations India Limited - Manipal Foundation

(c) Names of key management personnel as per Ind AS 24 irrespective of whether transactions have occurred or not:

Key Management Personnel	- Dr. H. Sudarshan Ballal, Director and Non-Executive Chairman - Mr. Dilip Jose, Managing Director and Chief Executive Officer - Dr. Ranjan R Pai, Director - Mr. T V Mohandas Pai, Director (upto July 14, 2023) - Mr. Rajen Padukone, Director (upto July 14, 2023) - Mr. Puneet Bhatia, Director - Mr. Mitesh Daga, Director (upto July 14, 2023) - Mr. Vaitheeswaran Scetharaman, Director - Mr. Narayanan Kumar, Nominee Director - Mr. Syed Fidah Bin Ismail Alsagoff, Director (w.e.f September 16, 2023) - Mr. Ved Prakash Kalanoria, Director (w.e.f September 16, 2023) - Mr. Ravi Lambah, Director (w.e.f September 26, 2023) - Mr. Kaikhushru Shivax Nargolwala, Director (w.e.f October 10, 2023) - Ms Varini Sharma, Director (w.e.f January 31, 2024)
--------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

(d) Names of additional related parties as per Companies Act, 2013 with whom transactions have taken place during the year:

Chief Financial Officer	- Mr. Sameer Agarwal
Company Secretary	- Mr. Sathish Kolar Ramamoorthy

Transactions with the above related parties during the year :

Name of related party	Nature of transaction	₹ in crore)	
		March 31, 2025	March 31, 2024*
MEMG International India Private Limited	Royalty charges (included under legal and professional expense)	35.61	29.59
	Hospital Services rendered	0.00#	0.00#
Manipal Global Education Services Private Limited	Hospital Services rendered	-	0.82
	Amount received from related party	-	0.47
Merittrac Services Private Limited	Staff welfare expenses	0.24	-
	Rent expense	0.00#	0.00#
	Amount paid to related party	0.24	0.00#
Manipal Health Systems Private Limited	Rent expense	0.26	0.26
	Amount paid to related party	0.17	0.30
	Sale of equity instruments by MHEWT	-	434.52
ManipalCigna Health Insurance Company Limited	Insurance expense	13.99	9.70
Polaris Healthcare Investments Pte. Ltd.	Acquisition of MHSPL	1,012.86	-
Kangto Investments Pte. Ltd.	Recovery of expenses incurred on behalf of the related party	0.27	-



Manipal Health Enterprises Private Limited  
Notes to the Consolidated Financial Statements for the year ended March 31, 2025

Stempeutics Research Private Limited	Rent income	0.23	0.20
	Amount received from related party	0.23	0.22
	Hospital Services rendered	0.01	0.01
Remuneration to key management personnel (KMP)	Short-term employee benefits ^	9.71	110.21
	Doctors professional fees	4.59	4.92
Manipal Foundation	Corporate Social Responsibility Expenditure	13.60	7.59
Manipal Academy of Higher Education	Management Fees	39.02	33.78
	Hospital Services rendered	52.10	47.29
	Diagnostic Services rendered	4.50	4.48
	Telereporting expense	0.94	0.81
	Reimbursement of expenses incurred on behalf of the company	7.47	7.26
	Recovery of expenses incurred on behalf of the related party	6.62	5.27
	Lease Rent expense	3.03	2.02
	Amount received from related party	93.08	85.92
	UNext Learning Private Limited	Hospital Services Rendered	0.88
	Amount received from related party	0.82	0.14
Signify Innovations India Limited	Purchase of Assets	0.74	-
Sikkim Manipal University	Management Fees	1.46	0.84
	Recovery of expenses incurred on behalf of the related party	0.52	0.18
Akna Medical Specialities Private Limited	Amount received from related party	1.00	-
Igenetic Diagnostics Private Limited	Recovery of expenses incurred on behalf of the related party	0.35	0.38

^ Short-term employee benefits [including payment in lieu of cancellation of ESOP for the year ended March 31, 2024, also refer note 42.1 and 42.2] to KMP and it does not include the provisions made with respect of gratuity, compensated absences and ESOP, as they are determined on the Company as a whole.

**Balances payable to related parties are as follows:**

		(₹ in crore)	
Name of related party	Nature of balances	March 31, 2025	March 31, 2024 <sup>a</sup>
MEMG International India Private Limited	Trade payables	13.47	8.71
	Other trade payables	0.61	0.43
Key Management Personnel	Trade payables	0.12	0.10
Manipal Academy of Higher Education	Trade payable	0.25	0.32
UNext Learning Private Limited	Trade payables	-	0.12
Manipal Health Systems Private Limited	Trade payables	0.09	-
Signify Innovations India Limited	Trade payables	0.74	-
Igenetic Diagnostics Private Limited	Trade payables	-	0.42

**Balances receivable from related parties are as follows:**

		(₹ in crore)	
Name of related party	Nature of balances	March 31, 2025	March 31, 2024 <sup>a</sup>
Manipal Global Education Services Private Limited	Other receivables	-	0.77
MEMG International India Private Limited	Other receivables	-	0.07
Kangto Investments Pte. Ltd.	Other receivables	0.27	-
Manipal Health Systems Private Limited	Security deposits	0.97	0.88
ManipalCigna Health Insurance Company Limited	Prepaid Insurance	-	12.10
	Advance to suppliers	0.24	-
Stempeutics Research Private Limited	Other receivables	0.09	0.09
Manipal Academy of Higher Education	Other receivables	12.75	10.83
	Trade receivables	0.71	0.35
Sikkim Manipal University	Other receivables	0.76	0.22
UNext Learning Private Limited	Other receivables	0.71	-
Igenetic Diagnostics Private Limited	Other receivables	1.74	1.42

\* Refer note 32 b.

# Represents value less than ₹ 0.01 crore

**Terms and conditions of transactions with related parties**

The above-mentioned transactions from / to related parties are made on terms equivalent to those that prevail in arm's length transactions. For the year ended March 31, 2025 and year ended March 31, 2024, the Company has not recorded any impairment of receivables relating to amounts owed by related parties. This assessment is undertaken each financial year through examining the financial position of the related party and the market in which the related party operates.



(This space has been intentionally left blank)



Name of the Entity	Country of Incorporation	Relationship as at March 31, 2025	% of effective ownership interest held (directly and indirectly)	% of voting rights held	Net Asset (total Assets minus total liabilities)		Share in profit and loss		Share in other comprehensive income		Share in total comprehensive income	
					March 31, 2025		March 31, 2025		March 31, 2025		March 31, 2025	
					Amount	% of consolidated net assets	Amount	% of consolidated profit and loss	Amount	% of consolidated other comprehensive income	Amount	% of total comprehensive income
<b>Parent</b>												
- Manipal Health Enterprises Private Limited	India	Holding Company			5,214.77	77.21%	47.77%	535.41	45.55%	(2.51)	47.78%	532.90
<b>Indian Subsidiaries</b>												
- Manipal Hospitals (Dwarka) Private Limited (refer note 51)	India	Subsidiary	100.00%	100.00%	174.37	2.58%	7.41%	83.08	-2.36%	0.13	7.46%	83.21
- Healthmap Diagnostics Private Limited	India	Subsidiary	50.08%	50.08%	161.63	2.39%	-0.11%	(1.26)	8.89%	(0.49)	-0.16%	(1.75)
- Manipal Hospitals Private Limited	India	Subsidiary	100.00%	100.00%	1,250.59	18.32%	29.56%	331.32	18.33%	(1.01)	29.62%	330.31
- Manipal Hospitals (Bangalore) Private Limited	India	Subsidiary	100.00%	100.00%	3.80%	0.05%	4.79%	53.71	1.63%	(0.09)	4.81%	53.62
- Manipal Hospitals (East) India Private Limited ("MHEIPL") (formerly known as AMRI Hospitals Private Limited and AMRI Hospitals Limited)	India	Step-down subsidiary	84.07%	84.07%	(568.05)	-8.41%	10.12%	113.46	25.77%	(1.42)	10.05%	112.04
- Manipal Hospitals Synergie Private Limited ("MHSPL") (formerly known as Medica Synergie Private Limited)	India	Subsidiary	84.94%	84.94%	301.64	4.47%	0.56%	6.27	0.00%	-	0.56%	6.27
- Manipal Hospitals Eastern India Private Limited ("MH Eastern") (formerly known as Medica Hospitals Private Limited)	India	Step-down subsidiary	84.94%	84.94%	165.43	2.45%	-0.93%	(10.37)	-8.53%	0.47	-0.89%	(9.90)
- Manipal Hospitals Bengal Private Limited ("MH Bengal") (formerly known as North Bengal Clinic Private Limited ("NBCPL"))	India	Step-down subsidiary	82.24%	82.24%	20.84	0.31%	0.10%	1.09	2.72%	(0.15)	0.08%	0.94
- HCMCT Silo **	India	Subsidiary			-381.99	-5.66%	-0.97%	(10.88)	1.63%	(0.09)	-0.98%	(10.97)
<b>Foreign Subsidiaries</b>												
- Manipal Health Enterprises International Pte Ltd	Singapore	Subsidiary	100.00%	100.00%	5.35	0.08%	0.23%	2.57	-1.63%	0.09	0.24%	2.66
<b>Joint Venture</b>												
- Terralis Technologies Private Limited	India	Joint Venture	20.59%	20.59%	-	-	0.00%	-	0.00%	-	0.00%	-
<b>Associates</b>												
- I-Genetics Diagnostics Private Limited	India	Associate	42.17%	42.17%	-	-	0.00%	-	0.00%	-	0.00%	-
<b>Sub total</b>					6,601.03			1,104.40		(5.07)		1,099.33
<b>Non-controlling interest</b>												
- Healthmap Diagnostics Private Limited	India	Subsidiary			170.50	2.52%	-0.06%	(0.62)	4.54%	(0.25)	-0.08%	(0.87)
- Manipal Hospitals (East) India Private Limited ("MHEIPL") (formerly known as AMRI Hospitals Private Limited and AMRI Hospitals Limited)	India	Step-down subsidiary			(81.53)	-1.21%	1.61%	18.08	4.17%	(0.23)	1.60%	17.85
- Manipal Hospitals Synergie Private Limited ("MHSPL") (formerly known as Medica Synergie Private Limited)	India	Subsidiary			19.12	0.28%	0.08%	0.94	0.00%	-	0.08%	0.94
- Manipal Hospitals Eastern India Private Limited ("MH Eastern") (formerly known as Medica Hospitals Private Limited)	India	Step-down subsidiary			33.19	0.49%	-0.20%	(2.19)	-1.27%	0.07	-0.19%	(2.12)
- Manipal Hospitals Bengal Private Limited ("MH Bengal") (formerly known as North Bengal Clinic Private Limited ("NBCPL"))	India	Step-down subsidiary			11.56	0.17%	0.01%	0.12	0.54%	(0.03)	0.01%	0.08
<b>NCI total</b>					152.84			16.32		(0.44)		15.88
<b>Gross total</b>					6,753.87	100.00%	100.00%	1,120.72	100.00%	(5.51)	100.00%	1,115.21
Adjustment arising on consolidation					(753.72)			(39.05)		0.44		(38.61)
<b>Total</b>					6,000.15			1,081.67		(5.07)		1,076.60

\*\* refer note 1(b)



Name of the Entity	Country of Incorporation	Relationship as at March 31, 2024	% of effective ownership interest held (directly and indirectly)	% of voting rights held	Net Asset (total Assets minus total liabilities)		Share in profit and loss		Share in other comprehensive income		Share in total comprehensive income	
					March 31, 2024*		March 31, 2024*		March 31, 2024*		March 31, 2024*	
					% of consolidated net assets	Amount	% of consolidated profit and loss	Amount	% of consolidated other comprehensive income	Amount	% of total comprehensive income	Amount
<b>Parent</b>												
- Manipal Health Enterprises Private Limited	India	Holding Company			90.77%	3,898.00	64.79%	336.50	19.01%	(0.65)	65.08%	335.85
<b>Indian Subsidiaries</b>												
- Manipal Hospitals (Dwarka) Private Limited (refer note 51)	India	Subsidiary	100.00%	100.00%	2.12%	91.16	11.29%	58.65	0.29%	(0.01)	11.36%	58.64
- Healthmap Diagnostics Private Limited	India	Subsidiary	50.08%	50.08%	3.69%	158.47	-12.00%	(62.32)	1.97%	(0.07)	-12.09%	(62.39)
- Manipal Hospitals Private Limited	India	Subsidiary	100.00%	100.00%	21.43%	920.29	45.01%	233.82	18.13%	(0.62)	45.19%	233.20
- Manipal Hospitals (Bengaluru) Private Limited	India	Subsidiary	100.00%	100.00%	4.72%	202.83	7.10%	36.88	2.92%	(0.10)	7.13%	36.78
- Manipal Hospitals (East) India Private Limited ("MHEIPL") (formerly known as AMRI Hospitals Private Limited and AMRI Hospitals Limited)	India	Step-down subsidiary	84.07%	84.07%	-15.84%	(680.09)	1.06%	5.52	50.58%	(1.73)	0.73%	3.79
- HCMCT Silo **	India	Subsidiary			-8.64%	(371.02)	-5.46%	(28.34)	-4.39%	0.15	-5.46%	(28.19)
<b>Foreign Subsidiaries</b>												
- Manipal Health Enterprises International Pte Ltd	Singapore	Subsidiary	100.00%	100.00%	0.06%	2.69	-0.03%	(0.16)	-	-	-0.03%	(0.16)
<b>Joint Venture</b>												
- Terras Technologies Private Limited	India	Joint Venture	20.59%	20.59%	-	-	-	-	-	-	-	-
<b>Associate</b>												
- I-Genetics Diagnostics Private Limited	India	Associate	42.17%	42.17%	-	-	-	580.55	-	(3.03)	-	577.52
<b>Sub total</b>						4,222.33						
<b>Non-controlling interest</b>												
- Healthmap Diagnostics Private Limited	India	Subsidiary	3.99%	-11.96%		171.37		(62.15)	1.83%	(0.05)	-12.05%	(62.20)
- Manipal Hospitals (East) India Private Limited ("MHEIPL") (formerly known as AMRI Hospitals Private Limited and AMRI Hospitals Limited)	India	Step-down subsidiary	-2.31%	0.20%		(99.38)		1.05	9.65%	(0.33)	0.14%	0.72
<b>NCI total</b>						71.99		(61.10)		(0.38)		(61.48)
<b>Gross total</b>					100.00%	4,294.32	100.00%	519.45	100.00%	(3.41)	100.00%	516.04
<b>Adjustment arising on consolidation</b>						(206.82)		13.71		0.03		13.74
<b>Total</b>						4,087.50		533.16		(3.38)		529.78

\* Refer note 32 b

\*\* refer note 1(b)



45 Material partly-owned subsidiaries -

- i) Manipal Hospitals Synergie Private Limited ("MHSPL") (formerly known as Medica Synergie Private Limited) - Subsidiary
- ii) Manipal Hospitals Eastern India Private Limited ("MH Eastern") (formerly known as Medica Hospitals Private Limited) - Subsidiary of MHSPL
- iii) Manipal Hospitals Bengal Private Limited ("MH Bengal") (formerly known North Bengal Clinic Private Limited ("NBCPL")) - Subsidiary of MHSPL

Financial information of subsidiaries that have material non-controlling interests is provided below:

Proportion of equity interest held by the parent :

Name	Country of incorporation and operation	March 31, 2025
Manipal Hospitals Synergie Private Limited ("MHSPL") (formerly known as Medica Synergie Private Limited)	India	84.94%
Manipal Hospitals Eastern India Private Limited ("MH Eastern") (formerly known as Medica Hospitals Private Limited)	India	84.94%
Manipal Hospitals Bengal Private Limited ("MH Bengal") (formerly known North Bengal Clinic Private Limited)	India	82.24%

Information regarding non-controlling interest

(₹ in crore)

March 31, 2025

Accumulated balances of material non-controlling interest:

Manipal Hospitals Synergie Private Limited ("MHSPL") (formerly known as Medica Synergie Private Limited)	19.12
Manipal Hospitals Eastern India Private Limited ("MH Eastern") (formerly known as Medica Hospitals Private Limited)	33.19
Manipal Hospitals Bengal Private Limited ("MH Bengal") (formerly known North Bengal Clinic Private Limited)	11.56

Profit/(loss) including OCI allocated to material non-controlling interest:

Manipal Hospitals Synergie Private Limited ("MHSPL") (formerly known as Medica Synergie Private Limited)	0.94
Manipal Hospitals Eastern India Private Limited ("MH Eastern") (formerly known as Medica Hospitals Private Limited)	(2.12)
Manipal Hospitals Bengal Private Limited ("MH Bengal") (formerly known North Bengal Clinic Private Limited)	0.09

The summarised financial information of these subsidiaries is provided below. This information is based on amounts before inter-company eliminations.

Summarised statement of profit and loss for the period starting from July 01, 2024 till March 31, 2025:

(₹ in crore)

	MHSPL	MH Eastern	MH Bengal	Total
	March 31, 2025	March 31, 2025	March 31, 2025	March 31, 2025
Revenue from operations	2.00	482.30	70.20	554.50
Other income	0.80	0.64	-	1.44
Finance Income	7.33	1.07	0.04	8.44
Purchase of medical consumables	-	(105.58)	(17.08)	(122.66)
Changes in inventories of medical consumables	-	(3.61)	(0.56)	(4.17)
Employee benefits expense	0.12	(126.75)	(12.28)	(138.91)
Finance cost	-	(22.99)	(1.62)	(24.61)
Depreciation and amortization expense	(0.01)	(32.27)	(4.95)	(37.23)
Other expenses	(1.85)	(204.68)	(32.36)	(238.89)
<b>Profit / (loss) before tax</b>	<b>8.39</b>	<b>(11.87)</b>	<b>1.39</b>	<b>(2.09)</b>
Income tax	(2.12)	1.49	(0.31)	(0.94)
<b>Profit / (loss) for the period from continuing operations</b>	<b>6.27</b>	<b>(10.38)</b>	<b>1.08</b>	<b>(3.03)</b>
Other comprehensive income for the period	-	0.47	(0.15)	0.32
<b>Total comprehensive income / (loss) for the period</b>	<b>6.27</b>	<b>(9.91)</b>	<b>0.93</b>	<b>(2.71)</b>
Attributable to non-controlling interests	0.94	(2.12)	0.09	(1.09)
Dividends paid to non-controlling interests	-	-	-	-

Summarised balance sheet as at:

(₹ in crore)

	MHSPL	MH Eastern	MH Bengal	Total
	March 31, 2025	March 31, 2025	March 31, 2025	March 31, 2025
Current assets	34.85	139.37	17.30	191.52
Non-current assets	267.93	459.56	57.30	784.79
Current liabilities	(0.98)	(168.40)	(40.52)	(209.90)
Non-current liabilities	(0.17)	(265.13)	(13.26)	(278.56)
<b>Equity</b>	<b>301.63</b>	<b>165.40</b>	<b>20.82</b>	<b>487.85</b>
Attributable to:				
Equity holders of parent	282.51	132.21	9.26	423.98
Non-controlling interest	19.12	33.19	11.56	63.87

Summarised cash flow information for the period ended:

(₹ in crore)

	MHSPL	MH Eastern	MH Bengal	Total
	March 31, 2025	March 31, 2025	March 31, 2025	March 31, 2025
Operating activities	0.57	(1.31)	11.36	10.62
Investing activities	(62.75)	(50.83)	(3.43)	(117.01)
Financing activities	-	31.17	(5.57)	25.60
<b>Net increase in cash and cash equivalents</b>	<b>(62.18)</b>	<b>(20.97)</b>	<b>2.36</b>	<b>(80.79)</b>



46 Material partly-owned subsidiaries - Healthmap Diagnostics Private Limited

Financial information of subsidiaries that have material non-controlling interests is provided below:

Proportion of equity interest held by the parent :

Name	Country of incorporation and operation	March 31, 2025	March 31, 2024*
Healthmap Diagnostics Private Limited	India	50.08%	50.08%

Information regarding non-controlling interest

Accumulated balances of material non-controlling interest:

	(₹ in crore)	
	March 31, 2025	March 31, 2024*
Healthmap Diagnostics Private Limited (refer note 53)	170.50	171.37

Loss including OCI allocated to material non-controlling interest:

	March 31, 2025	March 31, 2024*
Healthmap Diagnostics Private Limited	(0.87)	(62.21)

The summarised financial information of these subsidiaries is provided below. This information is based on amounts before inter-company eliminations.

Summarised statement of profit and loss for the year ended:

	(₹ in crore)	
	March 31, 2025	March 31, 2024*
Revenue from operations	211.80	181.47
Other income	4.46	3.97
Finance Income	0.68	0.62
Purchase of medical consumables	(58.43)	(51.29)
Changes in inventories of medical consumables	1.32	2.70
Employee benefits expense	(52.47)	(44.83)
Finance cost	(8.28)	(8.98)
Depreciation and amortization expense	(26.23)	(29.91)
Other expenses	(71.71)	(63.38)
<b>Profit/ (Loss) before tax and exceptional items</b>	<b>1.14</b>	<b>(9.63)</b>
<b>Exceptional loss / (gain)</b>	<b>2.40</b>	<b>114.50</b>
<b>Loss before tax</b>	<b>(1.26)</b>	<b>(124.13)</b>
Income tax	(0.76)	0.56
Deferred tax	0.74	(0.22)
<b>Loss for the year from continuing operations</b>	<b>(1.24)</b>	<b>(124.47)</b>
Other comprehensive loss for the year	(0.49)	(0.13)
<b>Total comprehensive loss for the year</b>	<b>(1.73)</b>	<b>(124.60)</b>
Attributable to non-controlling interests	(0.87)	(62.21)
Dividends paid to non-controlling interests	-	-

Summarised balance sheet as at:

	(₹ in crore)	
	March 31, 2025	March 31, 2024*
Current assets	123.24	109.62
Non-current assets	171.92	186.82
Current liabilities	(61.60)	(62.97)
Non-current liabilities	(71.93)	(75.00)
<b>Equity</b>	<b>161.63</b>	<b>158.47</b>
<b>Attributable to:</b>		
Equity holders of parent	(8.87)	(12.90)
Non-controlling interest	170.50	171.37

Summarised cash flow information for the year ended:

	(₹ in crore)	
	March 31, 2025	March 31, 2024*
Operating activities	45.42	17.80
Investing activities	(26.23)	(32.27)
Financing activities	(14.44)	13.31
<b>Net increase in cash and cash equivalents</b>	<b>4.75</b>	<b>(1.16)</b>

\* Refer note 32 b.



**Manipal Health Enterprises Private Limited**  
**Notes to the Consolidated Financial Statements for the year ended March 31, 2025**

**47 Material partly-owned subsidiaries - Manipal Hospitals (East) India Private Limited ("MHEIPL") (formerly known as AMRI Hospitals Private Limited and AMRI Hospitals Limited)**

Financial information of subsidiaries that have material non-controlling interests is provided below:

**Proportion of equity interest held by the parent:**

Name	Country of incorporation and operation	March 31, 2025	March 31, 2024
Manipal Hospitals (East) India Private Limited ("MHEIPL") (formerly known as AMRI Hospitals Private Limited and AMRI Hospitals Limited)	India	84.07%	84.07%

**Information regarding non-controlling interest**

(₹ in crore)

	March 31, 2025	March 31, 2024
<b>Accumulated balances of material non-controlling interest:</b>		
Manipal Hospitals (East) India Private Limited ("MHEIPL") (formerly known as AMRI Hospitals Private Limited and AMRI Hospitals Limited)	(81.53)	(99.38)
<b>Profit including OCI allocated to material non-controlling interest:</b>		
Manipal Hospitals (East) India Private Limited ("MHEIPL") (formerly known as AMRI Hospitals Private Limited and AMRI Hospitals Limited)	17.85	0.72

The summarised financial information of these subsidiaries is provided below. This information is based on amounts before inter-company eliminations.

**Summarised statement of profit and loss for the year ended March 31, 2025 and period starting from September 20, 2023 till March 31, 2024:**

(₹ in crore)

	March 31, 2025	March 31, 2024
Revenue from operations	1,137.18	568.05
Other income	5.15	2.60
Finance Income	1.66	0.46
Purchase of medical consumables	(290.11)	(153.70)
Changes in inventories of medical consumables	1.27	(3.43)
Employee benefits expense	(171.04)	(78.67)
Finance cost	(152.88)	(78.79)
Depreciation and amortization expense	(76.76)	(34.09)
Other expenses	(436.31)	(215.78)
<b>Profit before tax</b>	<b>18.16</b>	<b>6.65</b>
Deferred tax	(95.31)	-
<b>Profit for the year / period</b>	<b>113.47</b>	<b>6.65</b>
Other comprehensive loss for the year / period	(1.42)	(2.06)
<b>Total comprehensive income for the year / period</b>	<b>112.05</b>	<b>4.59</b>
Attributable to non-controlling interests	17.85	0.72
Dividends paid to non-controlling interests	-	-

**Summarised balance sheet as at:**

(₹ in crore)

	March 31, 2025	March 31, 2024
Current assets	143.57	193.53
Non-current assets	1,311.03	1,103.68
Current liabilities	(196.42)	(214.25)
Non-current liabilities	(1,826.11)	(1,762.94)
<b>Equity</b>	<b>(567.93)</b>	<b>(679.98)</b>
<b>Attributable to:</b>		
Equity holders of parent	(486.40)	(580.60)
Non-controlling interest	(81.53)	(99.38)

**Summarised cash flow information for the year ended:**

(₹ in crore)

	March 31, 2025	March 31, 2024
Operating activities	191.94	289.53
Investing activities	(124.51)	(67.53)
Financing activities	(101.74)	(191.41)
<b>Net increase in cash and cash equivalents</b>	<b>(34.31)</b>	<b>30.59</b>



48 Reconciliation of movements of liabilities to cash flows arising from financial liabilities

Particulars	Term loans	Lease liabilities	Term loan from others	Loan for purchase of capital asset	(₹ in crore)
					Total
Debt as at April 01, 2024*	3,929.35	1,186.26	-	14.64	5,130.25
Additions on account of acquisition of subsidiary (refer note 32 a)	164.25	20.23	0.03	-	184.51
Interest accrued but not due as at April 01, 2024	0.96	-	-	-	0.96
Addition during the year	-	440.00	-	-	440.00
Cash flows including interest paid					
- Proceeds from borrowings/leases	898.87	-	-	5.91	904.78
- Repayment of borrowings/leases	(242.55)	(50.21)	-	(5.04)	(297.80)
- Interest paid	(330.34)	(114.33)	-	(1.31)	(445.98)
Non-cash changes					
- Ind AS adjustment with respect to unamortised loan processing charges	1.45	-	-	-	1.45
- Interest expense	331.37	136.04	-	1.31	468.72
- Interest capitalised	-	7.08	-	-	7.08
- Lease liability reversed	-	(6.73)	-	-	(6.73)
Interest accrued but not due as at March 31, 2025	(2.09)	-	-	-	(2.09)
Debt as at March 31, 2025	4,751.27	1,618.34	0.03	15.51	6,385.15

Particulars	Term loans	Lease liabilities	Loan for purchase of capital asset	(₹ in crore)
				Total
Debt as at April 01, 2023*	2,141.60	1,099.61	8.09	3,249.30
Additions on account of acquisition of subsidiary (refer note 32 c)	1,733.46	6.04	-	1,739.50
Interest accrued but not due as at April 01, 2023	3.48	-	-	3.48
Addition during the year	-	113.67	-	113.27
Cash flows including interest paid				
- Proceeds from borrowings/leases	309.55	-	10.19	319.74
- Repayment of borrowings/leases	(255.19)	(37.84)	(3.64)	(296.27)
- Interest paid	(266.97)	(110.85)	(0.96)	(378.78)
Non-cash changes				
- Ind AS adjustment with respect to unamortised loan processing charges	(25.40)	-	-	(25.40)
- Interest expense	289.78	125.51	0.96	425.25
- Lease liability reversed	-	(9.88)	-	(9.88)
Interest accrued but not due as at March 31, 2024	(0.96)	-	-	(0.96)
Debt as at March 31, 2024*	3,929.35	1,186.26	14.64	5,139.25

\* Refer note 32 b.

49 Other Statutory information

- (i) The Group do not have any Benami property, where any proceeding has been initiated or pending against the Group for holding any Benami property.  
(ii) The Group has balance with below- mentioned companies struck off under section 248 of Companies Act, 2013:

Name of struck off Company	Nature of transactions with struck-off Company	Balance outstanding		Relationship with the Struck off company, if any, to be disclosed
		(₹ in crore)		
		As at March 31, 2025	As at March 31, 2024	
T2K Fire & Security Private Limited	Retention Money	0.02	0.04	None
	Creditors for Capital Goods	0.01	0.02	None

- (iii) The Group do not have any charges or satisfaction which is yet to be registered with ROC beyond the statutory period  
(iv) The Group is in compliance with number of layers of companies, as prescribed under clause (87) of Section 2 of the Act read with the Companies (Restriction on number of Layers) Rules, 2017  
(v) The Group have not traded or invested in Crypto currency or Virtual Currency during the financial year.  
(vi) The Group have not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall:  
(a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Group (Ultimate Beneficiaries) or  
(b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries  
(vii) The Group have not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Group shall:  
(a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or  
(b) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries,  
(viii) The Group does not have any such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961)  
(ix) The Group has not been declared wilful defaulter by any bank or financial institution or other lender.  
(x) The Group has complied with the number of layers prescribed under the Companies Act, 2013.

50 Dues to Micro and Small Enterprises as per the Micro, Small and Medium Enterprises Development Act, 2006 (MSMED):

	(₹ in crore)	
	March 31, 2025	March 31, 2024
(i) Principal amount due to suppliers registered under the MSMED Act and remaining unpaid as at year end	36.14	29.88
(ii) Interest due to suppliers registered under the MSMED Act and remaining unpaid as at year end	0.01	0.01
(iii) Principal amounts paid to suppliers registered under the MSMED Act, beyond the appointed day during the year	-	-
(iv) Interest paid, other than under Section 16 of MSMED Act, to suppliers registered under the MSMED Act, beyond the appointed day during the year	-	-
(v) Interest paid, under Section 16 of MSMED Act, to suppliers registered under the MSMED Act, beyond the appointed day during the year	-	-
(vi) Interest due and payable towards suppliers registered under MSMED Act, for payments already made	-	-
(vii) Further interest remaining due and payable for earlier years	0.70	0.13

51 The Board of Directors at its meeting held on December 14, 2021, have approved the Scheme of Amalgamation ("the Scheme") of Manipal Hospitals (Jaipur) Private Limited, ("Transferor Company") with Manipal Hospitals (Dwarka) Private Limited ("Transferee Company") with an appointed date of April 1, 2022. During the year ended March 31, 2023, MHJPL has filed an application with the National Company Law Tribunal (NCLT), Bengaluru Bench. During the year ended March 31, 2024, NCLT has approved the Scheme and the effect of the Scheme has been given in the Consolidated Financial Statements.

The merger being under common control, has been accounted in accordance with Appendix C of Ind AS 103 "Business Combinations" and hence there will be no impact on the Consolidated Financial Statements, other than recognition of deferred tax asset (DTA).



52 In the months of May and June, 2024, the Company raised ₹ 750.00 crore through rights issue from the existing shareholders, the proceeds of the rights issue were utilised for the acquisition of 84.94% shareholding in Manipal Hospitals Synergie Private Limited (formerly known as Medica Synergie Private Limited) (refer note 32 a).

53 During the year ended March 31, 2025, the Regional Director South-East Region has confirmed the scheme of amalgamation between Healthmap Diagnostics Private Limited and Medeis Pathlabs India Private Limited with the appointed date as April 01, 2024, and the effect of the scheme is reflected in the Consolidated Financial Statements

The merger being under common control, has been accounted in accordance with Appendix C of Ind AS 103 "Business Combinations" and hence there will be no impact on the Consolidated Financial Statements.

**54 Events after the reporting date**

(a) Subsequent to the year ended March 31, 2025, the Company sub-divided its equity shares by reducing the nominal value of each equity share from ₹ 10 to ₹ 2. Accordingly, each equity share of ₹ 10 was sub-divided into five equity shares of ₹ 2 each. As a result, the Authorised Capital of ₹ 135,00,00,000 which was earlier divided into 135,000,000 equity shares of ₹ 10 each was changed to 675,000,000 equity shares of ₹ 2 each and the Issued and Paid up Capital of ₹ 77,06,24,340 which was earlier divided into 77,062,434 equity shares of ₹ 10 each was changed to 385,312,170 equity shares of ₹ 2 each.

(b) Subsequent to the year ended March 31, 2025, the shareholders of the Company approved a bonus issue of equity shares in the ratio of 2:1, i.e., two equity shares for every one equity share held. To accommodate the bonus issue, the Authorised Share Capital was increased from ₹ 135,00,00,000 divided into 675,000,000 equity shares of ₹ 2 each to ₹ 255,00,00,000 divided into 1,275,000,000 equity shares of ₹ 2 each. Upon allotment of bonus shares, an amount of ₹ 154,12,48,680 would be capitalised from the Company's free reserves.

As per our report of even date attached

For BSR & Co. LLP  
Chartered Accountants  
Firm Registration number : 101248W/W - 100022



Siddhartha Sharma  
Partner  
Membership number: 118756

Date : May 30, 2025  
Place : Bengaluru

For and on behalf of the Board of Directors of  
Manipal Health Enterprises Private Limited



Dilip Joshi  
Managing Director & CEO  
DIN: 03591692

Date : May 30, 2025

Dr. H. Sudarshan Ballal  
Chairman & Director  
DIN: 01195055

Date : May 28, 2025



Sameer Agarwal  
Chief Financial Officer

Date : May 28, 2025  
Place : Bengaluru

Sathish Kolar Ramamoorthy  
Company Secretary  
Membership number: A15203

Date : May 28, 2025